gemcitabine has been researched along with fluorouracil in 1243 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 29 (2.33) | 18.2507 |
| 2000's | 454 (36.52) | 29.6817 |
| 2010's | 567 (45.62) | 24.3611 |
| 2020's | 193 (15.53) | 2.80 |
| Authors | Studies |
|---|---|
| Corbett, TH; Edelstein, M; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Paluch, J; Polin, L; White, K | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Albanese, C; Alzani, R; Avanzi, N; Ballinari, D; Bensimon, A; Brotherton, D; Cattoni, M; Ciavolella, A; Croci, V; Fiorentini, F; Healy, S; Isacchi, A; Marchesi, V; Menichincheri, M; Molinari, A; Moll, J; Montagnoli, A; Patton, V; Pesenti, E; Rainoldi, S; Santocanale, C; Sola, F; Tenca, P; Tibolla, M; Valsasina, B; Vanotti, E; Volpi, D | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Albanese, C; Alli, C; Ballinari, D; Bargiotti, A; Caldarelli, M; Ciavolella, A; Cirla, A; Colombo, M; Colotta, F; Croci, V; D'Alessio, R; D'Anello, M; Ermoli, A; Fiorentini, F; Forte, B; Galvani, A; Giordano, P; Isacchi, A; Martina, K; Menichincheri, M; Molinari, A; Moll, JK; Montagnoli, A; Orsini, P; Orzi, F; Pesenti, E; Pillan, A; Roletto, F; Santocanale, C; Scolaro, A; Tatò, M; Tibolla, M; Valsasina, B; Vanotti, E; Varasi, M; Vianello, P; Volpi, D | 1 |
| Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU | 1 |
| Ahn, CH; Gong, YD; Jeon, MK; Kong, JY; Lee, YB; Yoon, H | 1 |
| Bourguignon, JJ; Dimas, K; Eleutheriades, A; Foscolos, GB; Georgakopoulou, S; Khan, H; Kourafalos, VN; Mirjolet, JF; Moutsos, VI; Papanastasiou, I; Pondiki, S; Prassa, M; Riganas, S; Serin, G; Theodoropoulou, M; Tsotinis, A; Vamvakides, A; Zaniou, A | 1 |
| Abdelhamed, S; Athikomkulchai, S; Awale, S; Dibwe, DF; Miyatake, R; Saiki, I; Ueda, JY; Yokoyama, S | 1 |
| Dimas, K; Eleutheriades, A; Foscolos, GB; Georgakopoulou, S; Khan, H; Kourafalos, VN; Mantelas, A; Mirjolet, JF; Moutsos, VI; Papanastasiou, I; Pondiki, S; Prassa, M; Riganas, S; Serin, G; Theodoropoulou, M; Tsotinis, A; Vamvakides, A; Zaniou, A | 1 |
| Chin, J; Ekins, M; Hahn, D; Kang, H; Kim, H; Lee, J; Lee, Y; Mun, B; Nam, SJ; Park, Y; Venkat Reddy, M; Wang, W | 1 |
| Huang, CG; Li, CS; Li, XM; Lv, CT; Meng, LH; Wang, BG; Xu, GM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Awale, S; Do, TN; Esumi, H; Le, TH; Nguyen, HX; Nguyen, MT; Nguyen, NT | 1 |
| de Lima Ferreira, LP; de Melo Rêgo, MJB; de Moraes Gomes, PAT; de Siqueira, LRP; Leite, ACL | 1 |
| Maltais, R; Perreault, M; Poirier, D; Roy, J | 1 |
| Bergonzini, C; Carbone, D; Cascioferro, S; Cirrincione, G; Dekker, H; Diana, P; Funel, N; Geerke, D; Giovannetti, E; Mantini, G; Parrino, B; Peters, GJ; Petri, GL | 1 |
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Ghazaly, E; Kariuki, BM; McGuigan, C; Pepper, C; Serpi, M; Slusarczyk, M | 1 |
| Guo, H; Sun, S; Wang, G | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Macdonald, JS; Schnall, SF | 1 |
| Bamberger, U; Boven, E; Feller, N; Jansen, WJ; Pinedo, HM; van der Wilt, CL | 1 |
| Lawrence, TS; Robertson, JM; Shewach, DS | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 2 |
| Andersen, JS; Brown, TD; Burris, HA; Casper, ES; Cripps, MC; Green, MR; Moore, MJ; Portenoy, RK; Rothenberg, ML; Storniolo, AM; Tarassoff, PG; Von Hoff, DD | 1 |
| Rothenberg, ML | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Burris, HA | 1 |
| Burris, H; Storniolo, AM | 1 |
| Andersen, J; Burris, HA; Cripps, MC; Dorr, FA; Green, MR; Modiano, MR; Moore, MJ; Nelson, R; Portenoy, RK; Rothenberg, ML; Stephens, CD; Storniolo, AM; Tarassoff, P; Von Hoff, DD | 1 |
| Devriendt, D; Klastersky, J | 1 |
| Michael, M; Moore, M | 1 |
| Ballatori, E; Del Favero, A; Roila, F | 1 |
| Kinsella, AR; Smith, D | 1 |
| Garcia, L; Goodwin, AL; Von Hoff, DD | 1 |
| Abrams, RA; Regine, WF | 1 |
| Blaszkowsky, L | 1 |
| Cascinu, S; Catalano, G; Graziano, F | 1 |
| Alonso, S; Castellano, D; Cortes-Funes, H; Diaz-Puente, M; Gravalos, C; Hidalgo, M; Hitt, R; Paz-Ares, L | 1 |
| Bareck, E; Brodowicz, T; Hejna, MH; Kornek, GV; Lang, F; Lenauer, J; Raderer, M; Scheithauer, W; Valencak, JB; Weinländer, GS | 1 |
| Reeves, W; Tippin, DB; Vogelzang, NJ | 1 |
| Barni, S; Cascinu, S; Catalano, G; Cellerino, R; Frontini, L; Fusco, V; Giordani, P; Giuliodori, L; Labianca, R; Luporini, G; Pancera, G; Pessi, MA; Piazza, E; Silva, RR | 1 |
| Brunet, R; Fonck, M | 1 |
| Grant, S; Poplin, E; Roberts, J; Rubin, E; Tombs, M | 1 |
| Arning, M; Diebold, T; Hochmuth, K; Huhn, D; Langrehr, J; Neuhaus, P; Oettle, H; Pelzer, U; Riess, H; Schmidt, CA; Vogl, TJ | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA | 1 |
| André, T; Balosso, J | 1 |
| Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP | 1 |
| Adak, S; Berlin, JD; Blaszkowsky, L; Flinker, D; Harris, JE; Vaughn, DJ | 1 |
| Allegra, CJ; Chabner, BA; Chu, E; Grem, JL; Johnston, PG; Multani, P; Ryan, D; Takimoto, CH | 1 |
| Bianco, AR; Damiano, V; De Lorenzo, S; Fabbrocini, A; Libroia, A; Matano, E; Tagliaferri, P | 1 |
| Barret, JM; Etiévant, C; Hill, BT | 1 |
| Dumas, MC; Rini, BI; Stadler, WM; Taber, DA; Vogelzang, NJ; Wade, JL | 1 |
| Au, E | 1 |
| Alabiso, O; Bortolini, M; Botta, M; Buosi, R; Chiappino, I; Clara, R; Grosso, M; Mussa, A; Satolli, A; Zai, S; Zanon, C | 1 |
| Colarian, J; Fowler, D; Poolos, S; Schor, J | 1 |
| Beauchamp, RD; Benson, AB; Berlin, J; Catalano, PJ; Talamonti, MS; Vaughn, DJ; Whittington, R | 1 |
| Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG | 1 |
| Firby, PS; Hedley, DW; Moore, MJ; Rauchwerger, DR | 1 |
| Arning, M; Arnold, D; Herrenberger, J; Huhn, D; Kindler, M; Korsten, EW; Langrehr, J; Musch, R; Oettle, H; Pelzer, U; Reitzig, P; Riess, H; Stroszczynski, C | 1 |
| Barni, S; Cascinu, S; Catalano, G; Catalano, V; Curti, C; Farinati, E; Frontini, L; Graiff, C; Labianca, R; Pessi, MA; Picone, G; Zonato, S | 1 |
| Arnold, D; Oettle, H; Riess, H | 1 |
| Arnold, D; Hempel, C; Oettle, H; Riess, H | 1 |
| Heinemann, V | 5 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Ludwig, CU; Maurer, CA; Pampallona, S; Rauch, DP | 1 |
| Gershanovich, ML; Ignashov, AM; Ivanova, NE; Kokhanenko, NIu; Osipenko, SK; Rybakov, GV | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Löhr, JM | 1 |
| Abbruzzese, JL; Breslin, TM; Cleary, KR; Crane, CH; Dackiw, AP; Evans, DB; Harbison, DB; Hess, KR; Janjan, NA; Jean, ME; Lee, JE; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE | 1 |
| Pestieau, SR; Schnake, KJ; Stuart, OA; Sugarbaker, PH | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A | 1 |
| Brátová, M; Kohout, P; Králícková, P; Melichar, B; Solichová, D; Zadák, Z | 1 |
| Crane, CH; Evans, DB; Wolff, RA | 1 |
| André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F | 1 |
| Glimelius, B; Hafström, L; Nygren, P; Permert, J | 1 |
| Bruckner, HW; Evans, A; Kozuch, P; Petryk, M | 1 |
| Bunnell, CA; Burstein, HJ; Winer, EP | 1 |
| Abal, M; Agusto, S; Almira, E; Balbiani, L; Castilla, JL; Fein, L; Jovtis, S; Lewi, D; Marantz, A; Muiño, M; Pasccon, G; Pinckevicius, R; Reale, M; Uranga, G | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R | 1 |
| Coudray, AM; Faivre, S; Gespach, C; Louvet, C; Raymond, E | 1 |
| Goulart, BH; Lynch, TJ; Martins, RG | 1 |
| Lawrence, TS; McGinn, CJ | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Bansback, N; Calvert, N; Crellin, A; Forman, D; Larvin, M; Morris, E; Radstone, D; Ward, S | 1 |
| Bontenbal, M; Smorenburg, CH; Sparreboom, A; Verweij, J | 1 |
| Araneo, M; Barzdins, A; Bruckner, HW; DeGregorio, P; Frager, D; Grossbard, ML; Homel, P; Kozuch, P; Marino, J; Robin, A | 1 |
| Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ | 1 |
| Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Buscail, L; Escourrou, J; Faure, P; Moreau, J; Pages, P | 1 |
| Benasso, M; Corvò, R; Marchetti, G; Merlano, M; Numico, G; Pallestrini, E; Ricci, I; Rosso, R; Sanguineti, G; Santelli, A; Vitale, V | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P | 1 |
| Geoffroy, FJ; George, CM; Kollipara, P; Rini, BI; Stadler, WM; Vogelzang, NJ | 1 |
| Moore, MJ | 1 |
| Okada, S | 1 |
| Awada, A; Batter, V; Beex, L; Biganzoli, L; Cufer, T; Hamilton, A; Lohrisch, C; Nooij, M; Piccart, M | 1 |
| Kelly, S; Nguyen, M; Sun, D; Urrabaz, R; Weitman, S | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Delclos, M; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, AB | 1 |
| Bareck, E; Depisch, D; Ploner, M; Puhalla, H; Scheithauer, W; Stiglbauer, W | 1 |
| Fung, MC; Sakata, T | 1 |
| Zielinski, CC | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Ryan, DP; Willett, CG | 1 |
| Büchler, MW; Friess, H; Solioz, M; Xu, ZW | 1 |
| Büchler, MW; Friess, H; Kleeff, J; Liu, S; Shi, X | 1 |
| Benson, AB; Berlin, JD; Catalano, P; Haller, DG; Kugler, JW; Thomas, JP | 1 |
| Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Oettle, H; Riess, H | 1 |
| Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
| Ansari, R; Desai, AA; Krauss, S; Rini, BI; Stadler, WM; Vogelzang, NJ | 1 |
| Kulke, MH | 2 |
| Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U | 1 |
| Barsoum, J; Brickelmaier, M; Carmillo, A; Goelz, S; Qin, XQ | 1 |
| Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M | 1 |
| Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A | 1 |
| Bankhead, C | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, H; Berlin, JD; Binger, K; Feierabend, C; Marrocha, R; Morgan-Meadows, S; Mulkerin, D; Thomas, JP; Volkman, J; Wilding, G | 1 |
| Azria, D; Prost, P; Ychou, M | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Besse, B; Spano, JP | 1 |
| Blackstock, AW; McMullen, KP | 1 |
| Hayashi, H; Hayashi, Y; Kamata, T; Kanno, M; Michiwa, Y; Minatoya, G; Onishi, I; Takeda, K; Takeda, T | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Mackey, JR; Young, JD | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Borner, M; Herrmann, R; Hess, V; Ludwig, C; Morant, R; Roth, AD; Salzberg, M | 1 |
| Blackstock, AW; Lawrence, TS; McGinn, C | 1 |
| Boxberger, F; Brueckl, V; Brueckl, WM; Hahn, EG; Hautmann, M; Hohenberger, W; Jüngert, B; Wein, A | 1 |
| Barone, C; Basso, M; Battelli, C; Cassano, A; Corsi, DC; Longo, R; Pozzo, C; Quirino, M; Schinzari, G | 1 |
| Abbruzzese, JL | 2 |
| Haller, DG | 3 |
| Okusaka, T | 1 |
| el-Rayes, BF; Philip, PA; Shields, AF; Vaitkevicius, V | 1 |
| Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD | 1 |
| El-Rayes, BF; Philip, PA | 1 |
| Grem, JL; Schuler, B; Szabo, E; Wright, MA | 1 |
| Berlin, JD; Rothenberg, ML | 1 |
| Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Seidman, AD | 1 |
| Herfarth, Ch | 1 |
| Bernacki, RJ; Chaudhary, ND; Greco, W; Hoffman, RM; Kobayashi, T; Mazurchuk, R; Pera, P; Spernyak, J; Veith, J; Wu, M | 1 |
| Yeo, CJ | 1 |
| Schramm, H | 1 |
| Oettle, H | 2 |
| McGinn, CJ; Zalupski, MM | 1 |
| Cerretani, D; Correale, P; Francini, G; Giorgi, G; Marsili, S; Messinese, S; Petrioli, R; Pinto, E; Pozzessere, D; Roviello, F; Sabatino, M | 1 |
| Calvanese, A; Ceciarini, F; Cerretani, D; Correale, P; Di Palma, T; Francini, G; Giorgi, G; Marsili, S; Messinese, S; Neri, A; Pellegrini, M; Petrioli, R; Pinto, E; Pozzessere, D; Sabatino, M | 1 |
| Adsay, V; Day, J; El-Rayes, BF; Heilbrun, LK; Jain, V; Philip, PA; Shields, AF; Vaishampayan, U; Zalupski, MM | 1 |
| Chan, WK; Chang, FY; Chao, Y; Chi, KH; Lee, RC; Lee, SD; Li, CP; Teng, HC; Yen, SH | 1 |
| Claude, L; Mornex, F | 1 |
| Bodoky, G | 1 |
| George, C; Huo, D; Karrison, T; Ryan, CW; Stadler, WM; Vogelzang, NJ; Yang, X; Zimmerman, TM | 1 |
| Ito, H; Katoh, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimamura, F; Shimizu, H; Togawa, A; Yoshidome, H | 1 |
| Cooper, AJ; Johnson, CD; Whitehouse, PA | 1 |
| Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F | 1 |
| Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E | 1 |
| Bulgaru, A; Egorin, M; Goel, S; Harvey, E; Hochster, H; Ivy, P; Leibes, L; Lockwood, G; Mani, S; Muggia, F; Renshaw, G; Wadler, S; Zamboni, W | 1 |
| Bai, YR; Chen, Y; Guo, WJ; Lu, DQ; Wu, GH; Wu, XD; Yao, Y; Zhou, RH | 1 |
| Matsumoto, G; Okamoto, A; Tsuruta, K | 1 |
| Cornelio, GH; Gordon, EM; Hall, FL; Levy, JP; Liu, L; Lorenzo, CC; Reed, RA | 1 |
| Kurokawa, S; Matsuzaki, A; Morita, T; Tokue, A | 1 |
| Balzarini, P; Bonora, A; Ennas, MG; Grigolato, P; Moore, PS; Sartoris, S; Scarpa, A; Sorio, C; Tecchio, C | 1 |
| Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N | 1 |
| Seidman, A | 1 |
| Crane, CH | 1 |
| Arita, Y; Hisano, T; Ito, T; Kawabe, K; Nawata, H | 1 |
| Balasubramanian, S; Chandraratna, RA; Eckert, RL | 1 |
| Addeo, A; Bellone, G; Bertelli, GF; Bertetto, O; Chiappino, I; Heouaine, A; Merlano, M; Novarino, A; Ritorto, G | 1 |
| Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B | 1 |
| Dietrich, M; Grossbard, ML; Kozuch, P; Malamud, S; Mathew, S; Rachamalla, R | 1 |
| De Gelder, V; De Ridder, L; Dierckx, RA; Lambert, B; Slegers, G; Thierens, H | 1 |
| Berger, MR; Leible, M; Sänger, J; Seelig, MH | 1 |
| Hedley, D; Knox, JJ; Moore, MJ; Oza, A; Pond, GR; Siu, LL | 1 |
| Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L | 1 |
| Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V | 1 |
| Chen, JS; Cheng, AL; Hsu, C; Hsu, CH; Li, CC; Liu, HT; Lu, YS; Shen, YC; Wu, CY; Yang, CH; Yeh, KH | 1 |
| Abbruzzese, A; Caraglia, M; Ceciarini, F; Correale, P; Francini, G; Giorgi, G; Guarnieri, A; Marsili, S; Messinese, S; Micheli, L; Nencini, C; Neri, A; Petrioli, R; Piccolomini, A; Prete, SD; Vuolo, G | 1 |
| Chen, LT; Chen, SC; Chuang, WL; Su, YC; Wu, WC | 1 |
| Boige, V; Ducreux, M; Malka, D | 2 |
| Stadler, WM | 1 |
| Castro Kreder, N; Franken, NA; Haveman, J; Peters, GJ; Rodermond, HM; Stalpers, LJ; van Bree, C; Zdzienicka, MZ | 1 |
| Cerretani, D; Cetta, F; Clerici, M; Correale, P; Francini, G; Giorgi, G; Guarnieri, A; Marsili, S; Messinese, S; Petrioli, R; Pinto, E; Savelli, V | 1 |
| Akiyama, T; Doi, T; Hirata, K; Homma, H; Katsuki, S; Machida, T; Mezawa, S; Murakami, K; Sato, T; Takanashi, K | 1 |
| Alakavuklar, M; Coker, A; Oztop, I; Sagol, O; Tarhan, O; Yaren, A; Yavuzsen, T; Yilmaz, U | 1 |
| Cesák, T; Kohlová, T; Melichar, B; Nová, M; Urminská, H | 1 |
| Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Aoki, K; Matsumura, Y; Okusaka, T | 1 |
| Bhalla, KN; Gillespie, TW; Harris, WB; Kooby, D; Landry, J; Meyers, M; Small, W; Staley, CA | 1 |
| Allendorf, JD; Chabot, JA; Chen, J; Ennis, RD; Fine, RL; Fogelman, DR; Schreibman, SM; Schrope, BA | 1 |
| Duan, XN; Liu, YH; Shen, WJ; Wan, YL; Wang, DM; Yang, YM; Yu, SP; Zhou, G | 1 |
| Cooper, H; Eisenberg, BL; Freedman, G; Hoffman, JP; Meropol, NJ; Pingpank, JF; Ross, EA; Sasson, AR; Wetherington, RW | 1 |
| Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S | 1 |
| A'hern, R; Eisen, T; Gore, M; Hackett, S; James, M; Moss, C; Pyle, L; Waters, JS | 1 |
| Hirai, I; Kawago, M; Kokawa, Y; Nishida, M; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T; Yuzaki, M | 1 |
| Baba, Y; Ishikawa, T; Kamimura, T; Mizuno, K; Oota, H; Watanabe, K; Yoshida, T | 1 |
| Hobbs, KB; Kroll, DJ; Seewaldt, VL; Shaw, HS | 1 |
| Lordick, F | 1 |
| Barauskas, G; Brasiūnas, V; Brasiūniene, B; Juozaityte, E | 1 |
| Dono, K; Hashimoto, K; Kubota, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, H; Umeshita, K; Yamamoto, S | 1 |
| Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE | 1 |
| Brunner, TB; Meyer, T; Sauer, R; Schwab, D | 1 |
| Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX | 1 |
| Rini, BI; Small, EJ; Weinberg, V | 1 |
| Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M | 1 |
| Claude, L; Flandin, I; Khodri, M; Kubas, A; Mazeron, R; Mornex, F; Partensky, C; Wautot, V | 1 |
| Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Takeyama, O; Usui, Y | 1 |
| Argiris, A; Haraf, DJ; Kao, J; Milano, MT; Mittal, BB; Salama, JK; Stenson, KM; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Chikamoto, A; Hiraoka, T; Ikeda, O; Imuta, M; Kanemitsu, K; Kudo, K; Nakahara, O; Takamori, H; Tanaka, H; Tsuji, T; Yamashita, Y | 1 |
| Chen, E; Feld, R; Hedley, D; Knox, JJ; Moore, MJ; Nematollahi, M; Oza, A; Pond, GR; Siu, LL; Zhang, J | 1 |
| Büchler, MW; Erkan, M; Esposito, I; Friess, H; Giese, NA; Giese, T; Ketterer, K; Kleeff, J | 1 |
| Dühmke, E; Heinemann, V; Thoma, M; Weingandt, H; Wilkowski, R | 1 |
| Buck, M; Byrne, MJ; Cameron, F; De Melker, Y; Dewar, J; Joseph, D; Lund, H; Newman, M; Phillips, M; Powell, A; Spry, N; Van Hazel, G | 1 |
| Choi, SB; Kim, SR; Lee, HY; Yuh, YJ | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Aldrighetti, L; Balzano, G; Bonetto, E; Bordonaro, R; Cordio, S; Di Carlo, V; Galli, L; Luppi, G; Milandri, C; Nicoletti, R; Oliani, C; Passardi, A; Passoni, P; Reni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Barauskas, G; Brasiūniene, B; Juozaityte, E | 1 |
| Jaglowski, JR; Leure-Dupree, AE; McLaughlin, PJ; Smith, JP; Verderame, MF; Zagon, IS | 1 |
| Berdzik, J; Creaven, PJ; Hoffman, JL; Intengan, ME; Javle, MM; Khushalani, N; Litwin, AM; Pendyala, L; Ramnath, N; Rustum, YM; Slocum, HK; Smith, PF; Stewart, CC; Toth, K | 1 |
| Belcheva, A; Ellis, LM; Evans, DB; Fan, F; Gallick, GE; Gray, MJ; Klagsbrun, M; Liu, W; McCarty, MF; Somcio, R; Stoeltzing, O; Wey, JS | 1 |
| Thongprasert, S | 1 |
| Barletta, E; Carlini, P; Di Costanzo, F; Doni, L; Gasperoni, S; Iop, A; Massidda, B; Mattioli, R; Moscetti, L; Recchia, F; Tralongo, P | 1 |
| Lutz, MP | 1 |
| Brachtel, EF; Brugge, WR; Fernandez-del Castillo, C; Ryan, DP; Sahani, D; Willett, CG | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Ben-Josef, E; Chang, AE; Colletti, LM; Hejna, GF; Lawrence, TS; McGinn, CJ; Normolle, DP; Schneider, BJ; Zalupski, MM | 1 |
| Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A | 1 |
| Aquino, A; Bonmassar, E; Caraglia, M; Correale, P; Cusi, MG; Del Vecchio, MT; Formica, V; Francini, G; Giorgi, G; La Placa, M; Micheli, L; Montagnani, F; Nencini, C; Prete, S; Prete, SP; Terrosi, C; Tsang, KY | 1 |
| Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A | 1 |
| Balzano, G; Bonetto, E; Di Carlo, V; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Philip, PA | 1 |
| Bubis, JA; Dragnev, KH; Rigas, JR | 1 |
| Ikeda, H; Ikeda, M; Ito, Y; Kagami, Y; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H | 1 |
| Bajardi, E; Caraglia, M; Carli, AF; Cicero, G; Correale, P; Del Prete, S; Francini, G; Fulfaro, F; Gebbia, N; Greco, E; Intrivici, C; Marsili, S; Vuolo, G | 1 |
| Aquino, A; Bonmassar, E; Correale, P; Cusi, MG; Del Vecchio, MT; Ferrari, F; Francini, G; Giorgi, G; Intrivici, C; Marsili, S; Micheli, L; Nencini, C; Placa, ML; Tsang, KY | 1 |
| Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP | 1 |
| Furuse, J; Gotohda, N; Ishii, H; Kinoshita, T; Konishi, M; Nakachi, K; Nakagohri, T; Suzuki, E; Takahashi, S; Yoshino, M | 1 |
| Cho, JY; Lee, DK; Lee, SJ; Nam, JS; Paik, YH; Park, MS; Yoon, DS; Yu, JS | 1 |
| Eklund, JW; Mulcahy, MF; Trifilio, S | 1 |
| Berlin, JD | 1 |
| Brom, R; Candelaria, M; Cantu, D; Cetina, L; Chanona, J; de la Garza, J; Dolores, R; Duenas-Gonzalez, A; Gonzalez, A; Lopez-Graniel, C; Uribe, J | 1 |
| Büchler, MW; di Mola, FF; Di Sebastiano, P; Felix, K; Friess, H; Giese, NA; Hartel, M; Hinz, U; Mascetta, G; Selvaggi, F; Wente, MN | 1 |
| Cunningham, D; Hill, A; Maisey, NR; Massey, A; Norman, AR; Oates, J | 1 |
| Ko, AH; Tempero, MA | 2 |
| Baba, H; Matsumoto, G; Okamoto, A; Shimada, Y; Tsurta, K | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS | 1 |
| Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA | 1 |
| Adusumilli, PS; Chan, MK; Chou, TC; Eisenberg, DP; Fong, Y; Hendershott, KJ; Mullerad, M; Yu, Z | 1 |
| Chang, YS; Cho, JY; Chung, JB; Lee, DK; Lee, SJ; Paik, YH; Park, MS; Song, SY; Yoon, DS; Yu, JS | 1 |
| Barstis, JL; Black, AC | 1 |
| Bai, LY; Chen, PM; Poh, SB | 1 |
| Flores, AM; Rocha Lima, CM | 1 |
| Fumoleau, P; Levy, C | 1 |
| Aguilar, EA; Carbonero, AI; Delgado, FJ; Espinosa, JC; García López, JL; García Ribas, I; García, JJ; Guzmán, MC; Jericó, JF; Martos, CF; Mena, AC; Muñoz, ML; Plazas, JG; Rovira, PS; Santasusana, JM; Valera, JS | 1 |
| Bruns, C; Dühmke, E; Heinemann, V; Thoma, M; Wilkowski, R | 1 |
| Bassi, C; Boz, G; De Paoli, A; Falconi, M; Innocente, R; Pederzoli, P; Rossi, C; Tosolini, GC; Trovò, MG | 1 |
| Bekaii-Saab, TS; Chen, CS; Li, J; Melvin, WS; Muscarella, P; Zhu, J | 1 |
| Akiyama, T; Homma, H; Mezawa, S; Takahashi, S | 1 |
| Arii, S; Nakamura, N; Teramoto, K | 1 |
| Danquah, G; Jacobs, MJ; Mittal, VK; Ng, J; ReMine, SG; Saidi, RF; Williams, F | 1 |
| Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
| Muss, HB; Perez, E | 1 |
| Ando, K; Kamata, T; Kitabayashi, H; Ochiai, T; Shimada, H; Tsujii, H; Yamada, S; Yasuda, S | 1 |
| Chua, YJ; Cunningham, D | 1 |
| Crane, CH; Evans, DB; Pisters, PW; Varadhachary, G; Wolff, RA | 2 |
| de Jager, J; Stebbing, J | 1 |
| Dieringer, P; Jonasch, E; Mathew, P; Pagliaro, LC; Rodney, A; Tannir, N | 1 |
| Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Yoon, SJ; Yoon, SM | 1 |
| Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M | 1 |
| Hirono, S; Ina, S; Kawai, M; Tani, M; Terasawa, H; Uchiyama, K; Yamaue, H | 1 |
| Brueckl, WM; Brunner, TB; Grabenbauer, GG; Meyer, T; Sauer, R; Tinkl, D | 1 |
| Chen, Z; Jian, Z; Li, J; Li, X; Li, Y; Lv, X; Pei, H; Xia, K | 1 |
| Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T | 1 |
| Chang, JY; Chao, Y; Chen, LT; Cheng, AL; Chuang, TR; Hsu, C; Hsu, CH; Jan, CM; Liu, TW; Shiah, HS; Whang-Peng, J; Yu, WL | 1 |
| Büchler, P; Ganten, TM; Haas, TL; Koschny, R; Schader, MB; Schulze-Bergkamen, H; Stremmel, W; Sykora, J; Untergasser, A; Walczak, H | 1 |
| Funakoshi, A; Sumii, T | 1 |
| Ch'ang, HJ; Chang, JY; Chang, MC; Chen, LT; Cheng, AL; Hsu, C; Lin, JT; Liu, TW; Lu, YS; Shiah, HS; Wang, CC; Wang, HP; Whang-Peng, J | 1 |
| Berrios, M; Cordova, A; de Aretxabala, X; Gallardo, J; Hepp, J; Leon, J; Maluenda, F; Roa, I; Roa, JC | 1 |
| Gibb, RK; Hagemann, A; Mutch, DG; Norris, L; Powell, MA; Rader, JS; Viviano, D; Wright, JD | 1 |
| Cavallo, D; Colombi, A; Giglio, M; Iavicoli, S; Marinaccio, A; Ursini, CL | 1 |
| Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D | 1 |
| Ito, Y; Tokudome, N | 1 |
| Smith, IE | 1 |
| A-Hon, K; Kamiyama, Y; Komiyama, Y; Satoi, S; Takahashi, H; Takahashi, K; Takai, S; Terakawa, N; Yanagimoto, H | 1 |
| Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A | 2 |
| Bruns, C; Heinemann, V; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Endo, I; Fujii, Y; Ichikawa, Y; Kubota, T; Miura, Y; Shimada, H; Tanaka, K; Togo, S; Ueda, M | 1 |
| Bonetto, E; Bordonaro, R; Cereda, S; Cordio, S; Di Carlo, V; Galli, L; Johnson, CD; Milandri, C; Passoni, P; Reni, M; Spreafico, A; Staudacher, C | 1 |
| Goldstein, D; Karapetis, C; Steer, CB; Strickland, A; Yip, D | 1 |
| Hirakawa, K; Ren, J; Yashiro, M; Zhang, X | 1 |
| Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, S; Tsujie, M; Umeshita, K | 1 |
| Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H | 1 |
| Neoptolemos, JP; Smith, DB | 1 |
| Barrier, R; Davila, E; Ernstoff, MS; Halabi, S; Picus, J; Rini, B; Small, EJ; Stadler, WM | 1 |
| Bellone, G; Bertetto, O; Buffolino, A; Busso, V; Carbone, A; Emanuelli, G; Novarino, A; Scirelli, T; Smirne, C; Tosetti, L | 1 |
| Nagaoka, S; Okabe, Y; Ono, N; Saito, F; Sata, M; Suga, H; Toyonaga, A; Tsuruta, O | 1 |
| Baba, Y; Ishikawa, N; Ishikawa, T; Kamimura, T; Mafune, Y; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Ushiki, T; Watanabe, K; Yoshida, T | 1 |
| Jackisch, C | 1 |
| Behrens, R; Buechner-Steudel, P; Fleig, WE; Kleber, G; Kuss, O; Lindig, U; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Chen, G; Chen, H; Friess, H; Greenblatt, DY; Guo, J; Kleeff, J; Leung, PS; Liao, Q; Shen, S; Zhao, Y | 1 |
| Chen, G; Guo, JC; Jiang, H; Niu, BZ; Wu, WW; Zhang, LY; Zhao, YP | 1 |
| Bleeker, G; Henson, R; Meng, F; Naus, PJ; Patel, T; Wehbe, H | 1 |
| Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA | 1 |
| Brasiūnas, V; Brasiūniene, B; Juozaityte, E | 1 |
| Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y | 1 |
| Lee, AW; Ng, WT; Pang, ES; Soong, IS; Wong, DH; Yau, TK; Yeung, RM | 1 |
| Ahmad, SA; Firdaus, I; Howington, JA; James, L; Jazieh, AR; Lowy, AM; Redmond, K; Reed, MF; Rose, P; Roychowdhury, D; Safa, M; Sussman, JJ | 1 |
| Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H | 1 |
| Leoni, V; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Cengel, KA; Plastaras, JP | 1 |
| Siefker-Radtke, A | 1 |
| Earle, CC; Krzyzanowska, MK; Kuntz, KM; Weeks, JC | 1 |
| Neifeld, JP | 1 |
| Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H | 1 |
| Fujiwara, T; Gochi, A; Kagawa, S; Tanaka, N; Teraishi, F; Uno, F | 1 |
| de Gelder, V; De Ridder, L; De Vos, F; Lambert, B; Slegers, G; Thierens, H; Van de Wiele, C | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
| Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T | 1 |
| Lahans, T | 1 |
| Bae, DS; Choi, CH; Huh, SJ; Kim, BG; Kim, TJ; Kim, WY; Lee, JH; Lee, JW; Nam, HR | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Lee, HR; Lee, J; Lee, JK; Lee, KT; Lim, DH; Lim, HY; Park, BB; Park, JO; Park, K; Park, YS | 1 |
| Cheng, B; Liu, K; Qiu, DB; Wang, GB | 1 |
| Kindler, HL | 1 |
| Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J | 1 |
| Ikemoto, T; Imura, S; Miyake, K; Morine, Y; Shimada, M; Yoshizumi, T | 1 |
| Brunetti, E; Bucci, B; Michienzi, S; Misiti, S; Panacchia, L; Patriarca, V; Stigliano, A; Toscano, V; Verga Falzacappa, C | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Kim, R; Saif, MW | 1 |
| Moore, MJ; Welch, SA | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Cina, S; Dietrich, D; Figer, A; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, B; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Janjan, NA; Krishnan, S; Rana, V; Varadhachary, GR; Wolff, RA | 1 |
| Fukushima, M; Maruyama, R; Nio, Y; Toga, T | 1 |
| Cereda, S; Galli, L; Reni, M | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 2 |
| El-Rayes, B; Griffith, KA; Kalemkerian, GP; Muler, JH; Philip, PA; Schneider, BJ; Zalupski, MM | 1 |
| Gemma, A; Kawakami, A; Kudoh, S; Li, C; Matsuda, K; Minegishi, Y; Noro, R; Ogawa, N; Seike, Y; Shionoya, A | 1 |
| Chin, SN; Knox, JJ; Pond, GR; Riechelmann, RP; Townsley, CA | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E | 1 |
| Chen, GY; Hong, X; Lu, L; Wang, M; Yang, ZY; Zhang, CH | 1 |
| Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E | 1 |
| Blackstock, AW; Butler, J; Ove, R; Russo, S | 1 |
| Abou-Alfa, GK; O'Reilly, EM | 1 |
| Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD | 1 |
| Amato, RJ; Khan, M | 1 |
| Fakih, M; Gibbs, J; Iyer, RV; Javle, MM; Kepner, J; Kuvshinoff, B; Lawrence, D; Soehnlein, N | 1 |
| Allendorf, JD; Bill, A; Chabot, JA; DiGiorgi, M; Fine, RL; Goetz, N; Hall, M; Lauerman, M; Remotti, H; Schrope, B; Sherman, W; Vakiani, E | 1 |
| André, T; Blanchard, P; Huguet, F | 1 |
| Alberici, F; Bongiovanni, C; Brighenti, M; Buti, S; Buzio, C; Chiesa, MD; Passalacqua, R | 1 |
| Dong, P; Jiang, AC; Li, L; Wan, Y; Yu, ZW | 1 |
| Fu, de L; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yu, XJ | 1 |
| Blum, HE; Harder, J; Kummer, O; Olschewski, M; Opitz, O; Otto, F | 1 |
| Ghaneh, P; Neoptolemos, JP; Raraty, M; Smith, R; Tudor-Smith, C | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Saisho, H; Sato, T; Tanaka, K; Yamao, K; Yonemoto, N | 1 |
| Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Boeck, HP; Boeck, S; Geissler, M; Golf, A; Heinemann, V; Hochhaus, A; Hoehler, T; Kettner, E; Ko, Y; Kojouharoff, G; Lordick, F; Mahlberg, R; Neugebauer, S; Schmid, B; Schoppmeyer, K; Seipelt, G; Stauch, M; Wein, A | 1 |
| Brasiūniene, B; Juozaityte, E | 1 |
| Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A | 1 |
| Bjerregaard, JK; Pfeiffer, P | 1 |
| Borg, M; Carroll, S; Davies, T; Goldstein, D; Graham, P; Harvey, J; Iacopetta, B; Kneebone, A; Macleod, C; Millar, JL; Ngan, SY; Reece, WH; Spry, N; Zissiadis, Y | 1 |
| Rödel, C; Sauer, R; Weiss, C | 2 |
| Chang, HM; Cho, JY; Do, YR; Hong, DS; Kim, SY; Kim, YH; Lee, KE; Lee, KH; Ryu, MH; Song, HS | 1 |
| Benson, AB; Small, W; Wahl, AO; Wisinski, KB | 1 |
| Endlicher, E; Golder, S; Grossmann, J; Herfarth, H; Herold, T; Kullmann, A; Kullmann, F; Schlottmann, K; Troppmann, M | 1 |
| Araki, H; Kamiyama, Y; Matsui, Y; Satoi, S; Sohgawa, M; Takahashi, K; Takai, S; Terakawa, N; Toyokawa, H; Yanagimoto, H | 1 |
| Alkis, N; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Er, O; Uner, A; Yamac, D; Yildiz, R | 1 |
| Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P | 1 |
| Bajetta, E; Bodoky, G; Dietrich, D; Figer, A; Glimelius, B; Grawe, P; Herrmann, R; Hess, V; Ruhstaller, T; Saletti, P; Scheithauer, W | 1 |
| Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Takeda, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T | 1 |
| Ikeda, H; Kobayashi, M; Morita, T; Nakano, K; Nukui, A; Sugaya, Y; Suzuki, K; Yuzawa, M | 1 |
| Afchain, P; André, T; Balosso, J; Dupuis, O; Huguet, F; Lledo, G; Louvet, C; Mineur, L; Moureau-Zabotto, L; Phélip, JM; Touboul, E; Vendrely, V | 1 |
| Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA | 1 |
| Correale, P; Francini, G; Miano, S; Montagnani, F; Pascucci, A; Petrioli, R; Sciandivasci, A; Tanzini, G; Testi, W | 1 |
| Chie, EK | 1 |
| Kim, YT | 1 |
| Hayashi, T; Homma, H; Ihara, H; Ishiwatari, H; Kato, J; Kawano, Y; Matsunaga, T; Miyanishi, K; Niitsu, Y; Okuda, T; Sato, Y; Takada, K; Takahashi, M; Takahashi, S; Takanashi, K | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A | 1 |
| Rocha-Lima, CM | 1 |
| Bacigalupo, A; Benasso, M; Corvò, R; Marcenaro, M; Margarino, G; Ponzanelli, A; Vigo, V | 1 |
| Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R | 1 |
| Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K | 1 |
| Hezel, AF; Zhu, AX | 1 |
| Bertoldi, I; Correale, P; Fioravanti, A; Francini, G; Miracco, C; Montagnani, F | 1 |
| Aparicio, T; Azzedine, A; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Bevilacqua, G; Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Del Tacca, M; Funel, N; Giovannetti, E; Mey, V; Mosca, F; Nannizzi, S; Pollina, LE; Ricciardi, S | 1 |
| Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W | 1 |
| Erovic, BM; Heiduschka, G; Kloimstein, P; Martinek, H; Selzer, E; Skoda, C; Thurnher, D; Vormittag, L; Wachek, V; Wrba, F | 1 |
| Alschuler, L; Block, KI; Gyllenhaal, C; Kranz, S; Roddy, GD; Rubin, D | 1 |
| Brenner, WS; Fournier, C; Fracasso, PM; Gao, F; James, J; Marsh, S; McLeod, HL; Picus, J; Tan, BR; Yen-Revollo, JL | 1 |
| Barbarot, V; Courant-Menanteau, M; Lewden-Bernadac, B; Perrocheau, G; Thomare, P | 1 |
| Eley, HL; McDonald, PS; Russell, ST; Tisdale, MJ | 1 |
| Vikram, B | 1 |
| Fujita, T | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Starling, N; Sultana, A; Tudur Smith, C | 1 |
| Correale, P; Cusi, MG; Del Vecchio, MT; Fioravanti, A; Francini, E; Francini, G; Ginanneschi, C; Martellucci, I; Montagnani, F; Remondo, C; Rotundo, MS; Tagliaferri, P; Tassone, P | 1 |
| Hee, SW; Leong, SS; Lim, WT; Poon, D; Rajan, S; Tan, EH; Tay, MH; Toh, CK; Wee, J | 1 |
| Jonasch, E; Mathew, P; Ng, CS; Pagliaro, L; Siefker-Radtke, A; Tannir, NM; Thall, PF; Wang, X; Wood, C; Wooten, L | 1 |
| Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY | 1 |
| Saif, MW | 3 |
| Akhmedjanova, V; Aubert, C; Ciccolini, J; Ea, S; Giacometti, S | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Dietrich, D; Figer, A; Gerber, D; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, BC; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F | 1 |
| Arizumi, M; Arizumi, T; Hirano, K; Isayama, H; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T | 1 |
| Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J | 1 |
| Bang, S; Chung, JB; Kim, YJ; Park, JY; Park, SW; Song, SY | 1 |
| Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| Boehm, KA; Cartwright, T; Richards, DA | 1 |
| Donahue, B; Hiotis, SP; Hochster, HS; Marti, JL; Newman, E; Ryan, T | 1 |
| Kayahara, M; Kitagawa, S; Minato, H; Mouri, H; Ohta, T; Ohtsubo, K; Tsuchiyama, T; Watanabe, H | 1 |
| Alberti, DB; Attia, S; Bailey, HH; Campbell, TC; Cleary, JF; Eickhoff, JC; Holen, KD; Huie, MS; Liu, G; McFarland, TA; Morgan-Meadows, S; Mulkerin, DL; Schelman, WR; Tevaarwerk, AJ; Traynor, AM; Wilding, G | 1 |
| Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K | 1 |
| Saif, MW; Wasif, N | 1 |
| Abrams, R; Ammar, A; Benson, AB; Cass, CE; Dicker, AP; Elsaleh, H; Farrell, JJ; Garcia, M; Lai, R; Macdonald, J; Mackey, JR; Regine, WF | 1 |
| Boku, N; Fukutomi, A; Hashimoto, T; Hironaka, S; Nishimura, T; Onozawa, Y; Taira, K; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Cardenal Escarcena, A; Fernández Sarabia, MT; García Bernardo, L; Rodríguez García, JM; Serrano Vicente, J | 1 |
| Twombly, R | 1 |
| Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J | 1 |
| Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP; Salanti, G | 1 |
| Dilulio, J; Ganju, V; Khamly, K; Leong, T; Matera, A; Michael, M; Milner, AD; Muller, A; Ngan, SY; Price, T; Strickland, AH; Zalcberg, JR | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, MJ; Kim, TY; Lee, SH; Oh, DY | 1 |
| Hollender, J; Kovalova, L; McArdell, CS | 1 |
| Kitade, H; Kwon, AH; Matsui, Y; Mergental, H; Satoi, S; Takahashi, K; Takai, S; Tanigawa, N; Toyokawa, H; Yanagimoto, H | 1 |
| Crane, CH; Evans, DB; Fleming, JB; Settle, SH; Varadhachary, G; Wolff, RA | 1 |
| Foo, KF; Wang, ML | 1 |
| Braconi, C; Henson, R; Lang, M; Patel, T | 1 |
| Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ | 1 |
| Antón, A; Carrasco, E; Chan, S; Delozier, T; du Bois, A; Frimodt-Moller, B; Fumoleau, P; Harrison, M; Huober, J; Jones, A; Kreienberg, R; Llombart, A; Lluch, A; Mayordomo, JI; Romieu, G; Schneeweiss, A; Tubiana-Hulin, M; Vaury, AT | 1 |
| Dörken, B; Hilbig, A; Oettle, H; Pelzer, U; Riess, H; Roll, L; Stieler, J | 1 |
| Favaudon, V; Hennequin, C; Quero, L | 1 |
| Ch'ang, HJ; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Huang, CL; Hwang, TL; Jan, CM; Lin, JT; Shiah, HS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
| Aoshima, K; Kadowaki, T; Oda, Y; Tanaka, M; Tanaka, S; Uehara, T; Yokoi, A | 1 |
| Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS | 1 |
| Finn, RS; Zhu, AX | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Bantleon, R; Farkas, E; Kehlbach, R; Werner, M; Wiesinger, B; Wiskirchen, J | 1 |
| Ben-Josef, E; Chang, AE; Colletti, L; Desai, S; Francis, IR; Greenson, JK; Griffith, KA; Hampton, J; Lawrence, TS; Simeone, D; Zalupski, MM | 1 |
| Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM | 1 |
| Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B | 1 |
| Pawlega, J; Zygulska, AL | 1 |
| Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pezzuolo, D; Seta, RD; Tartarini, R; Torri, T | 1 |
| Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY | 1 |
| Sorscher, SM | 1 |
| Arima, K; Hasegawa, Y; Kise, H; Nishikawa, K; Soga, N; Sugimura, Y; Yamada, Y | 1 |
| Clark, JI; Crawford, DE; Gandour-Edwards, R; Hussey, M; Lange, MK; Lara, PN; Mack, PC; Van Veldhuizen, PJ | 1 |
| Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J | 1 |
| Bisegna, R; Bonfili, P; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F; Sica, G; Tombolini, V | 1 |
| Mistafa, O; Stenius, U | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Sargent, M; Schafer, C; Seufferlein, T | 1 |
| Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F | 1 |
| Li, J; Saif, MW | 2 |
| Sherman, WH | 1 |
| Choi, DW; Choi, SH; Heo, JS; Lee, HG; You, DD | 1 |
| Abbruzzese, JL; Arumugam, T; Choi, W; Fournier, KF; Gallick, GE; Logsdon, CD; Marquis, L; McConkey, DJ; Ramachandran, V; Wang, H | 1 |
| Alvarado-Miranda, A; Arrieta, O; Bargallo-Rocha, E; Gamboa-Vignolle, C; Lara-Medina, F; Morales-Barrera, R; Perez-Sanchez, V; Ramirez-Ugalde, T; Saavedra-Perez, D; Zinser-Sierra, J | 1 |
| Crane, CH; Curran, W; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, K; Wolff, RA | 1 |
| Hollender, J; Kovalova, L; Mcardell, CS; Moser, R; Ort, C; Pazhepurackel, V; Siegrist, H; Weissbrodt, D | 1 |
| Hoimes, C; Merl, M; Pham, T; Saif, MW | 1 |
| Alvarez Sánchez, MV; Alvarez, M; Baltar Arias, R; Gómez Martínez, P; Soto Iglesias, S; Vázquez Astray, E; Vázquez Rodríguez, S | 1 |
| Custodio, A; Díaz-Rubio, E; Puente, J; Sastre, J | 1 |
| Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Armesilla, AL; Brown, J; Darling, JL; Goessl, E; Guo, X; Pandey, S; Wang, W; Xu, B | 1 |
| Halldén, G | 1 |
| Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
| Han, DJ; Hwang, JY; Kim, JE; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, JS; Lee, SK; Lee, SS; Park, DH; Seo, DW; Yoo, C | 1 |
| Ahlgren, J; Ahlin, C; Carlsson, L; Hansen, J; Jansson, T; Malmberg, L; Malmström, A; Svensson, JH; Westberg, R | 1 |
| Bender, GP; Masellis, AM; Sielaff, TD | 1 |
| Andreu, J; Carles, J; Serrano, C; Suárez, C | 1 |
| Booth, CM; Eisenhauer, EA; Ohorodnyk, P | 1 |
| Adab, F; Chau, I; Crellin, A; Cunningham, D; Dunn, J; Eatock, M; Falk, S; Harper, PG; Herrmann, R; Leonard, P; Neoptolemos, JP; Ostrowski, J; Scheithauer, W; Smith, D; Steward, W; Stocken, DD; Thompson, J; Tudur-Smith, C; Valle, JW; West, J | 1 |
| Puglisi, F | 1 |
| Macarulla, T; Tabernero, J | 1 |
| Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Ito, Y; Karasawa, K; Kazumoto, T; Nemoto, K; Nishimura, Y; Nishino, S; Ogawa, K; Ogawa, Y; Ogo, E; Okuno, Y; Onishi, H; Shibuya, H; Shibuya, K; Uchida, N | 1 |
| Bergaglio, M; Ceribelli, A; De Placido, S; Del Prete, S; Di Lorenzo, G; Federico, P; Lalle, M; Marino, M; Merola, C; Merola, G; Milella, M; Montella, L; Palmieri, G; Petillo, L | 1 |
| Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Behl, S; Behrens, R; Buechner-Steudel, P; Fahlke, J; Fleig, WE; Kleber, G; Kuss, O; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Boeck, S; Boettcher, HD; Bruns, CJ; Fietkau, R; Flentje, M; Heinemann, V; Herbst, M; Hinke, A; Miethe, S; Ostermaier, S; Rau, HG; Sauer, R; Scholten, T; Wilkowski, R | 1 |
| Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C | 1 |
| Akahori, T; Doh, J; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Nomi, T; Sho, M; Tamamoto, T; Tanaka, T; Yamada, T; Yamato, I | 1 |
| Lillemoe, KD; Nakeeb, A; Simianu, VV; Zyromski, NJ | 1 |
| Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S | 1 |
| Gerhardt, T; Heller, J; Höblinger, A; Rings, D; Sauerbruch, T; Schepke, M | 1 |
| Gupta, S; Mallik, S; Munshi, A | 1 |
| Chandrasekhar, R; Fakih, M; Gibbs, JF; Iyer, RV; Khushalani, NI; May, KS; McCloskey, SA; Thomas, CR; Wilding, GE; Yang, GY; Yendamuri, SS | 1 |
| Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM | 1 |
| Cheung-Lau, G; Dawson, DW; Dawson, NA; Farrell, J; Guha, C; Hines, OJ; Horvath, S; Kurdistani, SK; Manuyakorn, A; Paulus, R; Reber, H; Seligson, DB; Tze, S | 1 |
| Bi, ZF; Chen, DL; Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD | 1 |
| Majumdar, AP; Patel, BB | 1 |
| Christians, K; Evans, DB; Lal, A | 1 |
| Backlund, DC; Berlin, JD; Parikh, AA | 1 |
| Albanell, J; Bellmunt, J; Calvo, E; Carles, J; Lázaro, M; López, R; Pérez-Gracia, JL; Rubió, J; Trigo, JM; Virizuela, JA | 1 |
| Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS | 1 |
| Amano, R; Hirakawa, K; Hirakawa, T; Nakao, S; Nakata, B; Okita, Y; Shinto, O; Tamura, T; Yamada, N | 1 |
| Boku, N; Fukuda, H; Fukutomi, A; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Nakamura, K; Ohkawa, S; Okusaka, T | 1 |
| Aldrighetti, L; Cereda, S; Nicoletti, R; Passoni, P; Reni, M; Viganò, MG; Villa, E | 1 |
| Albrecht, H; Boxberger, F; Hahn, EG; Hohenberger, W; Konturek, PC; Männlein, G; Ostermeier, N; Reulbach, U; Roehrig, S; Wein, A; Wolff, K | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F | 1 |
| Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Messersmith, WA; Murphy, KM; Nallapareddy, S; Norris-Kirby, A; Rudek, MA; Weekes, CD | 1 |
| Edina, M; László, L; Tamás, N | 1 |
| Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY | 1 |
| Grossgoupil, M; Ravaud, A | 1 |
| McIntosh, D; Shaukat, A | 1 |
| Cooke, EW; Hazard, L | 1 |
| Mehta, SP | 1 |
| Biasco, G; Brandi, G; Di Cicilia, R; Di Marco, M; Macchini, M; Nobili, E; Vecchiarelli, S | 1 |
| Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T | 1 |
| Correale, P; Del Vecchio, MT; Francini, G; Ginanneschi, C; Licchetta, A; Loiacono, L; Mannucci, S; Migali, C; Remondo, C; Rotundo, MS; Tagliaferri, P; Tassone, P; Tsang, KY | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Apetoh, L; Bruchard, M; Chalmin, F; Chevriaux, A; Ghiringhelli, F; Ladoire, S; Martin, F; Mignot, G; Rébé, C; Vincent, J | 1 |
| Chung, EK; Hahn, OM; Karrison, T; Kasza, K; Manchen, E; Posadas, EM; Stadler, WM | 1 |
| Glimelius, B | 1 |
| Alexander, R; David, V; Garofalo, M; Hanna, N; Jabbour, S; Pandya, N; Poppe, M; Regine, WF; Yovino, S | 1 |
| Abbruzzese, A; Arcuri, FP; Caraglia, M; Carducci, A; Correale, P; Del Vecchio, MT; Loiacono, L; Marra, M; Migali, C; Misso, G; Remondo, C; Tagliaferri, P; Tassone, P | 1 |
| Angeli, A; Badalamenti, G; Berruti, A; Daffara, F; De Francia, S; Del Buono, S; Dogliotti, L; Ferrero, A; Intrivici, C; Kalomirakis, E; Papotti, M; Priola, A; Ratti, R; Santini, D; Sperone, P; Terzolo, M; Vincenzi, B; Volante, M; Zaggia, B | 1 |
| Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R | 1 |
| DeMorrow, S; Frampton, GA; Lazcano, EA; Li, H; Mohamad, A | 1 |
| Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M | 1 |
| Benson, AB; Catalano, PJ; Cooper, H; Harris, W; Hoffman, J; Landry, J; Staley, C; Talamonti, M; Xu, N | 1 |
| Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Kadish, SP; McDade, TP; Piperdi, B; Piperdi, M; Shim, JK; Sullivan, ME; Tseng, JF; Whalen, GF | 1 |
| Blackman, G; Bridgewater, J; Collis, C; Gillmore, R; Goodchild, K; Laurence, V; Meyer, T; Raouf, S; Tobias, J | 1 |
| Blaha, L; Dott, W; Kovalova, L; Zounkova, R | 1 |
| Buti, S; Caminiti, C; Chiesa, MD; Donini, M; Lazzarelli, S; Lheshi, A; Mattioli, R; Mazza, G; Passalacqua, R; Re, GL; Simon, S; Simonelli, C | 1 |
| Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Isufi, I; Kaley, K; Saif, MW; Syrigos, K | 1 |
| Hu, Y; Liao, Q; Zhang, Q; Zhao, YP; Zhou, T | 1 |
| Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN | 1 |
| Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ | 1 |
| Brandt, R; Lane, HA; Lassota, P; McSheehy, PM; O'Reilly, T; Wartmann, M | 1 |
| Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N | 1 |
| Komori, S; Matsui, S; Mori, R; Osada, S; Sanada, Y; Takahashi, T; Tokuyama, Y; Tomita, H; Yamaguchi, K; Yoshida, K | 1 |
| Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M | 1 |
| Gong, W; He, Z; Jiang, J; Li, X; Qin, R; Shi, C; Tian, R; Wang, M; Wang, X; Zhang, Z | 1 |
| Bellone, G; Brondino, G; Ciuffreda, L; Cristiano, C; Giacobino, A; Novarino, A; Prati, A; Vizio, B | 1 |
| Fleming, JB; Katz, MH; Lee, JE; Pisters, PW | 1 |
| Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y | 1 |
| Giaccone, G; Rajan, A | 1 |
| Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R | 1 |
| Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L | 1 |
| Baumunk, D; Fotopoulou, C; Schmidt, SC; Schumacher, G | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Holzman, DC | 1 |
| Jonasch, E; Lim, ZD; Ng, C; Richey, SL; Tannir, NM | 1 |
| Anai, H; Hasegawa, M; Kichikawa, K; Maeda, S; Masada, T; Morimoto, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T; Yamamoto, K | 1 |
| Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J | 1 |
| Abrams, RA; Benson, AB; Hoffman, JP; Konski, AA; Lustig, R; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Aparicio, T; Azzedine, A; Barhoumi, M; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY | 1 |
| Atkinson, BJ; Byfield, SD; Feng, C; Jonasch, E; Lal, LS; Miller, LA; Pagliaro, LC; Tannir, NM | 1 |
| Paglino, C; Porta, C | 1 |
| Gill, S; Kim, C; Owen, D | 1 |
| Coban, I; El-Rayes, BF; Kauh, JS; Kneuertz, PJ; Kooby, DA; Maithel, SK; Sarmiento, J; Staley, CA; Volkan Adsay, N | 1 |
| Oberstein, PE; Saif, MW | 1 |
| Chang, BW; Saif, MW | 1 |
| Kang, SP; Saif, MW | 1 |
| Arnold, D; Dörken, B; Herrenberger, J; Kindler, M; Korsten, FW; Oettle, H; Pelzer, U; Reitzig, P; Riess, H; Stieler, J | 1 |
| Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY | 1 |
| Abenhardt, W; Brudler, O; Brugger, W; diGioia, D; Freier, W; Gitsch, G; Heinemann, V; Hurtz, HJ; Jonat, W; Kettner, E; Rösel, S; Stemmler, HJ; Tesch, H; Tessen, HW | 1 |
| Ch'ang, HJ; Chang, JY; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Chiu, YF; Hsieh, RK; Hsu, CH; Hwang, TL; Lin, PW; Lin, YL; Shan, YS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| Berlin, JD; Cardin, DB; Castellanos, EH | 1 |
| Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Park, JY | 1 |
| Centeno, B; Helm, J; Hodul, P; Hoffe, S; Kim, J; Klapman, J; Malafa, M; Patel, M; Springett, G; Valone, T | 1 |
| Anne, PR; Berger, AC; Chervoneva, I; Kennedy, EP; Mitchell, EP; Rosato, EL; Showalter, TN; Yeo, CJ; Zhan, T | 1 |
| Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP | 1 |
| Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C | 1 |
| Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M | 1 |
| Bassi, C; Cantore, M; Fiorentini, G; Mambrini, A; Orlandi, M; Torri, T | 1 |
| Adler, M; Dörken, B; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Stieler, J | 1 |
| Chen, YX; Lin, Y; Shi, J; Xie, WF; Zhu, CP | 1 |
| Bodoky, G; Ciuleanu, TE; La Stella, PJ; Pover, G; Spigel, DR; Tebbutt, NC; Timcheva, C | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Bergerat, JP; Delpeuch, A; Leveque, D; Rob, L | 1 |
| Fujita, H; Kurata, N; Mahawithitwong, P; Manabe, T; Mizumoto, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Sakai, H; Tanaka, M | 1 |
| Donders, AR; Oostendorp, LJ; Ottevanger, PB; Stalmeier, PF; van der Graaf, WT | 1 |
| Balaraman, S; Gustafson, G; Huang, J; Jury, R; Khilanani, P; Margolis, J; McIntosh, B; Nadeau, L; Robertson, JM | 1 |
| Bae, K; Dicker, AP; Elsaleh, H; Farrell, JJ; Guha, C; Wong, J | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Ellinger, S; Henne-Bruns, D; Klapperstueck, T; Knippschild, U; Kreyes, A; Landfester, K; Udelnow, A; Walther, P; Wohlrab, J; Würl, P | 1 |
| Bockhorn, M; Effenberger, KE; Güngör, C; Izbicki, JR; Kalinina, T; Vashist, YK; Yekebas, E; Zander, H | 1 |
| Blackstock, AW; Fuchs, CS; Goldberg, RM; Hollis, D; Mamon, HJ; Mayer, RJ; Niedzwiecki, D; Tan, BR; Tepper, JE | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
| Giannini, OH; González, ME; González, P; Saldaña, B | 1 |
| Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M | 1 |
| Brunner, TB; Fietkau, R; Sauer, R | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Lowery, MA; O'Reilly, EM | 1 |
| Bhattacharyya, M; Eddouadi, A; Francis, J; Halldén, G; Lemoine, NR | 1 |
| Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N | 1 |
| Milella, M; Sperduti, I; Vaccaro, V | 1 |
| Ko, AH | 1 |
| Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Sato, T; Sato, Y; Sonoda, T; Takimoto, R; Yoshida, M | 1 |
| Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I | 1 |
| Lorenz, J; Mössner, J; Thrum, S; Wiedmann, M | 1 |
| Kosuge, T | 1 |
| Bu, HJ; Chen, Y; Liu, QH; Ni, CY; Yu, DH; Zhang, J; Zhao, CY; Zhu, MH | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Kuo, YH; Tien, YW; Yang, SH | 1 |
| Fukunaga, K; Hirata, Y; Iida, H; Kakuno, A; Morita, M; Murata, S; Nishigami, T; Tamura, M; Tani, S; Yamanaka, N | 1 |
| Abbruzzese, J; Abdalla, EK; Balachandran, A; Bhosale, P; Charnsangavej, C; Chopin-Laly, X; Crane, CH; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Varadhachary, G; Vauthey, JN; Wang, H; Wang, X; Wolff, R | 1 |
| Colucci, G; D'Amico, C; Di Lauro, L; Giannarelli, D; Giotta, F; Latorre, A; Mariani, L; Pizzuti, L; Sergi, D; Vici, P; Vizza, E | 1 |
| Anai, H; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T | 1 |
| Ben-Josef, E; Lawrence, TS | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Conroy, T; Mitry, E | 1 |
| Ackland, SP; Borg, M; Brown, C; Bydder, S; Carroll, S; Cummins, MM; Gebski, VJ; Goldstein, D; Harvey, J; Horvath, L; Hruby, G; Porter, IW; Selva-Nayagam, S; Shapiro, J; Spry, N; Underhill, C; van Hazel, GA; Wratten, C | 1 |
| Apetoh, L; Ghiringhelli, F; Martin, F | 1 |
| Arazi, L; Bittan, H; Cooks, T; Efrati, M; Horev-Drori, G; Keisari, Y; Kelson, I; Lazarov, E; Schmidt, M | 1 |
| Aydemir, I; Inan, S; Ozbilgin, K; Uluer, ET; Vatansever, HS | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Lau, PC; Ng, WT; Yu, SC; Zheng, SF | 1 |
| Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC | 1 |
| Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A | 1 |
| Konishi, M | 1 |
| de Ávila Lucas, AI; Domingo, E; Grande-Pérez, A; Gutiérrez-Rivas, M; López-Galíndez, C; Lorenzo-Redondo, R; Olivares, I; Sánchez-Jiménez, C; Toledano, V | 1 |
| Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Alexander, R; Goloubeva, O; Hanna, N; Herman, JM; Laheru, D; Maidment, BW; Pandya, N; Regine, WF; Schulick, R; Wolfgang, C; Yovino, S | 1 |
| Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V | 1 |
| Colantonio, I; Comino, A; Crook, T; Denaro, N; Gasco, M; Lattanzio, L; Lo Nigro, C; Merlano, M; Monteverde, M; Natoli, G; Russi, E; Syed, N; Vivenza, D | 1 |
| Hansen, TF; Jakobsen, A; Jensen, LH; Lindebjerg, J; Ploen, J | 1 |
| Chahine, G; Farhat, F; Ghosn, M; Kattan, J; Nasr, F; Saroufim, A | 1 |
| Choi, M; Kim, R; Saif, MW | 1 |
| Baschnagel, A; Jury, R; Margolis, J; Nadeau, L; Robertson, JM; Shah, C; Stein, J | 1 |
| Govindarajan, R; Hung, SW; Mody, HR | 1 |
| Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Takasu, A | 1 |
| Colucci, G; Di Maio, M; Giuliani, F; Perrone, F | 1 |
| Iwasaki, H; Kai, M; Katano, M; Morifuji, Y; Onishi, H; Suyama, K | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Borg, M; Goldstein, D; Halkett, G; Kneebone, A; Reece, W; Short, M; Spry, N; Zissiadis, Y | 1 |
| Audrain, O; Boucher, E; Boudjema, K; Le Roux, G; Manfredi, S; Mesbah, H; Pracht, M; Raoul, JL; Sulpice, L | 1 |
| Abbruzzese, A; Apollinari, S; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Cusi, MG; Misso, G; Pastina, P; Sperlongano, P; Tagliaferri, P; Tassone, P | 1 |
| Gu, MF; He, LJ; Li, JJ; Liu, LZ; Luo, GY; Xu, GL; Yan, CX; Yuan, WX; Zhang, HM; Zhang, R | 1 |
| Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK | 1 |
| Gradishar, WJ | 1 |
| Chen, Y; Liang, X; Lin, C; Luan, Q; Ma, F; Meng, X; Pei, W; Qian, H; Wang, H; Zhan, Q; Zhang, X; Zhao, P; Zhao, Z; Zhou, S | 1 |
| Inaba, Y; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Tanaka, T | 1 |
| El-Rayes, BF; Zafar, SF | 1 |
| Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH | 1 |
| Cai, XY; Cai, YC; Cao, Y; Hu, WH; Jiang, WQ; Jin, Y; Shi, YX; Xia, XY; Zhang, WD | 1 |
| Costello, E; Greenhalf, W; Neoptolemos, JP | 1 |
| Jiang, C; Li, YX; Shen, H; Yi, XP | 1 |
| Bekaii-Saab, TS; Bloomston, M; Ellison, EC; Kleiber, B; Li, X; Martin, LK; Zalupski, M | 1 |
| Baake, G; Boeck, S; Clemens, MR; Gauler, TC; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Höhler, T; Jung, A; Kettner, E; Klein, S; Ko, YD; Kojouharoff, G; Märten, A; Neugebauer, S; Rubanov, O; Vehling-Kaiser, U; von Weikersthal, LF; Waldschmidt, D; Winkelmann, C | 1 |
| Bertetto, O; Ceccarelli, M; Chiappino, I; Ciccone, G; Ciuffreda, L; Giacobino, A; Napoletano, R; Novarino, AM; Satolli, MA; Schena, M | 1 |
| Anthoney, A; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Cox, TF; Dervenis, C; Ghaneh, P; Glimelius, B; Halloran, CM; Lacaine, F; Lerch, MM; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Smith, D; Tebbutt, NC; Valle, JW; Verbeke, CS | 1 |
| Chang, YS; Cho, SH; Kang, SY; Kim, JH; Kim, MH; Kim, MY; Kim, SH; Kim, YJ; Lee, JS; Lee, KW; Lee, SY; Min, KU; Song, WJ; Yang, MS | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Hwang, JH; Im, SA; Kim, JH; Kim, JS; Kim, TY; Lim, JH; Yoon, YB | 1 |
| Abo, T; Isomoto, H; Nagayasu, T; Nanashima, A; Nonaka, T; Nonaka, Y; Uehara, M | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Hong, GB; Li, CY; Song, LQ; Sun, HB; Zhou, JX | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ | 1 |
| Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V | 1 |
| Drebin, JA; Pippin, JA; Singla, S | 1 |
| Alexandrescu, S; Becheanu, G; Buica, F; Croitoru, A; Diculescu, M; Dinu, I; Gheorghe, L; Gramaticu, I; Herlea, V; Hrehoret, D; Luca, I; Lupescu, I; Popescu, I; Simionov, I | 1 |
| Casado, FJ; Molina-Arcas, M; Pastor-Anglada, M; Pérez-Torras, S; Trigueros-Motos, L | 1 |
| Aguilar-Ponce, JL; Alvarez-Avitia, MA; Arrieta, O; Castillo-Hernández, C; Cruz López, JC; De la Garza-Salazar, J; González-Ramírez, I; Granados-García, M; Lara-Cruz, G; Maldonado-Magos, F; Martinez-Juárez, I; Medina-Santillan, R | 1 |
| Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG | 1 |
| Cha, BH; Hwang, JH; Jeong, SH; Kim, JE; Kim, JW; Kim, N; Lee, DH; Lee, SH; Park, YS; Yoo, JY | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Barner, M; Boeck, S; Clemens, MR; Egg, R; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Goritschan, C; Greten, TF; Heinemann, V; Jung, A; Kirchner, T; Klein, S; Kojouharoff, G; Laubender, RP; Mansmann, U; Märten, A; Neumann, J; Vehling-Kaiser, U; Winkelmann, C | 1 |
| Apetoh, L; Boireau, W; Bruchard, M; Chalmin, F; Chevriaux, A; Connat, JL; Derangère, V; Ghiringhelli, F; Kanellopoulos, J; Martin, F; Mignot, G; Rébé, C; Ryffel, B; Simon, B; Végran, F | 1 |
| Krug, S; Michl, P | 1 |
| Bischoff, S; Caca, K; Kubicka, S; Nehls, O; Pelzer, U; Riess, H; Sinn, M; Stieler, JM; von Weizsäcker, F | 1 |
| Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ | 1 |
| Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M | 1 |
| Knox, JJ; Zhu, AX | 1 |
| Chiorean, EG; Hardacre, JM; Krishnamurthi, S; Lenz, HJ; Mulcahy, M; Obel, J; Rocha-Lima, CS; Safran, H; Small, W; Talamonti, M | 1 |
| Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H | 1 |
| Itami, J; Ito, Y; Kondo, S; Mayahara, H; Morizane, C; Morota, M; Murakami, N; Okusaka, T; Sumi, M; Ueno, H | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Hasuike, Y; Hirao, S; Iwagami, Y; Kira, T | 1 |
| Akahori, T; Hokutoh, D; Kinoshita, S; Nakajima, Y; Nomi, T; Sho, M; Yamato, I; Yasuda, S | 1 |
| Shurin, MR | 1 |
| Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N | 1 |
| Cai, H; Canto, MI; Chang, KJ; Donehower, RC; Herman, JM; Hoffe, SE; Klapman, J; Laheru, DA; Pawlik, TM; Reid, T; Rosemurgy, A; Savage, DT; Shah, RJ; Taylor, GE; Tran, PT; Wang, H; Wild, AT; Wolfgang, CL; Ziegler, MA | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Rieken, S; Schirmacher, P; Welzel, T; Werner, J | 1 |
| Ciccolini, J; Evrard, A; Lacarelle, B | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HJ; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Oh, DY; Yoon, YK | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Chau, I; Cunningham, D; Hubner, RA; Worsnop, F | 1 |
| Abrams, RA; Bridgewater, J; Crosby, T; Cummins, S; Falk, S; Griffiths, G; Hurt, CN; Jephcott, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Radhakrishna, G; Ray, R; Roy, R; Staffurth, J; Wasan, H | 1 |
| Büchler, MW; Combs, SE; Diener, MK | 1 |
| Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Einsele, H; Germer, CT; Hartlapp, I; Isbert, C; Kenn, W; Kunzmann, V; Müller, J; Scheurlen, M; Steger, U | 1 |
| Drebin, JA; Feldman, MD; Giantonio, BJ; Ginsberg, G; Harlacker, K; Heitjan, DF; Kochman, ML; Metz, JM; O'Dwyer, PJ; Plastaras, JP; Sohal, DP; Sun, W; Teitelbaum, UR | 1 |
| Barzotti, E; Drudi, F; Fantini, M; Gianni, L; Giuliani, J; Lotti, N; Ravaioli, A; Ridolfi, C; Santelmo, C; Tamburini, E; Tassinari, D | 1 |
| Chatzaki, E; Constantinidis, TC; Darwiche, K; Domvri, K; Kakolyris, S; Karamanos, NK; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Scheithauer, W; Van Cutsem, E | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Dolgikh, SD; Gapbarov, ACh; Polysalov, VN; Veriasova, NN | 1 |
| El-Hadaad, HA; Wahba, HA | 1 |
| Conter, HJ; Lim, ZD; Millikan, RE; Ng, CS; Tannir, NM | 1 |
| Duffy, A; Greten, TF; Liewehr, DJ; Rahma, OE; Steinberg, SM | 1 |
| Chauffert, B; Ghiringhelli, F; Wiazzane, N | 1 |
| Fu, Z; Wang, X; Yin, H; Zhang, X | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Del Bene, F; Germani, M; Magni, P; Terranova, N | 1 |
| Chindaprasirt, J; Khuntikeo, N; Ngamprasertchai, T; Pakkhem, A; Sookprasert, A; Ungarereevittaya, P; Wirasorn, K | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Jodrell, DI; Krippendorff, BF; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Huber, KE; Saif, MW; Savir, G | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Boeck, S; Haas, M; Heinemann, V | 1 |
| Gonzalez de Mejia, E; Johnson, JL | 1 |
| Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU | 1 |
| Hu, Y; Liao, Q; Wen, Z; You, L; Zhao, Y; Zhou, L | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Abel, G; Barthelmes, J; Dueregger, A; Guggenberger, F; Haunschild, J; Intelmann, D; Klocker, H; Ramoner, R; Sampson, N; Schuh, M; Stecher, G | 1 |
| Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z | 1 |
| Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S | 1 |
| Berrevoet, F; De Bosschere, K; Ferdinande, L; Geboes, K; Hav, M; Ky, V; Laurent, S; Monsaert, E; Troisi, RI; Van Damme, N; Vanderstraeten, E | 1 |
| Inagaki, A; Iwao, H; Izumi, Y; Miura, K; Nagayama, K; Shiota, M; Takahashi, K; Tanaka, M; Wanibuchi, H | 1 |
| Arakawa, K; Ide, M; Ishioka, NS; Itoh, H; Kaira, K; Kanai, Y; Mori, M; Nagamori, S; Ogawa, T; Ohshima, Y; Oriuchi, N; Oyama, T; Segawa, A; Shimizu, K; Sunaga, N; Sunose, Y; Takeyoshi, I; Tominaga, H; Yamaguchi, A | 1 |
| Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH | 1 |
| Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU | 1 |
| Bahary, N; Brand, R; Burton, SA; Heron, DE; Krasinskas, AM; Lembersky, B; Moser, AJ; Quinn, AE; Rajagopalan, MS; Wegner, RE; Zeh, HJ | 1 |
| Ashley, CE; Brinker, CJ; Brocato, TA; Butner, JD; Carnes, EC; Cristini, V; Koay, EJ; Pascal, J; Wang, Z | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Felder, MA; Perez Horta, Z; Qu, X; Rakhmilevich, AL; Sondel, PM | 1 |
| Duffy, AG; Greten, TF | 1 |
| Abbott, DE; Abbruzzese, JL; Aloia, TA; Crane, CH; Evans, DB; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Tran Cao, HS; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Chen, KT; Cohen, SJ; Cooper, HS; Denlinger, C; Devarajan, K; Hoffman, JP; Meyer, JE; Milestone, BN | 1 |
| Annels, NE; Billingham, L; Corrie, P; Cunningham, D; Eatock, M; Gabitass, RF; Middleton, G; Neoptolemos, JP; Pandha, H; Shaw, VE; Smith, D; Valle, J; Wadsley, J | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Garner, E; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Jackson, R; Lacaine, F; Lamb, RF; Mackey, JR; Mayerle, J; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Scarpa, A; Shannon, J; Tebbutt, NC; Valle, JW | 1 |
| Furuse, J | 1 |
| Apetoh, L; Ghiringhelli, F | 1 |
| Bestoso, E; Bianco, MT; Botta, C; Caraglia, M; Ciliberto, D; Conca, R; Correale, P; Cusi, MG; Fioravanti, A; Guglielmo, A; Guidelli, GM; Licchetta, A; Mantovani, G; Martino, E; Mini, E; Misso, G; Pastina, P; Pirtoli, L; Ridolfi, R; Rotundo, MS; Tagliaferri, P; Tassone, P | 1 |
| Bang, SM; Chung, JB; Kang, DR; Kim, KS; Park, JY; Park, MS; Park, SW; Seong, J; Song, SY; Yi, SW | 1 |
| Chen, Y; Ouyang, J; Ouyang, L; Yang, J | 1 |
| Azad, N; Blackford, A; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, R; Edil, BH; Faisal, F; Fishman, EK; Herman, J; Hruban, RH; Laheru, D; Le, DT; Olino, K; Rasheed, Z; Schulick, R; Tsai, HL; Wolfgang, C; Xia, C; Zheng, L | 1 |
| Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Berger, AK; Jäger, D; Springfeld, C; Weber, TF | 1 |
| Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS | 1 |
| Atxner, J; Buchwald, D; Happe, A; Kröz, M; Matthes, H; Popp, S; Schad, F | 1 |
| Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q | 1 |
| Baillet-Guffroy, A; Caudron, E; Eveleigh, L; Lê, LM | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Butturini, G; Carter, R; Cox, T; Cunningham, D; Dervenis, C; Ghaneh, P; Goldstein, D; Izbicki, JR; Jackson, R; Karapetis, C; Lacaine, F; Lind, PA; Mayerle, J; Middleton, MR; Neoptolemos, JP; O'Reilly, D; Oláh, A; Palmer, D; Rawcliffe, CL; Robinson, BA; Sand, J; Scarfe, A; Stocken, DD; Sumpter, K; Valle, JW | 1 |
| Bouvet, M; Chishima, T; Endo, I; Fleming, JB; Hiroshima, Y; Hoffman, RM; Katz, MH; Maawy, A; Miwa, S; Momiyama, M; Suetsugu, A; Tanaka, K; Uehara, F; Yano, S; Zhang, Y; Zhao, M | 1 |
| Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM | 1 |
| Kukongviriyapan, V; Prawan, A; Senggunprai, L; Sripa, B; Zeekpudsa, P | 1 |
| Goldberg, SN | 1 |
| Kolokythas, O; Le, T; Meng, Y; Soriano, SS; Wang, H; Wei, B; Willis, P; Wu, X; Yang, X; Zhang, F; Zhang, T | 1 |
| Jaiyesimi, I; Kizilbash, SH; Liang, JJ; Lipscomb, J; Ward, KC | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Aoyama, F; Hiyoshi, M; Kataoka, H; Sawaguchi, A; Takahashi, N | 1 |
| Cheng, J; Hong, DF; Liu, JW; Shen, GL; Shi, Y; Sun, XD; Wang, CY; Wang, ZF; Zhang, CW; Zhang, JG; Zhang, YB; Zhao, G | 1 |
| Bläuer, M; Hashimoto, D; Hirota, M; Ikonen, NH; Laukkarinen, J; Sand, J | 1 |
| Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL | 1 |
| Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A | 1 |
| Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F | 1 |
| Hussain, R; Iqbal, H; Jamshed, A | 1 |
| Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L | 1 |
| Kondratska, K; Kondratskyi, A; Lemonnier, L; Lepage, G; Morabito, A; Prevarskaya, N; Skryma, R; Yassine, M | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Camp, ER; Chaudhary, UB; Cole, DJ; Esnaola, NF; Garrett-Mayer, E; Hoffman, BJ; Marshall, DT; Montero, AJ; O'Brien, P; Orwat, KP; Romagnuolo, J; Thomas, MB | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J | 1 |
| Becker, G; Gaertner, J | 1 |
| Bernhard, J; Bodoky, G; Dietrich, D; Glimelius, B; Herrmann, R; Scheithauer, W | 1 |
| Jia, Y; Marks, E; Saif, MW | 1 |
| Abdelmohsen, K; Acosta, Ade J; Brody, JR; Burkhart, RA; Gorospe, M; Iacobuzio-Donahue, CA; Jimbo, M; Laheru, D; Lal, S; Lankapalli, RH; McAllister, F; Moughan, J; Pineda, DM; Winter, JM; Winter, KA; Witkiewicz, AK; Yeo, CJ | 1 |
| Bahra, M; Dörken, B; Gebauer, B; Hilbig, A; Pelzer, U; Riess, H; Sinn, M; Stieler, JM | 1 |
| Blanco Codesido, M; García Alfonso, P; Martín Jiménez, M; Muñoz Martín, AJ; Pérez Ramírez, S; Rupérez Blanco, AB | 1 |
| Ayuk, F; Bokemeyer, C; Brammer, I; Kröger, N; Mina, S; Nitsch, E; Pace, A; Schuch, G; Zander, A | 1 |
| Chan, S; Seidman, AD; Wang, J; Xu, B; Xu, C; Zhu, C | 1 |
| Cheon, YK; Hong, MJ; Lee, EJ; Lee, TY; Shim, CS | 1 |
| Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TW; Friese, K; Hepp, P; Janni, W; Jückstock, J; Lichtenegger, W; Lorenz, R; Pantel, K; Rack, B; Schindlbeck, C; Schneeweiss, A; Tesch, H; Zwingers, T | 1 |
| Aloia, TA; Cooper, AB; des Bordes, JK; Fleming, JB; Fogelman, D; Holmes, HM; Katz, MH; Lee, JE; Parker, NH; Vauthey, JN | 1 |
| Bartosiewicz, M; Boeck, S; Haas, M; Heinemann, V; Isaacson, J; Kirchner, T; Kleespies, A; Kruger, S; Laubender, RP; Mann, E; Ormanns, S; Raponi, M | 1 |
| Bruchard, M; Ghiringhelli, F | 1 |
| Adhikaree, J; Madhusudan, S | 1 |
| Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Kessel, KA; Naumann, P; Werner, J | 1 |
| Hoegdall, DT; Jensen, LH; Larsen, FO; Mellergaard, AH | 1 |
| Blum, H; Bruns, CJ; Camaj, P; Ellwart, JW; Ischenko, I; Jäckel, C; Jauch, KW; Krebs, S; Mysliwietz, J; Nelson, PJ; Niess, H; Renner, A; Zhao, Y | 1 |
| Anthoney, A; Archer, C; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Eatock, M; Evans, J; Falk, S; Garcia-Alonso, A; Greenhalf, W; Harrison, M; Hickish, T; Iveson, T; Madhusudan, S; McAdam, K; Middleton, G; Naisbitt, D; Nanson, G; Neoptolemos, J; Nicolson, M; Propper, D; Rawcliffe, C; Robinson, A; Roques, T; Ross, P; Shaw, V; Silcocks, P; Steward, W; Valle, J; Wadd, N; Wadsley, J | 1 |
| Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Bischoff, S; Dörken, B; Görner, M; Greten, TF; Heil, G; Lakner, V; Mölle, M; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Sinn, M; Stieler, JM | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Hong, DF; Hu, ZM; Huang, DS; Shang, MJ; Wu, WD; Zhang, CW; Zhao, DJ | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Chang, BW; Johung, KL; Saif, MW | 1 |
| Kaddis, N; Saif, MW | 1 |
| Lemstrová, R; Melichar, B; Mohelnikova-Duchonova, B; Souček, P | 1 |
| Cao, B; Li, Q; Liu, W; Yan, H; Yang, Y; Zhen, H | 1 |
| Braddock, M; Chen, YP; Lin, YQ; Shi, KQ; Wang, LR; You, J; Zheng, MH; Zhu, GQ; Zou, H | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Beohou, E; Bonnetain, F; Borg, C; Cleau, D; Demarchi, M; Dobi, E; Fein, F; Fiteni, F; Fratté, S; Jary, M; Kim, S; Monnien, F; Nerich, V; Nguyen, T; Pivot, X | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY | 1 |
| Papadatos-Pastos, D; Rabbie, R; Ross, P; Sarker, D; Thillai, K | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Cokmert, S; Demir, L; Dirican, A; Karabulut, B; Kucukzeybek, Y; Muslu, U; Tarhan, MO; Uslu, R; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Bearz, A; Bozzetti, R; Buti, S; Caminiti, C; Camisaschi, C; Castelli, C; Donini, M; Lazzarelli, S; Lo Re, G; Mattioli, R; Passalacqua, R; Rivoltini, L; Simonelli, C | 1 |
| Liu, GL; Luo, HY; Wang, DS; Wang, ZQ; Xu, RH; Zeng, ZL; Zhang, Y | 1 |
| Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E | 1 |
| Gong, J; Homma, S; Ito, M; Kajihara, M; Kan, S; Koido, S; Namiki, Y; Odahara, S; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Tsukinaga, S; Yoshida, K; Yoshizaki, S; Yusa, S | 1 |
| Chen, JS; Chou, WC; Hsu, HC; Huang, WK; Kuo, YC; Shen, WC; Tsang, NM; Yang, TS | 1 |
| Grąt, M; Kornasiewicz, O; Krasnodębski, M; Krawczyk, M; Patkowski, W; Stankiewicz, R | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Fu, M; Huang, H; Wang, C; Xie, J; Yang, A; Zhang, W | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Bonnetain, F; Dubreuil, O; Dupont-Gossard, AC; Fein, F; Gauthier, M; Landi, B; Lecomte, T; Lobry, C; Malka, D; Manet-Lacombe, S; Taïeb, J; Thirot-Bidault, A; Trouilloud, I; Zaanan, A | 1 |
| Katanyoo, K; Laopaiboon, M; Lumbiganon, P; Manusirivithaya, S; Supawattanabodee, B; Tangjitgamol, S | 1 |
| Bergaglio, M; Buonerba, C; Calabrese, F; Damiano, V; De Maio, AP; Di Lorenzo, G; Federico, P; Lalle, M; Marino, M; Merola, C; Milella, M; Montella, L; Ottaviano, M; Palmieri, G; Von Arx, C | 1 |
| Kitanaka, C; Okada, M; Sato, A; Seino, M; Seino, S; Shibuya, K; Suzuki, S; Takeda, H; Yoshioka, T | 1 |
| Cardwell, J; Chatterjee, D; Fleming, JB; Kang, Y; Katz, MH; Li, SQ; Roife, D; Suzuki, R; Thomas, RM; Truty, MJ; Wang, H; Wang, Y; Zhang, R | 1 |
| Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W | 1 |
| Gao, H; Han, M; Han, Y; Jiang, Q; Peng, J; Wang, C; Xie, J | 1 |
| Duchêne, B; Jonckheere, N; Tréhoux, S; Van Seuningen, I | 1 |
| Aktas, B; Balakan, O; Berk, V; Cinkir, Hy; Demirci, U; Helvaci, K; Kos, T; Kucukoner, M; Oztop, I; Sevinc, A; Tonyali, O; Turan, N; Unal, OU; Yildiz, R; Yilmaz, AU | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G | 2 |
| Brais, RJ; Chatzizacharias, NA; Corrie, P; Davies, S; Elias, A; Harper, SJF; Huguet, E; Jah, A; Jamieson, NV; Praseedom, RK; Xanthis, A | 1 |
| Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH | 1 |
| André, T; Aparicio, T; Bachet, JB; Berger, A; Bonnetain, F; Cojean Zeleck, D; Colussi, O; Coriat, R; Dousset, B; Hammel, P; Locher, C; Malka, D; Nordlinger, B; Paye, F; Pozet, A; Rougier, P; Sauvanet, A; Taieb, J; Tchinou, L; Vaillant, JC; Voron, T | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Cong, C; Dou, Y; Duan, L; Gao, A; Lai, Q; Sun, Y; Zheng, Y | 1 |
| Kukongviriyapan, V; Prawan, A; Samatiwat, P; Senggunprai, L | 1 |
| Böhlandt, A; Fischer, E; Groeneveld, S; Schierl, R | 1 |
| Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE | 1 |
| Bang, S; Chang, JS; Chung, JB; Chung, MJ; Kang, H; Oh, TG; Park, JY; Park, SW; Seong, J; Song, SY | 1 |
| Dawood, S; Kulkarni, S; Ramadwar, M; Rastogi, S; Sheth, V; Shrikhande, SV; Singh, A; Sirohi, B; Talole, S | 1 |
| Iida, M; Miyazawa, H; Nanjo, H; Shibata, S; Uchinami, H; Watanabe, G; Yamamoto, Y; Yoshida, M; Yoshioka, M; Yoshioka, T | 1 |
| Shimizu, S | 1 |
| André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN | 1 |
| Bonetti, A; Giuliani, J; Piacentini, P | 1 |
| Ampie, L; Bade, NA; Hartley, ML; Marshall, JL; Prins, PA | 1 |
| Honma, Y; Kato, N; Miyake, T; Suzumiya, J; Urano, T | 1 |
| Abe, H; Baghdadi, M; Higuchi, K; Hirano, S; Inoko, K; Nakamura, T; Nakanishi, S; Sato, S; Seino, K; Shichinohe, T; Takahashi, M; Takano, H; Takeuchi, S; Tsuchikawa, T; Usui, Y; Wada, H | 1 |
| Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM | 1 |
| Aishima, S; Baba, H; Harimoto, N; Hualin, W; Itoh, S; Maehara, Y; Shirabe, K; Takeishi, K; Uchihara, T; Yamashita, Y; Yoshizumi, T | 1 |
| Ali-El-Dein, B; Babjuk, M; Burger, M; Chang, SS; Clayman, RH; Daneshmand, S; Efstathiou, JA; Fritsche, HM; Gakis, G; Galland, S; Hrbacek, J; Keegan, KA; Mischinger, J; Morgan, TM; Olugbade, K; Rink, M; Schubert, T; Stenzl, A; Thalmann, GN; Todenhöfer, T; Zaid, HB | 1 |
| Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W | 1 |
| Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A | 1 |
| Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
| Antoch, G; Graf, D; Häussinger, D; Knoefel, WT; Kröpil, P; Riemer, J; Schneitler, S | 1 |
| Bujanda, L; Er, TK; Herreros-Villanueva, M | 1 |
| Alexandrow, MG; Bryant, VL; Elias, RM; McCarthy, SM; Yeatman, TJ | 1 |
| El-Rayes, B; Landry, J; Maithel, SK; Nanda, RH | 1 |
| Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Akiyama, T; Doi, T; Hirano, S; Hirata, K; Homma, H; Kogawa, K; Mezawa, S; Morii, K; Ohi, M; Takahashi, M; Takeuchi, M; Tanaka, S | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK | 1 |
| Bang, SM; Choi, JY; Choi, SH; Hwang, HK; Kang, CM; Lee, JH; Lee, WJ; Seong, JS | 1 |
| André, T; Bachet, JB; Bonnetain, F; Chibaudel, B; Hammel, P; Louvet, C; Validire, P | 1 |
| Bode, AM; Byun, S; Cho, YY; Dong, Z; Farrand, L; Jung, SK; Kwon, YJ; Lee, E; Lee, HJ; Lee, J; Lee, KW; Lee, SY; Shin, SH; Sin, HS; Tsang, BK; Um, SJ; Zhang, C | 1 |
| Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM | 1 |
| Alvaro, D; Bragazzi, MC; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Fraveto, A; Gaudio, E; Giuliante, F; Grazi, GL; Lustri, AM; Napoletano, C; Nevi, L; Renzi, A; Semeraro, R | 1 |
| Dodagoudar, C; Doval, DC; Goel, V; Goyal, P; John, MC; Mahanta, A; Patnaik, N; Singh, S; Talwar, V; Tiwari, S; Upadhyay, A | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Ashida, R; Ioka, T; Katayama, K; Sakon, M; Takahashi, H; Teshima, T | 1 |
| Allen, PJ; D'Angelica, MI; DeMatteo, RP; Do, RK; Fong, Y; Gönen, M; Groot Koerkamp, B; Jarnagin, WR; Kemeny, NE; Kingham, TP; Klimstra, DS; Konstantinidis, IT | 1 |
| Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
| Abbruzzese, JL; Abrams, RA; Chang, P; Crane, C; Freedman, GM; Guha, C; Hoffman, JP; Li, D; Liu, C; Moughan, J; Regine, WF; Safran, H; Winter, KA | 1 |
| Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V | 1 |
| Büning, C; Jürgensen, C; Mitroshkin, A; Prager, M; Schachschal, G; Voderholzer, W; Wentrup, R; Winkelmann, N | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Haddock, MG; Hallemeier, CL; Harmsen, WS; Kendrick, ML; Merrell, KW; Miller, RC; Quevedo, JF | 1 |
| Assadi, RK; Dholakia, AS; Ellsworth, SG; Ford, E; Grossman, SA; Hacker-Prietz, A; Herman, JM; Jaffee, EM; Laheru, DA; Lu, Y; Moningi, S; Pawlik, TM; Rosati, LM; Saeed, AM; Tran, PT; Weiss, MJ; Wild, AT; Wolfgang, CL; Ye, X | 1 |
| Mantripragada, KC; Safran, H | 1 |
| Li, D; O'Reilly, EM | 1 |
| Fan, Y; Gan, Y; Gu, J; Li, G; Tu, H; Wang, Q; Wu, Y; Yao, M; Yuan, H; Zhang, J | 1 |
| Chen, H; Li, Q; Tang, R; Wen, F; Wu, Y; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Endlicher, E; Gelbmann, C; Klebl, F; Kullmann, F; Messmann, H; Rogler, G; Schnoy, E; Troppmann, M | 1 |
| Blake, A; Hayes, JP; Helenowski, I; Huang, J; Kim, T; McGinn, CJ; Mulcahy, M; Rakhra, S; Robertson, J; Small, W; Strauss, JB | 1 |
| Lee, HS; Park, SW | 1 |
| Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A | 1 |
| Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN | 1 |
| Hoang, NT; Kadonosono, T; Kizaka-Kondoh, S; Kuchimaru, T | 1 |
| Arber, N; Kazanov, D; Pleban, S; Shapira, S; Tirosh, P | 1 |
| Allorge, D; Barthelemy, C; Bonnabry, P; Décaudin, B; Humbert, L; Lebecque, M; Odou, P; Pinturaud, M; Richeval, C; Sidikou, O; Simon, N; Soichot, M; Vasseur, M | 1 |
| Ellenrieder, V; König, A; Seufferlein, T | 1 |
| Chen, QW; Cheng, CS; Meng, ZQ; Ning, ZY; Shi, WD; Song, LB; Wang, K; Wang, P; Xie, J; Xu, LT; Zhang, CY; Zhu, XY; Zhuang, LP | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Beaudoin, A; Cano, P; Cripps, C; Dhesy-Thind, S; Do, T; Dowden, S; Gill, S; Grassin, H; Ko, YJ; Lam, WYH; Moore, M; Stewart, J; Zalewski, P; Zulfiqar, M | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E | 1 |
| Cheah, SL; Chua, ML; Fong, KW; Kusumawidjaja, G; Shwe, MT; Soong, YL; Tan, SH; Tan, TW; Wee, JT | 1 |
| Blanc, JF; Carrato, A; Ciardiello, F; de Jong, FA; Ektare, V; Gill, S; Hubner, RA; Patel, DA; Vogel, A; Yang, Y | 1 |
| Bohle, W; Egger, J; Hann, A; Zoller, WG | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Keane, FK; Kwak, EL; Lillemoe, KD; Ryan, DP; Wo, JY | 1 |
| Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M | 1 |
| Chen, Y; He, Q; Zhang, H | 1 |
| Dibbern, JL; Ghadban, T; Güngör, C; Izbicki, JR; Miro, JT; Reeh, M; Tsui, TY; Vashist, YK; Wellner, U | 1 |
| Brody, JR; Buchler, M; Costello, E; Dabbish, N; Ghaneh, P; Greenhalf, W; Grigoli, A; Halloran, C; Jiang, W; Jimbo, M; Leiby, BE; Neoptolemos, JP; Palmer, D; Tatarian, T; Winter, JM; Yeo, CJ | 1 |
| Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Aguila, FN; Chambers, LW; Hu, H; Huang, X; Knoble, JL; Liu, H; Patel, T; Zeng, M | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Hong, S; Zhang, L | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Beyer, G; Javed, MA; Kohlmann, T; Krug, S; Le, N; Neesse, A; Schober, M; Sund, M; Vinci, A | 1 |
| Are, C; Bhirud, AR; Lazenby, AJ; Lin, C; Ly, QP; Sasson, AR; Verma, V; Zheng, D | 1 |
| Abbott, DE; Ahmad, SA; Al Humaidi, AH; Choe, KA; Dhar, VK; Fu, B; Habib, DA; Hanseman, DJ; Kharofa, J; Kim, Y; Levinsky, NC; Olowokure, OO; Smith, M; Wang, J; Wilson, GC; Xia, BT | 1 |
| Arkenau, HT; Moschetta, M; Uccello, M | 1 |
| Han, X; Lu, N; Pan, Y; Xu, J | 1 |
| Kaura, S; Khan, ZM; MacEwan, JP; Yin, W | 1 |
| Darko, KO; He, C; Huang, Y; Liu, Z; Peng, M; Su, Q; Tao, T; Yang, X; Yin, T | 1 |
| Fields, RC; Hawkins, WG; Linehan, DC; Liu, J; Ohman, KA; Strasberg, SM; Tan, BR; Tan, MC | 1 |
| Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J | 1 |
| Artru, P; Bodère, A; Brac, C; Edeline, J; Le Pabic, E; Le Sourd, S; Leconte, B; Lièvre, A; Pracht, M; Viaud, J | 1 |
| Belk, KW; Kim, GP; Parisi, MF; Patel, MB; Pelletier, CL | 1 |
| Woo, SM | 1 |
| Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y | 1 |
| Beinse, G; Bonnetain, F; Borg, C; Bouché, O; Cleau, D; d'Engremont, C; de Mestier, L; Dupont-Gossart, AC; Fein, F; Heyd, B; Lakkis, Z; Louvet, C; Meurisse, A; Neuzillet, C; Rousseau, B; Tournigand, C; Vernerey, D; Vienot, A | 1 |
| Lamb, YN; Scott, LJ | 1 |
| Batist, G; Chanez, B; Gilabert, M; Giovanini, M; Kavan, P; Raoul, JL; Rho, YS; Turrini, O | 1 |
| Do, C; Han, Y; Smith, GS; Zhang, Z | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM | 1 |
| Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Shimamura, T; Tokuhisa, M | 1 |
| Baechmann, S; Boeck, S; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Kruger, S; Modest, DP; Ormanns, S; Remold, A; Werner, J | 1 |
| Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW | 1 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Abraham, T; Adair, JH; Butler, PJ; Clawson, GA; Fox, T; Gigliotti, CM; Kester, M; Linton, SS; Loc, WS; Martin, JA; Matters, GL; McGovern, CO; Smith, JP; Tabakovic, A; Tang, X; Wilczynski, ZR | 1 |
| Bahary, N; Epelboym, I; Hamad, A; Hogg, ME; Lee, KK; Steve, J; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Huang, WF; Jiang, JH; Nie, J; Tan, DW; Wang, XF; Zhou, Y | 1 |
| Sohal, DPS | 1 |
| Asada, H; Miyagawa, F; Sho, M; Sugano, Y | 1 |
| Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB | 1 |
| Algül, H; Azoitei, N; Bohnenberger, H; Frappart, PO; Gaedcke, J; Gieldon, L; Hampp, S; Hessmann, E; Hohwieler, M; Ihle, M; Kleger, A; Lechel, A; Lesina, M; Liebau, S; Lin, Q; Perkhofer, L; Reinhardt, HC; Romero Carrasco, MC; Ruess, DA; Russell, R; Schmitt, A; Schröck, E; Seufferlein, T; Sipos, B; Wagner, M; Wiesmüller, L | 1 |
| Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O | 1 |
| Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA | 1 |
| Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH | 1 |
| Cavaliere, A; Probst, KC; Slusarczyk, M; Westwell, AD | 1 |
| Jun, E; Kim, SC; Lee, CM; Lee, S; Oh, J; Shim, IK | 1 |
| Bennouna, J; Bouché, O; Conroy, T; Desseigne, F; Gourgou, S; Jarlier, M; Juzyna, B; Robert, M; Ychou, M | 1 |
| Cottica, D; Dezza, B; Grignani, E; Negri, S; Oddone, E; Sottani, C; Villani, S | 1 |
| Abdel-Wahab, M; Berriochoa, CA; Khorana, A; Kumar, AMS; Leyrer, CM; Matthew Walsh, R | 1 |
| Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S | 1 |
| Chang, JW; Chang, YH; Chuang, CK; Juan, YH; Liao, TY; Liaw, CC | 1 |
| Anthoney, A; Büchler, MW; Campbell, F; Carter, R; Cox, TF; Deakin, M; Dervenis, C; Ghaneh, P; Glimelius, B; Goldstein, D; Halloran, CM; Izbicki, JR; Jackson, R; Jones, O; Kleeff, J; Lerch, MM; Mayerle, J; McDonald, AC; Melling, J; Neoptolemos, JP; O'Reilly, DA; Oláh, A; Padbury, R; Palmer, DH; Raraty, M; Rawcliffe, CL; Scarfe, AG; Shannon, J; Smith, CJ; Strobel, O; Tebbutt, NC; Valle, JW | 1 |
| Deshmukh, SP; Epstein, JD; Keith, SW; Kozak, GM; Lavu, H; Scott, BB; Winter, JM; Yeo, CJ | 1 |
| Abdol Razak, NB; Adamska, A; Elaskalani, O; Emmanouilidi, A; Falasca, M; Kim, M; Metharom, P | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Friess, H; Goess, R | 1 |
| Liang, C; Liang, D; Meng, Q; Ni, Q; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Chang, JS; Chung, SY; Lee, BM; Lee, KJ; Seong, J | 1 |
| Alberts, SR; Hartgers, ML; Hassan, M; Jin, Z; Mahipal, A; Muppa, P; Nagorney, DM; Sanhueza, CT; Shubert, CR; Smyrk, TC; Truty, MJ | 1 |
| Anthoney, A; Aughton, K; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Elander, NO; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Lerch, MM; Mackey, JR; Mayerle, J; McDonald, AC; Neoptolemos, JP; Oláh, A; Palmer, DH; Scarfe, AG; Shannon, J; Tebbutt, NC; Valle, JW | 1 |
| Boeck, S; Caca, K; Ettrich, TJ; Fischer von Weikersthal, L; Freiberg-Richter, J; Fuchs, M; Haas, M; Heinemann, V; Held, S; Kanzler, S; Kruger, S; Kullmann, F; Kunzmann, V; Lerch, MM; Reinacher-Schick, A; Schenk, M; Siveke, JT; Westphalen, CB | 1 |
| Biankin, AV; Chantrill, L; Chin, V; Nagrial, A; O'Connor, CA; Scholten, RJ; Sjoquist, K; Yip, D | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Best, LM; Bussières, JF; Gurusamy, KS; Korva, M; Lennan, E; Tanguay, C | 1 |
| Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K | 1 |
| Bagust, A; Banks, L; Beale, S; Boland, A; Duarte, R; Greenhalgh, J; Kotas, E; Palmer, D; Richardson, M; Stainthorpe, A | 1 |
| Chang, HM; Hong, SM; Hwang, DW; Hwang, I; Jeong, JH; Kang, J; Kim, KP; Kim, MH; Kim, SC; Lee, JH; Lee, SK; Lee, SS; Park, DH; Ryoo, BY; Seo, DW; Shin, SH; Song, KB; Song, TJ; Yoo, C | 1 |
| Kellett, C; Kim, CA; Lambert, P; Zhang, H | 1 |
| Arafat, K; Attoub, S; Iratni, R; Khalaf, T; Sulaiman, S | 1 |
| Barney, C; Diaz, DA; Dillhoff, M; Grieco, C; Manilchuk, A; Pawlik, TM; Salloum, J; Schmidt, C; Walston, S; Williams, TM; Wuthrick, E | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K | 1 |
| Chouaib, S; Foucher, ED; Galon, J; Ghigo, C; Iovanna, J; Olive, D | 1 |
| Huang, KW; Kim, MD; Li, SP; Liang, PC; Pua, U; Qiu, YD; Song, TQ; Yang, PC | 1 |
| Chen, LH; Feng, L; Hu, CY; Mostofa, AGM; Suthe, SR; Wang, MH; Wang, WL; Weng, TH; Wu, ZG; Yao, HP | 1 |
| Canale, TD; Cheung, WY; Cho, H | 1 |
| Abrams, SL; Candido, S; Cervello, M; Cocco, L; Falasca, M; Lertpiriyapong, K; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Ratti, S; Rosalen, PL; Steelman, LS; Yang, LV | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 1 |
| Álvarez, R; Carrato, A; Díaz, R; García, A; Hidalgo, M; Laquente, B; Macarulla, T; Muñoz, A; Sastre, J | 1 |
| Chen, W; He, M; Liu, Q; Long, MM; Wang, H; Wang, J; Xu, SW; Yang, LH; Yang, RM; Zhan, M | 1 |
| Delpero, JR; Ewald, J; Gilabert, M; Marchese, U; Turrini, O | 1 |
| Chevalier, H; Neuzillet, C; Turpin, A | 1 |
| Fukuda, H; Fukutomi, A; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Katayama, H; Mizuno, N; Mizusawa, J; Okusaka, T; Ozaka, M; Ueno, H; Ueno, M | 1 |
| Hu, C; Li, Y; Lu, X; Qian, W; Xu, T | 1 |
| Berlin, J; Cardin, D; Das, S | 1 |
| Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC | 1 |
| Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A | 1 |
| Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H | 1 |
| Balachandar, V; Devi, SM; Kaavya, J; Mahalaxmi, I; Santhy, KS | 1 |
| Benigno, BB; Clayton, EA; Huang, C; Matyunina, LV; McDonald, JF; McDonald, LD; Vannberg, F | 1 |
| D'Haese, JG; Friess, H; Gloor, B; Hartmann, D; Kaufmann, B; Radenkovic, D; Stupakov, P | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Braiteh, FS; Chen, LT; Chiu, CF; Cunningham, D; de Jong, FA; Dean, AP; Hubner, RA; Jameson, GS; Lee, KH; Li, CP; Macarulla, T; Mamlouk, K; Schwartsmann, G; Shan, YS; Siveke, JT; Wang-Gillam, A | 1 |
| Coen, JJ; Efstathiou, JA; Jani, AB; Kucuk, O; Lautenschlaeger, T; Lee, CT; Parker, W; Rodgers, JP; Sandler, HM; Saylor, PJ; Shipley, WU; Souhami, L; Wu, CL; Zhang, P; Zietman, AL | 1 |
| Artru, P; Assenat, E; Bachet, JB; Ben Abdelghani, M; Biagi, JJ; Bouhier-Leporrier, K; Breysacher, G; Castan, F; Choné, L; Conroy, T; Cripps, C; Di Fiore, F; Faroux, R; Francois, E; Gourgou, S; Hammel, P; Hebbar, M; Jouffroy-Zeller, C; Juzyna, B; Kavan, P; Khemissa-Akouz, F; Lecomte, T; Legoux, JL; Malka, D; O'Callaghan, CJ; Raoul, JL; Rat, P; Sauvanet, A; Texereau, P; Volet, J; Wei, AC; Ychou, M | 1 |
| Barbier, E; Blanc, JF; Bourgeois, V; Desrame, J; Edeline, J; Malka, D; Manfredi, S; Michel, P; Neuzillet, C; Phelip, JM | 1 |
| Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U | 1 |
| Shi, S; Yu, X | 1 |
| Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T | 1 |
| Bates, SE; Chabot, JA; Manji, GA; Raufi, AG | 1 |
| Boige, V; Conroy, T; Ducreux, M; Hollebecque, A; Laurent-Puig, P; Malka, D; Seufferlein, T; Smolenschi, C; Van Laethem, JL | 1 |
| Romero, D | 1 |
| Soefje, SA | 1 |
| Jiménez Gordo, AM; López Gómez, M | 1 |
| Bekaii-Saab, T | 2 |
| Witjes, JA | 1 |
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Lubgan, D; Semrau, S | 1 |
| Chen, J; Li, Z; Pan, Z; Yao, J; Yao, Z; Zhang, Y | 1 |
| Conroy, T; Ducreux, M | 1 |
| Hu, Z; Huang, Y; Sun, Q; Wang, W; Yang, Q; Zhang, L; Zhang, Y; Zheng, H | 1 |
| Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN | 1 |
| Ghalali, A; Raasmaja, A; Stenius, U | 1 |
| Bumberová, M; Dolinský, J; Janega, P; Jurišová, S; Kašperová, B; Macúch, J; Mego, M | 1 |
| Fan, JF; Jiang, W; Kong, XY; Liao, SF; Lu, JX; Mi, JL; Qin, XL; Tang, HY; Xu, QL; Yao, DC; Yu, XW; Zhang, J; Zhang, RJ | 1 |
| Choi, DW; Choi, SH; Han, IW; Han, S; Heo, JS; Park, DJ; Ryu, Y | 1 |
| Bai, J; Chen, YS; Hou, PF; Liu, QH; Yong, HM; Zhang, XP; Zhu, MH; Zhuang, QX | 1 |
| Allegrini, V; Aversa, J; Ball, CG; Barrows, CE; Behrman, SW; Berger, AC; Cagigas, MN; Christein, JD; Dickson, PV; Dixon, E; Ecker, BL; Fisher, WE; Freedman-Weiss, M; Guzman-Pruneda, F; Hollis, RH; House, MG; Kent, TS; Kowalsky, SJ; Malleo, G; Salem, RR; Salvia, R; Schmidt, CR; Seykora, TF; Vollmer, CM; Zheng, R; Zureikat, AH | 1 |
| Autorino, R; Bisello, S; Brandi, G; Buwenge, M; Cammelli, S; Cellini, F; Cilla, S; Deodato, F; Macchia, G; Mattiucci, GC; Morganti, AG; Palloni, A; Tagliaferri, L; Valentini, V | 1 |
| Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Eid, R; Haddad, FG; Hajjar, AH; Kourie, HR | 1 |
| Assenat, E; Cassinotto, C; Kellil, T; Leon, P; Navarro, F; Panaro, F; Piardi, T; Rosso, E; Sega, V; Souche, R; Vendrell, J | 1 |
| Aloia, TA; Fogelman, DR; Ho, L; Javadi, S; Katz, MHG; Kim, MP; Lee, JE; McAllister, F; Prakash, LR; Tzeng, CD; Varadhachary, G; Vauthey, JN; Vreeland, TJ | 1 |
| Fu, DL; Jin, C; Warshaw, AL; Yang, F | 1 |
| Abbott, DE; Ahmad, SA; Dudeja, V; Fields, RC; Franceschi, D; Hawkins, WG; Kim, HJ; Kooby, DA; Lee, RM; Livingstone, AS; Macedo, FI; Maduekwe, U; Maithel, SK; Martin, RCG; Merchant, NB; Patel, SH; Ryon, E; Schwartz, P; Scoggins, CR; Weber, SM; Williams, G | 1 |
| Anota, A; Aparicio, T; Bachet, JB; Bonnetain, F; Charton, E; Chibaudel, B; Cohen, R; Dauba, J; Debourdeau, P; Desramé, J; Guerin-Meyer, V; Hammel, P; Lecomte, T; Louvet, C; Seitz, JF; Taieb, J; Tournigand, C; Volet, J | 1 |
| Maslov, DV; Matrana, M; Thomas, K | 1 |
| Auriemma, A; Bassi, C; Binco, A; Bonamini, D; Casciani, F; Casetti, L; Ciprani, D; D'Onofrio, M; Esposito, A; Landoni, L; Maggino, L; Malleo, G; Marchegiani, G; Melisi, D; Merz, V; Nessi, C; Paiella, S; Salvia, R; Secchettin, E; Sereni, E; Simionato, F; Tuveri, M; Viviani, E; Zecchetto, C | 1 |
| Büchler, MW; Hackert, T; Heger, U; Hinz, U; Klaiber, U; Liu, B; Michalski, CW; Sachsenmaier, M; Springfeld, C; Sun, H; Tanaka, M | 1 |
| Ai, P; Chen, N; Duan, B; Li, Y; Shi, H; Tian, J; Zhu, J | 1 |
| Debus, J; Grosu, AL; Huber, PE; Lopez Perez, R; Münz, F; Nicolay, NH; Rühle, A; Saffrich, R; Sisombath, S; Trinh, T; Vidoni, D; Wuchter, P; Zou, B | 1 |
| Boccia, R; Buresti, G; Carbonari, D; Cavallo, D; Chiarella, P; Ciervo, A; Colosio, C; Delrio, P; Fresegna, AM; Iavicoli, S; Jemos, C; Maiello, R; Maiolino, P; Mandić-Rajčević, S; Marchetti, P; Omodeo Salè, E; Rubino, FM; Ursini, CL | 1 |
| Cho, CS; Cuneo, KC; Griffith, KA; Kaza, R; Kim, E; Lawrence, TS; Nathan, H; Sahai, V; Shi, J; Sonnenday, CJ; Tran, NH; Zalupski, MM | 1 |
| Iyikesici, MS | 1 |
| Algül, H; Braren, R; Friess, H; Kaissis, G; Lohöfer, F; Muckenhuber, A; Rummeny, E; Schmid, R; Siveke, JT; Steiger, K; Weichert, W; Yen, HY; Ziegelmayer, S | 1 |
| Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N | 1 |
| Boeck, S; Crispin, A; D'Haese, JG; Gebauer, L; Haas, M; Heinemann, V; Ilmer, M; Kirchner, T; Kobold, S; Kruger, S; Kunz, WG; Mayerle, J; Ormanns, S; Ricke, J; Schirle, K; Schirra, J; von Bergwelt-Baildon, M; Werner, J; Westphalen, CB | 1 |
| Johnson, J; Li, L; Sharick, JT; Skala, MC | 1 |
| Ahmad, S; Hasan, B; Hussain, I; Jain, AG; Jehanzeb, S; Khan, AK; Khetpal, N; Rahman, AU; Rashid, MU; Sarvepalli, D; Ullah, W | 1 |
| Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y | 1 |
| Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B | 1 |
| Daunys, S; Matulis, D; Petrikaitė, V | 1 |
| Chikhladze, S; Fichtner-Feigl, S; Kousoulas, L; Lederer, AK; Reinmuth, M; Sick, O; Wittel, UA | 1 |
| Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z | 1 |
| Jin, C; Wen, F; Xu, T; Zhan, M; Zheng, H | 1 |
| Arias, J; Beca, JM; Berry, SR; Biagi, JJ; Chan, KKW; Cheng, S; Coburn, N; Dai, WF; Earle, C; Gavura, S; Guo, H; Isaranuwatchai, W; Kennedy, ED; McLeod, R; Meyers, BM; Mittmann, N; Qiao, L; Redmond-Misner, R; Schwartz, D; Welch, S | 1 |
| Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C | 1 |
| Bazhin, AV; Gasimov, E; Isayev, O; Werner, J; Zhu, Y | 1 |
| Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC | 1 |
| Asch, D; Beatty, GL; Domchek, SM; Nathanson, KL; O'Dwyer, PJ; Reiss, KA; Rosen, MA; Siegelman, ES; Wattenberg, MM; Yu, S | 1 |
| Caffrey, TC; Clement, EJ; Cook, LM; Costanzo-Garvey, D; DiMaio, DJ; Fisher, KW; Grandgenett, PM; Grem, JL; Hollingsworth, MA; Krieger, KL; Lagundžin, D; Law, HC; Qiao, F; Wagner, ZS; Woods, NT; Yu, F | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Chen, LT; Cunningham, D; Dean, A; Lee, KH; Li, CP; Macarulla Mercadé, T; Siveke, JT; Wang-Gillam, A | 1 |
| de Santibañes, E; de Santibañes, M; Mazza, O; Pekolj, J; Sanchez Clariá, R | 1 |
| Gowda, PS; Javed, A; Li, J; Lu, Y; Ponnazhagan, S; Trotter, TN; Xu, X; Yang, Y; Zhang, C | 1 |
| Belkouz, A; de Vos-Geelen, J; Eskens, FALM; Klümpen, HJ; Mathôt, RAA; Punt, CJA; van Gulik, TM; van Oijen, MGH; Wilmink, JW | 1 |
| Abu Hilal, M; Alseidi, A; Bassi, C; Besselink, MG; Bolm, L; Busch, OR; De Pastena, M; Del Chiaro, M; Gill, AJ; Groen, JV; Groot Koerkamp, B; Groot, VP; Halimi, A; He, J; Jang, JY; Keck, T; Malleo, G; Marchegiani, G; Mieog, JS; Mittal, A; Samra, JS; Steyerberg, EW; Strijker, M; Suhool, A; van Eijck, CH; van Roessel, S; Wolfgang, CL; Zarantonello, L | 1 |
| Besselink, MG; Creemers, GJ; de Groot, JWB; de Vos-Geelen, J; Haj Mohammad, N; Homs, MYV; Latenstein, AEJ; Mackay, TM; Molenaar, IQ; Ten Tije, BJ; van der Geest, LGM; van Eijck, CHJ; van Laarhoven, HWM; Wilmink, JW | 1 |
| Huang, J; Li, Q; Liao, W; Wu, Q; Zhang, N; Zhang, P | 1 |
| Dahabreh, IJ; García-Albéniz, X; Hernán, MA; Howlader, N; Logan, RW; Mariotto, AB; Petito, LC | 1 |
| Delpero, JR; Ewald, J; Garnier, J; Gilabert, M; Giovannini, M; Launay, S; Marchese, U; Moureau-Zabotto, L; Poizat, F; Turrini, O | 1 |
| Kubo, S; Tomita, N; Yamano, T | 1 |
| Antico, G; Blauer-Petersen, C; Doleh, Y; Lal, LS; Pishvaian, M | 1 |
| Sinn, M; Stein, A; Wege, H | 1 |
| Fu, X; Mao, L; Qiu, YD; Tang, N; Xie, WQ | 1 |
| Damarla, V; Dobrosotskaya, I; Khan, G; Kwon, D; Li, J; Raoufi, M; Seixas, T; Siddiqui, F; Thanikachalam, K; Winters, K; Wollner, I | 1 |
| Chang, SS | 1 |
| Kimura, S; Kurioka, Y; Matsumoto, T; Matsuo, Y; Miura, K; Morishita, H; Okazaki, U; Takagi, S; Takatani, M; Tsuduki, T | 1 |
| Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
| Fanchon, LM; Gangangari, K; Humm, JL; O'Donoghue, I; Pillarsetty, N; Russell, J; Yu, KH | 1 |
| Dwarkasing, RS; Eskens, FALM; Groot Koerkamp, B; Homs, MYV; Nuyttens, JJ; Suker, M; van Eijck, CHJ | 1 |
| Abushahin, L; Alexandra Diaz, D; Chen, W; Cloyd, JM; Dillhoff, M; Frankel, WL; Miller, ED; Noonan, A; Prabhakar, D; Williams, TM; Wolfe, AR; Yildiz, VO | 1 |
| Abdul-Rahim, O; Khushman, M; Phung, T; Surinach, A | 1 |
| Bodea, R; Mercea, V; Nemes, A; Vidra, R | 1 |
| Babu, S; Biankin, AV; Chang, DK; Escobar-Hoyos, LF; K Bai, JD; Kawalerski, RR; Leiton, CV; Otsuka, Y; Pan, CH; Scampavia, L; Shroyer, KR; Spicer, T; Sridharan, B; Torrente Gonçalves, M; Woo, M | 1 |
| Bachet, JB; Mas, L; Schwarz, L | 1 |
| Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K | 1 |
| Kasi, A; Paluri, RK; Posey, JA; Young, C | 1 |
| Bullock, A; Chiorean, EG; Oestreicher, N; Rowan, CG; Yeganegi, H | 1 |
| Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF | 1 |
| Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Chen, Y; Di, YS; He, L; Lam, LM; Liang, ST; Liao, Y; Tsang, YS; Xia, Q | 1 |
| Jin, J; Zhang, Y; Zheng, T; Zhou, L | 1 |
| Moir, JAG; Severs, GR; Tingle, SJ; White, SA | 1 |
| Bendell, J; Feeney, K; Gracián, AC; Hecht, JR; Hung, A; Lee, MA; Lin, Y; Lonardi, S; Muñoz, A; Ryoo, BY; Wainberg, ZA | 1 |
| Ahmad, S; Barrord, M; Choe, K; Esslinger, H; Kharofa, J; Latif, T; Olowokure, O; Patel, S; Poreddy, S; Smith, M; Sussman, J | 1 |
| Hines, OJ; Ye, L | 1 |
| Fogelman, D; Herman, J; Ikoma, N; Javle, M; Katz, MHG; Kim, M; Koay, EJ; Lee, JE; Overman, M; Pant, S; Perri, G; Prakash, L; Qiao, W; Tzeng, CW; Varadhachary, GR; Wolff, R | 1 |
| Du, J; Gu, J; Li, J | 1 |
| Bhutiani, N; Chen, Y; Li, Y; Martin, RCG; Pandit, H; Pulliam, ZR; Shi, X; Tan, M; Yu, Y; Zheng, Q | 1 |
| Astsaturov, I; Brachmann, RK; Cardin, DB; Cohen, SJ; Denlinger, CS; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, W; O'Neil, B; Shahda, S; Stagg, RJ; Uttamsingh, S; Weekes, C | 1 |
| Ceyhan, GO; Damm, M; Kordes, M; Maggino, L; Moir, J; Rosendahl, J; Schorn, S; Weniger, M | 2 |
| Ahmad, SA; Beg, MS; Chiorean, EG; Duong, M; Gandhi, NS; Guthrie, KA; Hochster, HS; Lowy, AM; Philip, PA; Sohal, DPS; Wade, JL; Wang-Gillam, A | 1 |
| Chen, WP; Huang, YM; Li, SL; Lu, L; Qi, CH; Qiao, SQ | 1 |
| Chie, EK; Jang, JY; Kim, BH; Kim, H; Kim, K; Kwon, W; Lee, KB; Lee, KH; Oh, DY | 1 |
| Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K | 1 |
| Byun, Y; Chie, EK; Choi, YJ; Han, Y; Jang, JY; Kang, JS; Kim, H; Kim, HS; Kim, YT; Kwon, W; Lee, K; Lee, SH; Oh, DY; Paik, WH; Ryu, JK | 1 |
| Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A | 1 |
| Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY | 1 |
| Adler, W; Bechstein, WO; Boeck, S; Croner, RS; Fietkau, R; Ghadimi, M; Golcher, H; Grützmann, R; Hohenberger, WM; Imhoff, D; Jacobasch, L; Keilholz, L; Lubgan, D; Neumann, UP; Oettle, H; Pirkl, A; Reinacher-Schick, A; Rutzner, S; Semrau, S; Uhl, W; Wittel, UA | 1 |
| Baltatzis, M; De Liguori Carino, N; Rodriquenz, MG; Siriwardena, AK | 1 |
| Antico, G; Cole, A; Doleh, Y; Malangone-Monaco, E; Noxon, V; Pishvaian, MJ | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Bouvet, M; Higuchi, T; Hoffman, RM; Kawaguchi, K; Nishino, H; Park, JH; Sugisawa, N; Tashiro, Y; Unno, M; Yamamoto, J | 1 |
| Clayton, EA; McDonald, JF; Pujol, TA; Qiu, P | 1 |
| Boldrini, L; Buwenge, M; Cellini, F; D'Aviero, A; Deodato, F; Dinapoli, N; Frascino, V; Macchia, G; Mattiucci, GC; Morganti, AG; Nardangeli, A; Valentini, V | 1 |
| El-Husseiny, AA; El-Mahdy, HA; Gamal El-Din, AM; Kandil, YI | 1 |
| Beijnen, JH; Derissen, EJB | 1 |
| Andergassen, U; Bauer, E; Beckmann, MW; Bekes, I; Blohmer, JU; Brucker, SY; de Gregorio, A; de Gregorio, N; Deniz, M; Fasching, PA; Fehm, TN; Fink, V; Forstbauer, H; Friedl, TWP; Häberle, L; Heinrich, G; Janni, W; Lato, K; Lorenz, R; Mahner, S; Müller, V; Rack, B; Schneeweiss, A; Schrader, I; Tesch, H | 1 |
| Chugh, P; Furukawa, M; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Kanai, M; Kawabe, K; Komatsu, Y; Nakamori, S; Okusaka, T; Ozaka, M; Sato, A; Shimizu, S; Sugimori, K; Tang, R; Ueno, M | 1 |
| Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J | 1 |
| El Shazely, B; Kim, JJ; Kuropka, B; Nath, A; Rodríguez-Rojas, A; Rolff, J; Santi, G; Weise, C | 1 |
| Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH | 1 |
| Ammori, JB; Bingmer, K; Hardacre, JM; Hue, JJ; Sugumar, K; Winter, JM | 1 |
| Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW | 1 |
| Karaca, M; Kayahan, N; Özet, A; Satış, H; Yapar, D | 1 |
| Arrigoni, E; Catanese, S; Crucitta, S; Cucchiara, F; Danesi, R; Del Re, M; Fornaro, L; Massa, V; Morganti, R; Pecora, I; Rofi, E; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Sardar, M; Shroff, RT | 1 |
| Chan, SK; Chan, SY; Choi, HC; Kwong, DL; Lam, KO; Lee, AW; Lee, VH; Leung, TW; Luk, MY; Tong, CC | 1 |
| Atias, D; Berger, R; Borgida, A; Cuggia, A; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Glick, Y; Golan, T; Grant, RC; Halperin, S; Holter, S; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Park, JP; Raitses-Gurevich, M; Renouf, DJ; Schaeffer, DF; Stossel, C; Wang, Y; Williamson, L; Wilson, JM; Wong, HL; Zhang, A; Zogopoulos, G | 1 |
| Bendell, J; Greil, R; Gueorguieva, I; Hecht, JR; Hozak, RR; Lin, Y; Lonardi, S; Lopez, CD; Macarulla, T; Muñoz Martin, AJ; Park, JO; Rao, S; Ryoo, BY; Sim, HW; Van Cutsem, E; Wang, H | 1 |
| Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D | 1 |
| Ergözen, S; Gümüş, T | 1 |
| Jaeger, M; Klassen, MD; Reinders, LMH; Schmidt, TC; Teutenberg, T; Tuerk, J; Vom Eyser, C | 1 |
| Al-Rajabi, R; Balducci, L; Banks, J; Brenner, W; Coveler, AL; Elquza, E; George, TJ; Hatoum, H; Hewitt, DB; Kennedy, E; Lavu, H; Leiby, B; Link, C; LoConte, N; Musher, B; Nissen, N; Rossi, G; Seng, J; Vaccaro, G; Vahanian, N; Yeo, CJ | 1 |
| Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M | 1 |
| Besselink, MG; Bonsing, BA; Bos, H; Bosscha, KP; Coene, PPLO; de Hingh, IHJT; de Vos-Geelen, J; Groot Koerkamp, B; Homs, MYV; Janssen, QP; Karsten, TM; Liem, MSL; Loosveld, OJL; Patijn, GA; van Dam, JL; van der Kolk, MB; van Eijck, CHJ; van Santvoort, HC; van Tienhoven, G; Wilmink, JW; Zonderhuis, BM | 1 |
| Han, HS; Hwang, JH; Kim, H; Kim, J; Lee, JC; Shin, DW; Yoon, YS | 1 |
| Astaras, C; Borner, M; De Dosso, S; Fritsch, R; Meisel, A; Siebenhüner, AR; Szturz, P; Winder, T | 1 |
| Amini, A; Attiyeh, MA; Chung, V; Melstrom, LG | 1 |
| Brown, ZJ; Cloyd, JM | 1 |
| Berger, AK; Bougatf, N; Busch, E; Hackert, T; Jäger, D; Springfeld, C; Werft, W | 1 |
| Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D | 1 |
| Alig, S; Bararia, D; Boeck, S; Haas, M; Haebe, S; Heinemann, V; Kobold, S; Kruger, S; Metzger, P; Ormanns, S; Rataj, F; Sams, L; von Bergwelt-Baildon, M; Weigert, O; Werner, J; Westphalen, CB; Zhang, D | 1 |
| Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Barth, DA; Djanani, A; Gantschnigg, A; Gerger, A; Greil, R; Horvath, L; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Rossmann, CH; Schaberl-Moser, R; Schlick, K; Schwarzenbacher, E; Stöger, H; Stotz, M | 1 |
| Ashrafi-Zadeh, A; Chan, DL; Chua, TC; Clarke, S; Diakos, C; Gill, A; Hruby, G; Jamieson, NB; Kneebone, A; Maloney, S; Mittal, A; Nahm, CB; Pavlakis, N; Samra, JS; Wijetunga, AR | 1 |
| Cho, IR; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK | 1 |
| Chung, V; Fakih, M; Franko, J; Le, VH; Paz, BI; Singh, G | 1 |
| Cui, J; Pan, LX; Tan, HF; Xiao, Z; Zhang, LL | 1 |
| Bartolini, G; Bernardini, L; Casadei-Gardini, A; Cucchetti, A; Frassineti, GL; Massa, V; Passardi, A; Rapposelli, IG; Vivaldi, C | 1 |
| Arima, S; Fukahori, M; Hashimoto, S; Honda, T; Ide, Y; Ido, A; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Baydogan, S; Dong, W; Fogelman, DR; Hasanov, M; Javle, MM; Katz, MHG; Kim, MP; Lotze, MT; McAllister, F; Mizrahi, JD; Mohindroo, C; Overman, MJ; Pant, S; Prakash, LR; Rogers, JE; Tzeng, CD; Varadhachary, GR; Wolff, RA | 1 |
| Ay, C; Barth, DA; Djanani, A; Fandler-Höfler, S; Gantschnigg, A; Gary, T; Gerger, A; Greil, R; Gressenberger, P; Hatzl, S; Horvath, L; Jost, PJ; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Schlick, K; Schwarzenbacher, E; Stotz, M | 1 |
| Cui, J; Cui, X; Gong, W; Han, X; Lau, WY; Li, H; Li, M; Li, X; Liu, Y; Ren, T; Song, X; Wang, L; Wang, X; Wu, W; Wu, X; Zhu, Y; Zou, L | 1 |
| Correia, C; Ferreira, A; Lapa, R; Santos, J; Urtti, A; Vale, N; Yliperttula, M | 1 |
| Chen, J; Hua, Q; Lin, Z; Pi, G; Wang, H; Yu, D; Zhang, D; Zhang, T; Zhao, L | 1 |
| Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ | 1 |
| Arscott, WT; Bear, A; Ben-Josef, E; Drebin, J; Lee, MK; Loaiza-Bonilla, A; Lukens, JN; Metz, J; Nead, KT; O'Hara, M; Plastaras, JP; Reiss, KA; Shabason, J; Shroff, SG; Teitelbaum, U; Venigalla, S; Wojcieszynski, A | 1 |
| Ata, FK; Yalcin, S | 1 |
| Baron, MK; Garrido-Laguna, I; Haaland, B; Moser, JC; Nevala-Plagemann, C; Wang, X | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Cavaletti, G; Celio, L; Damian, S; Malacrida, A; Mazzaferro, V; Miloso, M; Rigolio, R | 1 |
| Carvalho, T; Castillo Martin, M; Costa, B; Couto, N; Fior, R; Rebelo de Almeida, C; Tavares Barroso, M | 1 |
| Au, T; Biskupiak, J; Kharat, AA; Nelson, R | 1 |
| Amundsen, T; Doyle, J; Hall, JA; Raiyani, C; Wong, L | 1 |
| Hwang, JH; Kim, J; Kim, JH; Lee, JC; Lee, YS | 1 |
| Akouz, FK; Barbier, E; Bourgeois, V; Coriat, R; Dahan, L; Desrame, J; Edeline, J; Ghiringhelli, F; Lecomte, T; Louafi, S; Ly, VL; Malka, D; Manfredi, S; Michel, P; Molin, Y; Neuzillet, C; Perrier, H; Phelip, JM; Soularue, E; Terrebonne, E | 1 |
| Hong, TH; Kim, H; Lee, MA; Park, SJ; Shin, K; Suh, JH | 1 |
| Chao, Y; Lee, CY; Li, CP; Lin, LG; Yu, HY | 1 |
| Arias, J; Beca, J; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Forbes, L; Gavura, S; Habbous, S; Raphael, MJ; Raskin, W; Tai, X | 1 |
| Assenat, E; de la Fouchardière, C; Debourdeau, A; Desseigne, F; Fiess, C; Iltache, S; Mazard, T; Mollevi, C; Portales, F; Ychou, M | 1 |
| Elango, S; Finkelmeier, F; Koch, C; Pession, U; Queck, A; Schmidt, J; Trebicka, J; Trojan, J; Waidmann, O; Walter, D | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Arıkan, R; Atcı, MM; Ay, S; Doğan, İ; Dülgar, Ö; Gümüş, M; Öven, BB; Öztosun, B; Özyükseler, DT; Paksoy, N; Taştekin, D | 1 |
| Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H | 1 |
| Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S | 1 |
| Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
| Bates, SE; Hur, C; Ingram, MA; Kastrinos, F; Kong, CY; Lauren, BN; Lim, F; Manji, GA; Park, J; Pumpalova, Y | 1 |
| Abi Jaoude, J; Delahoussaye, AM; Feng, N; Fowlkes, N; Fujimoto, TN; Garcia Garcia, CJ; Gay, JP; Green, M; Marszalek, J; Molkentine, J; Taniguchi, CM | 1 |
| Cao, Y; Jiang, L; Jin, G; Ju, X; Liu, W; Ye, Y; Zhang, H; Zhao, X; Zhu, X | 1 |
| Inoue, Y; Ito, H; Mie, T; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Ushida, Y | 2 |
| Abe, Y; Daiku, K; Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Maeda, S; Nakabori, T; Ohkawa, K; Takada, R; Uehara, H; Urabe, M; Yamai, T | 1 |
| Ishii, M; Itano, O; Itano, S; Morinaga, J; Shirakawa, H | 1 |
| Li, X; Lu, W; Tang, K; Wang, L | 1 |
| Cai, MB; Li, ZM; Nie, YH; Tan, YR; Yang, Q; Zhu, HB | 1 |
| Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G | 1 |
| Fujita, Y; Hayashi, K; Hirano, A; Hori, Y; Inoue, T; Kataoka, H; Kato, A; Kato, H; Miyabe, K; Naiki-Ito, A; Naitoh, I; Natsume, M; Nishi, Y; Okumura, F; Sano, H; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Arciero, V; Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Isaranuwatchai, W; Luo, J; Mittmann, N; Parmar, A; Raphael, MJ; Tadrous, M | 1 |
| Lou, J; Lu, W; Tang, K; Wang, L | 1 |
| Ananda, S; Burge, M; Chee, CE; Clarke, K; Cooray, P; Fox, A; Gibbs, P; Harris, M; Knowles, B; Lee, B; Lipton, L; Mclachlan, SA; Nagrial, A; Nikfarjam, M; Pattison, S; Shapiro, J; Tebbutt, N; Thomson, B; Usatoff, V; Walpole, I; Wong, R; Zielinski, R | 1 |
| Hattori, N; Hayashi, M; Inokawa, Y; Kanda, M; Kodera, Y; Kurimoto, K; Nakayama, G; Otsu, T; Shimizu, D; Takami, H; Tanaka, C; Tanaka, H; Tanaka, N | 1 |
| Asagi, A; Hiasa, Y; Hino, K; Hyodo, I; Imamura, Y; Inoue, T; Kajiwara, T; Kanemitsu, K; Koizumi, M; Kokubu, M; Kumagi, T; Marui, K; Nadano, S; Nakasya, A; Nishide, N; Nishina, T; Numata, Y; Okujima, Y; Sakaguchi, C; Terao, T; Yoshimatsu, M | 1 |
| Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R | 1 |
| Artru, P; Assenat, E; Bauguion, L; Ben Abdelghani, M; Biagi, JJ; Bouché, O; Castan, F; Conroy, T; Evesque, L; Hammel, P; Lambert, A; Lecomte, T; Lopez, A; Mitry, E; Monard, L; Turpin, A; Wei, AC; Ychou, M | 1 |
| Bertram, M; Binninger, A; Chiabudini, M; Hegewisch-Becker, S; Hollerbach, SH; Jänicke, M; Kaiser-Osterhues, A; Kreher, S; Marschner, N; Reiser, M; von der Heyde, E; Wolf, T | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Mori, C; Okamoto, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T | 1 |
| Dong, LP; Liu, YM; Lu, WJ; Tang, KZ | 1 |
| Huitema, ADR; Otten, HM; Verkerk, K | 1 |
| Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M | 1 |
| Agyare, E; Bulusu, R; Ebesoh, D; Frimpong, E; Han, B; Inkoom, A; Ndemazie, NB; Trevino, J; Zhu, X | 1 |
| Artru, P; Auvray Kuentz, M; Coutzac, C; de Mestier, L; Drouillard, A; Hammel, P; Hautefeuille, V; Lecomte, T; Lièvre, A; Malka, D; Nardon, V; Pernot, S; Taieb, J; Touchefeu, Y; Tran-Minh, ML; Trouilloud, I; Turpin, A; Williet, N; Zaanan, A | 1 |
| Arora, P; Boyne, DJ; Brenner, DR; Cheung, WY; Gupta, A; Hernán, MA; Mackay, E; Wasiak, R | 1 |
| Fujimori, N; Fukuda, H; Furukawa, M; Furuse, J; Ikeda, M; Imaoka, H; Ishii, H; Kamata, K; Katanuma, A; Kataoka, T; Katayama, H; Kobayashi, S; Komatsu, Y; Miwa, H; Mizukoshi, E; Mizuno, N; Mizusawa, J; Nakachi, K; Ohba, A; Okano, N; Okusaka, T; Ozaka, M; Sasahira, N; Takayama, Y; Terashima, T; Todaka, A; Tsumura, H; Ueno, M; Yamamoto, T | 1 |
| Su, J; Wang, W; Yang, L; Zhou, F | 1 |
| Altaner, C; Altanerova, U; Jakubechova, J; Klimova, D; Nicodemou, A; Repiska, V; Styk, J; Szemes, T | 1 |
| Aldakkak, M; Christians, KK; Clarke, CN; Erickson, BA; Evans, DB; George, B; Hall, WA; Kamgar, M; Smith, ZL; Thalji, SZ; Tolat, PP; Tsai, S | 1 |
| Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Coburn, N; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Raphael, M; Saluja, R | 1 |
| Huang, W; Lai, J; Li, R; Li, X; Lin, Z; Tan, J; Wang, W; Yang, S | 1 |
| de Geus, SWL; Sachs, TE | 1 |
| Nowak, D; Quartucci, C; Rakete, S; Rooney, JPK | 1 |
| Aronson, A; Cohen, DJ; Fulop, DJ; Labiner, AJ; Lucas, AL; Sigel, KM; Wisnivesky, J; Wu, YL; Zylberberg, HM | 1 |
| Boutin, R; Catalano, P; Dotan, E; Ioffe, D; Lenchik, L; Li, D; Marques, HS; O'Dwyer, PJ; Simon, MA; Wagner, LI; Wong, TZ; Yao, X; Zhen, DB | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shinohara, Y; Shirakawa, T; Taguchi, H; Ueda, Y; Ueno, S; Ureshino, N | 1 |
| Abdallah, R; Ahmad, SA; Aminjonov, B; Boyer, E; Choi, YJ; Clavien, PA; Eshmuminov, D; He, J; Held, U; Helton, S; Hoffe, SE; Jang, JY; Katz, MHG; Kim, H; Lehmann, K; Lopez-Lopez, V; Maggino, L; Malinka, T; Malleo, G; Maloney, S; Palm, RF; Park, JY; Patel, S; Prakash, L; Rangelova, E; Rose, JB; Rössler, F; Sahora, K; Salvia, R; Schmocker, RK; Schneider, MA; Shaib, WL; Taieb, J; Timmermann, L; Wilson, GC; Yoo, C | 1 |
| Akdeniz, N; Beşiroğlu, M; Demirci, A; Ergün, Y; İnanç, M; Işikdoğan, A; Kaplan, MA; Kiliçkap, S; Küçüköner, M; Şendur, MAN; Topçu, A; Uncu, D; Urakçi, Z; Yerlikaya, H | 1 |
| Fu, L; Han, W; Lv, K; Tian, Y; Zhou, X | 1 |
| Akazawa, M; Asami, H; Shibahara, R; Takumoto, Y | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Okabe, Y; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Caron, M; Fitzgerald, TL; Nicolais, LM; Verdini, N | 1 |
| Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C | 1 |
| Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ | 1 |
| Bhardwaj, N; Chen, KT; Ebot, E; Fabrizio, D; Fleischmann, Z; Frampton, G; He, J; Hegde, P; Jin, D; Lofgren, KT; Madison, R; Moore, J; Newberg, J; Pishvaian, MJ; Schrock, A; Singhi, A; Sokol, E | 1 |
| Jiang, X; Lee, MJ; Lin, W; Luo, T; Tillman, L | 1 |
| Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L | 1 |
| Besselink, MG; Busch, OR; Doppenberg, D; Farina, A; Kazemier, G; Mebius, RE; Meijer, LL; van Ee, T; van Kooyk, Y; Versteijne, E; Wilmink, JW; Zwart, ES | 1 |
| Chang, I; Chang, WJ; Chen, R; Circelli, J; Harpel, Z; Rivera, J; Wei, R; Wu, S | 1 |
| Amin, M; Bansod, S; Boice, N; Brown, A; Grierson, PM; Lim, KH; Liu, J; Park, H; Pedersen, KS; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A | 1 |
| Çubukçu, E; Dede, DŞ; Deligönül, A; Dizdar, Ö; Doğan, A; Emre Yildirim, M; Eraslan, E; Erol, C; Esen, SA; Günel, N; Odabaş, H; Öksüzoğlu, ÖB; Özdemir, N; Özet, A; Şahin, AB; Şahin, TK; Sütcüoğlu, O; Turan, N; Uçar, G; Üner, A; Yazici, O; Yilmaz, F | 1 |
| Busch, OR; de Wilde, RF; Molenaar, IQ; Seelen, LWF; van Santvoort, HC; Wilmink, JW | 1 |
230 review(s) available for gemcitabine and fluorouracil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Multi-target compounds acting in cancer progression: Focus on thiosemicarbazone, thiazole and thiazolidinone analogues.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Drug Delivery Systems; Drug Discovery; Humans; Intracellular Signaling Peptides and Proteins; Neoplasms; Thiazoles; Thiazolidines; Thiosemicarbazones | 2019 |
Current status of carbazole hybrids as anticancer agents.
Topics: Antineoplastic Agents; Carbazoles; Cell Cycle Checkpoints; Cell Proliferation; Coumarins; Humans; Indoles; Pyrazoles; Pyrimidines; Structure-Activity Relationship | 2022 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Growth Substances; Humans; Immunologic Factors; Octreotide; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Taxoids | 1996 |
Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Bromodeoxyuridine; Combined Modality Therapy; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Idoxuridine; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1995 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasms; Polysaccharides, Bacterial; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidylate Synthase; Uracil | 1995 |
New developments in chemotherapy for patients with advanced pancreatic cancer.
Topics: Analgesics; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pain; Pancreatic Neoplasms | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1997 |
Clinical experience with gemcitabine in pancreatic carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Evaluation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Safety; Survival Rate; Treatment Outcome | 1997 |
Tumor resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Amplification; Humans; Methotrexate; Mutation; Neoplasms; Quinazolines; Thiophenes | 1998 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed | 1998 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Mitomycin; Neoplasm Metastasis; Nitrosourea Compounds; Pancreatic Neoplasms | 1998 |
Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
[Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Multicenter Studies as Topic; Palliative Care; Pancreatic Neoplasms; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 1999 |
Antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Methotrexate | 1999 |
Clinical update of gemcitabine in pancreas cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2000 |
[Adjuvant therapy of pancreatic carcinoma].
Topics: Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
The role of gemcitabine alone and in combination in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
[Palliative therapy of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Palliative Care; Pancreatic Neoplasms | 2001 |
Neoadjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2001 |
A systematic overview of chemotherapy effects in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis | 2001 |
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Methotrexate; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2001 |
New cytotoxic agents and schedules for advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Liposomes; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
[Preclinical studies of oxaliplatin in combination chemotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Mice; Models, Biological; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
Recent advances in the use of radiosensitizing nucleosides.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life | 2001 |
Pancreatic cancer: what the oncologist can offer for palliation.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Mutation; Neoplasm Recurrence, Local; Organophosphonates; Palliative Care; Pancreatic Neoplasms | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
[Radiotherapy and chemotherapy for unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycin; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage | 2002 |
What's new in pancreatic cancer treatment?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Analysis | 2002 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
Present and future treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2002 |
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Autonomic Nerve Block; Celiac Plexus; Cholestasis; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Digestive System Diseases; Fluorouracil; Gastric Outlet Obstruction; Gemcitabine; Humans; Neoplasm Metastasis; Neuralgia; Palliative Care; Pancreatic Neoplasms; Risk Factors; Stents | 2002 |
[Gemcitabine and pancreatic cancer].
Topics: Adenocarcinoma; Analgesia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Europe; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Chemoradiation with novel agents for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Rectal Neoplasms | 2002 |
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Capecitabine; Cell Membrane; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Tumor Cells, Cultured; Vidarabine | 2002 |
The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; Taxoids; Transcription Factors; Treatment Failure | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Future directions in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2002 |
Chemotherapy for biliary tract cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Japan | 2002 |
Developments in the systemic therapy of pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasm Proteins; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Signal Transduction; Topoisomerase I Inhibitors; United States | 2003 |
[Adjuvant and additive therapy for cancer of the pancreas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Folic Acid; Gemcitabine; Hematinics; Humans; Leucovorin; Male; Mitoxantrone; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Surveys and Questionnaires; Time Factors | 2003 |
Systemic therapy for advanced pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Signal Transduction; Topoisomerase I Inhibitors | 2002 |
Chemotherapeutic advances in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2003 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
Monotherapy options in the management of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
[Adjuvant treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Intraoperative Care; Metalloendopeptidases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organic Chemicals; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Phenylbutyrates; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Time Factors | 2003 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Random Allocation; Treatment Outcome | 2003 |
[Chemoradiation in pancreatic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2003 |
Pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2003 |
Advanced pancreatic cancer: is there a role for combination therapy?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine Endopeptidases; Deoxycytidine; Fluorouracil; Gemcitabine; Genes, ras; Glutamates; Guanine; Humans; Multienzyme Complexes; Pancreatic Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Sesquiterpenes | 2003 |
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
[Conservative therapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peripheral Blood Stem Cell Transplantation | 2004 |
Emerging drugs in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Growth Inhibitors; Humans; Immunotherapy; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Receptors, Growth Factor; Risk Factors; Survival Rate; Treatment Outcome | 2004 |
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Epithelial Cells; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2004 |
New approaches for pancreatic cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Infusions, Intra-Arterial; Japan; Pancreatic Neoplasms; Stem Cell Transplantation | 2004 |
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Preoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2004 |
[Chemoradiation for pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Time Factors | 2004 |
Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal | 2005 |
The role of chemotherapy in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Experience with docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2005 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids | 2005 |
Chemotherapy dosing in the setting of liver dysfunction.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Topotecan | 2005 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
[Combination chemotherapy in unresectable pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2006 |
[Systemic chemotherapy with gemcitabine for advanced biliary tract carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Treatment Outcome | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors | 2006 |
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Postoperative Complications; Radiotherapy Dosage | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Lung Neoplasms; Lymphoma, Non-Hodgkin; Mucositis; Neoplasms; Prednisone; Radiotherapy; Severity of Illness Index; Stomatitis; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2006 |
Chemoradiotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Palliative Care; Survival Analysis | 2006 |
[Chemotherapy for metastatic breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diphosphonates; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Meta-Analysis as Topic; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic | 2006 |
Capecitabine in carcinoma of the pancreas.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
[Arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Administration Schedule; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Mesenteric Artery, Superior; Mitomycin; Pancreatic Neoplasms; Quality of Life; Radiography; Survival Rate | 2006 |
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
Urachal carcinoma: surgical and chemotherapeutic options.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Gemcitabine; Hematuria; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Risk Factors; Umbilicus; Urachal Cyst; Urachus; Urinary Bladder Neoplasms | 2006 |
Pancreatic cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2007 |
Treatment of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Survival Rate | 2007 |
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2007 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur | 2007 |
Locally advanced pancreatic cancer: a review.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2007 |
Future chemoradiation strategies in pancreatic cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Radiotherapy, Adjuvant | 2007 |
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Digestive System Neoplasms; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms | 2007 |
Neoadjuvant and adjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis | 2008 |
[Chemotherapy and radiotherapy for inoperable pancreatic cancer. A survey of a Cochrane review].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Survival Rate | 2007 |
[Radiation therapy in pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2008 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Radiochemotherapeutic options for bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Radiography; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
New directions in the management of advanced pancreatic cancer: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Quinazolines | 2008 |
Systemic therapy for biliary tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
Topics: Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2008 |
Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Data Interpretation, Statistical; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
The integration of chemoradiation in the care of patient with localized pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2009 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DNA Repair; Fluorouracil; Gemcitabine; Humans; Neoplasms; Oxygen Consumption; Radiation Tolerance; Temozolomide | 2009 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Medical management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Helicobacter Infections; Helicobacter pylori; Humans; Male; Overweight; Palliative Care; Pancreatic Neoplasms; Risk Factors; Smoking | 2009 |
Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2009 |
Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Maximum Tolerated Dose; Palliative Care; Treatment Outcome | 2009 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Palliative Care; Pancreatic Neoplasms; Radiography; Spinal Neoplasms; Vinblastine; Vinorelbine | 2009 |
Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Predictive Value of Tests; Prognosis; Research Design; Risk Assessment; Risk Factors; Salvage Therapy; Survival Analysis | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Drug Therapy; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms | 2010 |
Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2010 |
Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Curcumin; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Survival Rate | 2010 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2010 |
Curative radiation therapy for pancreatic malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radiotherapy, Adjuvant; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment | 2010 |
Chemotherapy for thymic tumors: induction, consolidation, palliation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoadjuvant Therapy; Palliative Care; Procarbazine; Thymoma; Thymus Neoplasms; Vincristine | 2011 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Treatment of early-stage pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
[Second line chemotherapy for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2011 |
Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2011 |
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
[Evidences for adjuvant therapy of resected pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms | 2011 |
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Role of myeloid-derived suppressor cells in tumor immunotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Myeloid Cells; Neoplasms; T-Lymphocytes, Regulatory | 2012 |
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Ultrasonic Therapy | 2012 |
Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
What options are available for refractory pancreatic cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms | 2012 |
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Molecular Targeted Therapy; Mutation; Pancreatic Neoplasms; Signal Transduction | 2012 |
Role of chemotherapy in treatments for biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrimidines | 2014 |
New biomarkers and targets in pancreatic cancer and their application to treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; CD40 Antigens; Computational Biology; Deoxycytidine; Drug Therapy, Combination; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Gene Rearrangement; Hedgehog Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome | 2012 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Nausea; Neutropenia; Salvage Therapy; Stomatitis; Survival Analysis; Taxoids; Thrombocytopenia; Vomiting; Young Adult | 2013 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
[Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycin; Multicenter Studies as Topic; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.
Topics: Administration, Inhalation; Adsorption; Aerosols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Lung; Lung Neoplasms; Particle Size; Platinum Compounds; Small Cell Lung Carcinoma; Taxoids | 2013 |
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate | 2003 |
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Survival; Taxoids | 2013 |
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Survival; Treatment Outcome | 2013 |
Immunological off-target effects of standard treatments in gastrointestinal cancers.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cytotoxicity, Immunologic; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Taxoids; Tumor Escape; Tumor Microenvironment | 2014 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur | 2013 |
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunity, Cellular; Immunologic Factors; Interleukin-1beta; Neoplasms; Th17 Cells | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].
Topics: Animals; Carrier Proteins; CD4-Positive T-Lymphocytes; Deoxycytidine; Epoxy Compounds; Fluorouracil; Gemcitabine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inflammasomes; Interleukin-17; Interleukin-1beta; Mice; Myeloid Cells; Neoplasms; Neovascularization, Pathologic; NLR Family, Pyrin Domain-Containing 3 Protein; Tyrosine | 2014 |
Role of solute carrier transporters in pancreatic cancer: a review.
Topics: Adenocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2014 |
Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Mast Cells; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Tumor Microenvironment | 2014 |
Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans | 2014 |
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Mitomycin; Neoplasm Staging; Randomized Controlled Trials as Topic; Uterine Cervical Neoplasms | 2014 |
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Neoplasms; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Escape; Tumor Microenvironment | 2015 |
Pancreatic cancer, treatment options, and GI-4000.
Topics: Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Neoadjuvant Therapy; Pancreatic Neoplasms | 2016 |
Systemic Chemotherapy in Advanced Pancreatic Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2016 |
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Prognosis | 2016 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2016 |
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Estrogen Receptor Modulators; Fluorouracil; Gemcitabine; Humans; Metformin; Methotrexate; Neoplasms; Paclitaxel; Tubulin Modulators | 2017 |
[Chemotherapy for Biliary Tract Cancer].
Topics: Antineoplastic Agents; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Fluorinated nucleosides as an important class of anticancer and antiviral agents.
Topics: Antineoplastic Agents; Antiviral Agents; Deoxycytidine; Fluorine; Fluorouracil; Gemcitabine; HIV; Neoplasms; Nucleoside Transport Proteins; Nucleosides; Positron-Emission Tomography | 2017 |
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2018 |
A look at the progress of treating pancreatic cancer over the past 20 years.
Topics: Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms; Survival Rate | 2018 |
Chemotherapy and radiotherapy for advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
Topics: Adult; Antineoplastic Agents; Chemical Safety; Cyclophosphamide; Deoxycytidine; Endocrine Disruptors; Fluorouracil; Gemcitabine; Hazardous Substances; Humans; Ifosfamide; Nursing Staff, Hospital; Observational Studies as Topic; Occupational Exposure; Pharmacists; Pharmacy Technicians | 2018 |
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Models, Economic; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Technology Assessment, Biomedical | 2018 |
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia; Immunotherapy; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
Management and supportive treatment of frail patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Frail Elderly; Frailty; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction | 2019 |
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Tumor Burden | 2019 |
Selecting chemotherapy for pancreatic cancer: Far away or so close?
Topics: Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Margins of Excision; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2019 |
Neoadjuvant Treatment for Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2019 |
Systemic treatment of pancreatic cancer revisited.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2019 |
Managing the economic impact of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost Control; Cost-Benefit Analysis; Deoxycytidine; Early Detection of Cancer; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Pancreatic Neoplasms; Terminal Care | 2019 |
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Diabetes Mellitus; Diet; Drug Resistance, Neoplasm; Early Detection of Cancer; Fluorouracil; Gemcitabine; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Radiosurgery; Risk Factors; Spain | 2019 |
Adjuvant treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2019 |
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
Topics: Albumin-Bound Paclitaxel; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome | 2019 |
[New progress in the treatment of locally advance pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2019 |
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Second-line treatment for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with oth
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2020 |
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Survival Rate; Treatment Outcome; Tumor Microenvironment | 2020 |
Contemporary management of pancreas cancer in older people.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Enhanced Recovery After Surgery; Fluorouracil; Gemcitabine; Geriatric Assessment; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2021 |
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.
Topics: Cytarabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasms; Phosphorylation; Prodrugs; Pyrimidines | 2020 |
Biliary cancer: gateway to comprehensive molecular profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Leucovorin; Mutation; Oncogene Proteins, Fusion; Organoplatinum Compounds; Survival Rate | 2021 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease Management; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Precision Medicine | 2021 |
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Publication Bias; Treatment Outcome | 2021 |
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Update on Chemoresistance Mechanisms to First-Line Chemotherapy for Gallbladder Cancer and Potential Reversal Strategies.
Topics: Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans | 2023 |
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms | 2023 |
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Multicenter Studies as Topic; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2023 |
336 trial(s) available for gemcitabine and fluorouracil
| Article | Year |
|---|---|
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Retreatment; Survival Rate; Treatment Outcome | 1996 |
Objective outcome measures of quality of life.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Pain; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 1996 |
Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps; Male; Middle Aged; Morphine; Narcotics; Pain; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 1997 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed | 1998 |
Adjuvant therapy for pancreatic cancer: back to the future.
Topics: Antimetabolites, Antineoplastic; Clinical Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1998 |
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 1999 |
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Survival Analysis; Treatment Outcome | 1999 |
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 1999 |
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Time Factors; Treatment Outcome | 1999 |
Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 1999 |
A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 2000 |
A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; New England; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2000 |
Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms | 2000 |
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Treatment Outcome | 2000 |
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Survival Analysis | 2000 |
A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2001 |
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Survival Analysis | 2001 |
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Remission Induction | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2001 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Remission Induction; Survival Analysis | 2001 |
A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2002 |
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2002 |
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids | 2002 |
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2002 |
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Heart Arrest; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Thalidomide; Thromboembolism | 2002 |
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged | 2002 |
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Patients; Uracil | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Hand, Foot and Mouth Disease; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Syndrome; Treatment Outcome | 2003 |
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Switzerland | 2003 |
Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2003 |
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms | 2003 |
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taiwan; Treatment Outcome | 2003 |
[Experience with the treatment of advanced pancreatic cancer in Hungary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Treatment Outcome | 2003 |
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Male; Prognosis; Survival Rate | 2003 |
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Treatment Outcome | 2003 |
First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclin G; Cyclin G1; Cyclins; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Hemodynamics; Humans; Infusions, Intravenous; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Retroviridae; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain | 2004 |
Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2004 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Treatment Outcome | 2004 |
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2004 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2004 |
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Digestive System Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2004 |
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Radiometry; Time Factors; Treatment Outcome | 2004 |
Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
[Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Intraoperative Period; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Survival Rate | 2004 |
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Survival Analysis | 2005 |
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Hematologic Diseases; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Treatment Outcome | 2005 |
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Radiotherapy Dosage | 2005 |
5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Survival Analysis | 2005 |
[A phase II study of combination chemotherapy with gemcitabine, 5-fluorouracil, and cisplatin for advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Italy; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclin A; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Respiratory Tract Neoplasms; S Phase | 2005 |
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2005 |
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Analysis; Thrombocytopenia | 2005 |
Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neurotoxicity Syndromes; Organoplatinum Compounds; Stomach Neoplasms; Survival Rate | 2005 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Colorectal Neoplasms; Cytotoxicity, Immunologic; Deoxycytidine; Disease Progression; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes, Regulatory; Thymidylate Synthase; Treatment Outcome | 2005 |
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2005 |
A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2005 |
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle; Bone Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Doxorubicin; Fatigue; Female; Fluorouracil; Gemcitabine; Hepatitis B, Chronic; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Proteins; Paresthesia; Polyethylene Glycols; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Hyperbilirubinemia; Infusions, Intravenous; Male; Middle Aged; Mucositis; Neutropenia; Pancreatic Neoplasms; Patient Compliance; Quality of Life; Spain; Survival Analysis; Treatment Outcome | 2005 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Probability; Prognosis; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pneumonia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vitamin B Complex | 2006 |
Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Biomarkers; Cancer Care Facilities; Comet Assay; Cyclophosphamide; Cytarabine; Deoxycytidine; DNA Damage; Environmental Monitoring; Epidemiological Monitoring; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Italy; Lymphocytes; Male; Middle Aged; Mouth Mucosa; Nursing Staff, Hospital; Occupational Exposure; Pharmacy Service, Hospital | 2006 |
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunity, Cellular; Lipopolysaccharides; Liver Neoplasms; Macrophages; Male; Middle Aged; Monocytes; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Tumor Necrosis Factor-alpha | 2006 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2007 |
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life | 2006 |
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Survival Rate | 2006 |
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2006 |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Treatment Outcome | 2007 |
[Effect of combined treatment methods on quality of life in patients with pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Data Interpretation, Statistical; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Status; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2006 |
Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Treatment Outcome | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Comorbidity; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Korea; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2007 |
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2007 |
[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Carcinoembryonic Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Neutropenia; Treatment Outcome | 2007 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2007 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Metastasis; Recombinant Proteins; Thalidomide | 2008 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2007 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis | 2007 |
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome | 2008 |
The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Time Factors | 2007 |
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2008 |
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Compliance; Survival Analysis | 2008 |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2007 |
[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Salvage Therapy; Survival Rate | 2008 |
Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2008 |
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies | 2008 |
A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Treatment Outcome | 2008 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis | 2008 |
A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Survival Rate | 2007 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2008 |
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Injections, Subcutaneous; Interleukin-2; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Recombinant Proteins; Treatment Outcome | 2008 |
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Deoxycytidine; Drug Administration Schedule; Europe; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Karnofsky Performance Status; Male; Middle Aged; Pain; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Time Factors; Treatment Failure | 2008 |
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Administration, Oral; Adult; Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Staging; Pain; Pain Measurement; Palliative Care; Quality of Life; Switzerland; Time Factors; Treatment Outcome | 2008 |
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2009 |
Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate | 2009 |
Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2009 |
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; RNA, Messenger; Treatment Outcome | 2009 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Deoxycytidine; Drug Interactions; Enoxaparin; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Pancreatic Neoplasms; Prospective Studies; Research Design; Survival Analysis; Swine; Venous Thromboembolism | 2008 |
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2009 |
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Survival Analysis; Taxoids | 2009 |
Second-line therapy in refractory pancreatic cancer. results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2009 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chi-Square Distribution; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Remission Induction; Risk Assessment; Survival Analysis | 2009 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
[Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Maximum Tolerated Dose; Pancreatic Neoplasms | 2009 |
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Pilot Projects; Salvage Therapy; Survival Analysis | 2010 |
Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Japan; Kidney Diseases; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2009 |
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Prognosis; PTEN Phosphohydrolase; Thymidylate Synthase; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2009 |
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2010 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines | 2010 |
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Salvage Therapy; Taxoids | 2010 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Quality of Life; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Pilot Projects; Salvage Therapy; Survival Analysis; Thymus Neoplasms | 2010 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomis
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Young Adult | 2009 |
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Adenosquamous; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Survival Rate | 2010 |
Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Time Factors; Treatment Outcome; United States | 2010 |
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Demography; Deoxycytidine; Enhancer Elements, Genetic; Female; Fluorouracil; Gemcitabine; Genotype; Homozygote; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2011 |
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Chemotherapy followed by chemoradiotherapy for locally advanced non-metastatic pancreatic cancer - a new paradigm?
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Radiotherapy | 2010 |
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunotherapy; Leucovorin; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Recombinant Proteins; Survival Analysis; T-Lymphocytes, Regulatory | 2010 |
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chicago; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Survival Analysis | 2011 |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Mucositis; Thrombocytopenia; Treatment Outcome | 2010 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival; Taxoids | 2011 |
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy; Safety; Survival Analysis | 2010 |
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Intention to Treat Analysis; Interferon-alpha; Interleukin-2; Italy; Kidney Neoplasms; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2010 |
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2011 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; France; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2012 |
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Guideline Adherence; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Survival Analysis | 2012 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Remission Induction | 2011 |
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gemcitabine; Health Status Indicators; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2011 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2012 |
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2011 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taiwan | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2012 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Thymidylate Synthase | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis | 2011 |
Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure | 2011 |
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Germany; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2012 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2012 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2011 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2012 |
A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Male; Middle Aged; Treatment Outcome | 2012 |
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Middle Aged | 2011 |
The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2012 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Young Adult | 2012 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2012 |
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Statistics, Nonparametric; Treatment Outcome | 2012 |
Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies | 2012 |
Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Surveys and Questionnaires; Treatment Outcome | 2013 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Immunomodulation; Immunotherapy; Interleukin-2; Irinotecan; Killer Cells, Natural; Male; Middle Aged; Recombinant Proteins; T-Lymphocyte Subsets | 2012 |
Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Young Adult | 2013 |
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Republic of Korea | 2012 |
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Prognosis; Survival Analysis; Watchful Waiting | 2012 |
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2012 |
Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Survival; Survival Rate; Treatment Outcome | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2012 |
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy, Active; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Analysis; Treatment Outcome; Trisaccharides | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting | 2012 |
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Treatment Failure | 2013 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Radiotherapy | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2013 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; DNA Mutational Analysis; Drug Administration Schedule; Exanthema; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Regression Analysis; Treatment Outcome | 2013 |
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Europe; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Leucovorin; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
[ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms; Vincristine | 2013 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Survival Rate | 2014 |
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Translational Research, Biomedical | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2014 |
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Clinical benefit response in pancreatic cancer trials revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Causality; Comorbidity; Deoxycytidine; Disease-Free Survival; Drug Therapy; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Palliative Care; Pancreatic Neoplasms; Quality of Life; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2014 |
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Enoxaparin; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Thromboembolism | 2014 |
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Prodrugs; Proportional Hazards Models; Taxoids; Treatment Outcome; Tubulin Modulators | 2014 |
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunomagnetic Separation; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Taxoids | 2014 |
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Drug Administration Schedule; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Rabbits; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pain; Pancreatic Ducts; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cell Separation; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Recombinant Proteins; T-Lymphocytes, Regulatory; Time Factors; Treatment Outcome | 2015 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Positron-Emission Tomography; Retreatment; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2015 |
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Failure | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2015 |
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Implants; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; RNAi Therapeutics | 2015 |
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Protocols; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Translational Research, Biomedical | 2015 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2018 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Polymorphism, Genetic; RecQ Helicases; Reproducibility of Results | 2016 |
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life | 2016 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cytoplasm; Deoxycytidine; Disease-Free Survival; ELAV-Like Protein 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Tissue Array Analysis; Treatment Outcome | 2018 |
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate | 2016 |
Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.
Topics: Aged; Deoxycytidine; Duodenum; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery; Radiotherapy Dosage | 2017 |
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Retrospective Studies | 2017 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Interferon-alpha; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Missouri; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate | 2017 |
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retreatment; Treatment Outcome | 2017 |
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2017 |
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Margins of Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Analysis | 2019 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Young Adult | 2018 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53 | 2019 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Middle Aged; Pancreatic Neoplasms; Polyethylene Glycols; Progression-Free Survival; Proportional Hazards Models | 2018 |
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2019 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Diseases, Interstitial; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies | 2018 |
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma; Cisplatin; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin | 2019 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2018 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Prospective Studies; Young Adult | 2019 |
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomiz
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2019 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Radiotherapy, Intensity-Modulated | 2020 |
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Patient Safety; Treatment Outcome | 2020 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Markov Chains; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Quality-Adjusted Life Years | 2020 |
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors | 2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Salvage Therapy | 2020 |
Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated | 2020 |
Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunoglobulin Fc Fragments; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Wnt Proteins | 2020 |
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Perioperative Care; Prospective Studies; Treatment Outcome | 2020 |
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Sunitinib | 2020 |
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Analysis | 2021 |
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2020 |
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2020 |
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Tegafur | 2020 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib | 2021 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Interleukin-10; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Thrombocytopenia | 2021 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Standard of Care; Survival Analysis | 2022 |
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled t
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Efficacy and safety of two different adjuvant chemotherapy regimens in combination with concurrent chemoradiotherapy in treating patients with advanced nasopharyngeal carcinoma: A protocol for randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2021 |
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2021 |
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2021 |
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Markov Chains; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; United States | 2021 |
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Time Factors | 2022 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2021 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Radiosurgery | 2022 |
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms | 2023 |
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms | 2023 |
The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defin
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms; Prospective Studies; Quality of Life | 2023 |
678 other study(ies) available for gemcitabine and fluorouracil
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Proliferation; DNA; DNA Replication; Dose-Response Relationship, Drug; Fibroblasts; HeLa Cells; Humans; Mice; Mice, Nude; Mice, SCID; Minichromosome Maintenance Complex Component 2; Molecular Structure; Nuclear Proteins; Phosphorylation; Piperidones; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrroles; Rats; Small Molecule Libraries; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Cycle Proteins; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Protein Serine-Threonine Kinases; Pyrimidines; Pyrroles; Structure-Activity Relationship; Transplantation, Heterologous | 2010 |
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gene Knockdown Techniques; Humans; Multidrug Resistance-Associated Proteins; Pancreas; Pancreatic Neoplasms; RNA; RNA Interference; Tumor Cells, Cultured | 2011 |
Synthesis and anticancer activity of new 1-[(5 or 6-substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Crystallography, X-Ray; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; G2 Phase; Humans; Molecular Conformation; Piperazines; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship | 2010 |
Synthesis, σ₁, σ₂-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes.
Topics: Adamantane; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Structure; Pancreatic Neoplasms; Receptors, sigma | 2012 |
Uvaridacols E-H, highly oxygenated antiausterity agents from Uvaria dac.
Topics: Antineoplastic Agents, Phytogenic; Cyclohexenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pancreatic Neoplasms; Plant Stems; Thailand; Uvaria | 2012 |
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Female; Humans; Male; Mice; Mice, SCID; Molecular Structure; Neuralgia; Ovarian Neoplasms; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Protein Binding; Receptors, sigma; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Bioactive sesterterpenoids from a Korean sponge Monanchora sp.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Furans; Humans; Korea; Marine Biology; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Porifera; Sesterterpenes; Spiro Compounds; Stereoisomerism | 2013 |
Sulfur-containing cytotoxic curvularin macrolides from Penicillium sumatrense MA-92, a fungus obtained from the rhizosphere of the mangrove Lumnitzera racemosa.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Combretaceae; Crystallography, X-Ray; Drug Screening Assays, Antitumor; Humans; Macrolides; Molecular Conformation; Molecular Structure; Penicillium; Structure-Activity Relationship; Sulfur; Zearalenone | 2013 |
Chemical Constituents of Mangifera indica and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.
Topics: Antineoplastic Agents, Phytogenic; Drug Screening Assays, Antitumor; Humans; Mangifera; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pancreatic Neoplasms; Plant Bark; Triterpenes; Vietnam | 2016 |
Minor chemical modifications of the aminosteroid derivative RM-581 lead to major impact on its anticancer activity, metabolic stability and aqueous solubility.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Estranes; Humans; Liver; Molecular Structure; Solubility; Structure-Activity Relationship; Tumor Cells, Cultured; Water | 2020 |
Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Thiadiazoles; Thiophenes; Tumor Cells, Cultured | 2020 |
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |
Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytidine Monophosphate; Drug Screening Assays, Antitumor; Drug Stability; Hepatocytes; Humans; Neoplastic Stem Cells; Stereoisomerism; Uridine Monophosphate | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; Doxorubicin; Drug Resistance; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Mice; Mice, Nude; Morpholines; Neoplasms; Neoplasms, Experimental; Protein Binding; Transplantation, Heterologous; Triamterene; Tumor Cells, Cultured; Vincristine | 1995 |
Clinical benefit as a primary efficacy endpoint.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 1998 |
Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arachnoid; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Meningeal Neoplasms; Middle Aged | 1999 |
[Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Multicenter Studies as Topic; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 1999 |
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Incidence; Liver; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Retrospective Studies; Stents | 2000 |
In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Etoposide; Fluorouracil; Gemcitabine; Humans; Mitomycin; Models, Chemical; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
Squamous cell carcinoma of the pancreas with cystic degeneration.
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Jaundice; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Cyst; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2000 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Urinary Tract Infections | 2000 |
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transport Proteins; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Purine Nucleosides; Quinazolines; Thiophenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
[Experience with chemotherapy for advanced pancreatic carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2001 |
Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Ascitic Fluid; Chromatography, High Pressure Liquid; Deoxycytidine; Fluorouracil; Gemcitabine; Hypertonic Solutions; Hypotonic Solutions; Infusions, Parenteral; Isotonic Solutions; Male; Molecular Weight; Pharmaceutical Vehicles; Random Allocation; Rats | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Intestinal permeability in patients with chemotherapy-induced stomatitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Digestive System Neoplasms; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Intestinal Absorption; Intestinal Mucosa; Lactulose; Leucovorin; Male; Mannitol; Middle Aged; Paclitaxel; Permeability; Stomatitis; Tegafur; Treatment Outcome; Xylose | 2001 |
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Methotrexate; Paclitaxel | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2001 |
[Prognosis of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Patient Selection; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Sex Factors; Time Factors | 2001 |
Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Cycle; Cytarabine; Deoxycytidine; DNA Ligase ATP; DNA Ligases; Dose-Response Relationship, Drug; Enzyme Activation; Fluorouracil; Gemcitabine; Humans; Hydroxyurea; Tumor Cells, Cultured | 2002 |
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2002 |
[Therapy of gallbladder carcinoma. Experience of a central hospital].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Palliative Care; Postoperative Care; Regression Analysis; Survival Analysis; Time Factors | 2002 |
Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Division; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retroviridae; Ribonucleotide Reductases; Tetracyclines; Transfection; Tumor Cells, Cultured | 2002 |
Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; In Vitro Techniques; Inhibitory Concentration 50; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Ribonuclease, Pancreatic; Tumor Cells, Cultured | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Interferon-beta; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Esophageal Neoplasms; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Humans; Methotrexate; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Tumor Cells, Cultured | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retreatment | 2002 |
Chemoradiation protocols offer only incremental gains for pancreatic cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2002 |
[A case of vulval extramammary Paget's disease associated with pancreatic cancer that was successfully treated with chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Paget Disease, Extramammary; Pancreatic Neoplasms; Vulvar Neoplasms | 2002 |
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Palliative Care | 2003 |
Sustained partial response of an intra-abdominal desmoid tumor treated with gemcitabine, 5-fluorouracil and leucovorin.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fibromatosis, Aggressive; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Treatment Outcome | 2003 |
[Pancreatic carcinoma--overcome technically but not oncologically].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Risk Factors | 2003 |
High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.
Topics: Animals; Antineoplastic Agents; Arabinonucleosides; Cell Division; Colonic Neoplasms; Cytosine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2003 |
The recent past and future of adjuvant therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant | 2003 |
[Pancreatic cancer--diagnostics and therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Neoadjuvant Therapy; Pancreatic Neoplasms | 2003 |
Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line.
Topics: Brefeldin A; Cell Division; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2003 |
Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Fluorouracil; gamma-Linolenic Acid; Gemcitabine; Pancreatic Neoplasms | 2003 |
[Novel chemoradiotherapy for locally advanced pancreatic cancer using arterial infusion chemotherapy following the alteration of peripancreatic blood flow].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Intraoperative Care; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Survival Rate | 2003 |
Forced expression of cytidine deaminase confers sensitivity to capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Survival; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Models, Animal; DNA, Complementary; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Thymidylate Synthase; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2003 |
A novel cell line and xenograft model of ampulla of Vater adenocarcinoma.
Topics: Adenocarcinoma; Ampulla of Vater; Animals; Cell Adhesion; Common Bile Duct Neoplasms; Deoxycytidine; DNA Methylation; Fluorouracil; Gemcitabine; Genes, p16; Genes, p53; Genes, ras; Humans; Immunophenotyping; Interferon-gamma; Karyotyping; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Ploidies; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. IJROBP 2003;57:98-104.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymphatic Irradiation; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2004 |
Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Deoxycytidine; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Interferon-gamma; Ligands; Pancreatic Neoplasms; Plasmids; Protein Binding; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Tetrahydronaphthalenes; Time Factors; Transcription Factors | 2004 |
Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gamma Rays; Gemcitabine; Humans; Liver Neoplasms; Radiation-Sensitizing Agents; Spheroids, Cellular; Time Factors | 2004 |
Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemoembolization, Therapeutic; Colonic Neoplasms; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Liver Neoplasms; Male; Microspheres; Neoplasm Transplantation; Organ Size; Rats; Rats, Inbred Strains; Tumor Burden | 2004 |
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Pancreatic Neoplasms; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies | 2004 |
Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Heart Neoplasms; Humans; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction | 2004 |
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Neoplasm Metastasis; Survival Rate | 2004 |
Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line; CHO Cells; Cisplatin; Cricetinae; Deoxycytidine; DNA; DNA Repair; Dose-Response Relationship, Drug; Fluorouracil; Gemcitabine; X-Rays | 2004 |
Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Pancreatic Neoplasms | 2004 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fibrosis; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2003 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Dipyridamole; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms | 2004 |
[Histoculture drug response assay for solitary fibrous tumor--a case report].
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Diaphragm; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Muscle Neoplasms; Neoplasms, Fibrous Tissue; Taxoids | 2004 |
[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Male; Pancreatic Neoplasms; Quality of Life; Tegafur; Uracil | 2004 |
Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypersensitivity, Delayed; Methotrexate; Plant Extracts; Plant Proteins | 2004 |
[Pancreatic carcinoma: progress in therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Survival Rate | 2004 |
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Radiation Dosage; Retrospective Studies; Survival Analysis; Time Factors | 2004 |
[A case of successful treatment with combined 5-fluorouracil, adriamycin, cisplatin (FAP) therapy followed by Gemcitabine, UFT therapy and intra-arterial FAP therapy for unresectable advanced gallbladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Middle Aged; Tegafur; Uracil | 2004 |
Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Palliative Care; Prevalence; Prognosis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2004 |
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Energy Intake; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomatitis; Taxoids; Tissue Polypeptide Antigen; Urinary Bladder Neoplasms | 2004 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
[Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Quality of Life; Survivors | 2005 |
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins; RNA, Messenger; RNA, Small Interfering; Survival Rate | 2005 |
Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage | 2005 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
Impact of different treatment methods on survival in advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Stents; Survival Analysis; Time Factors | 2005 |
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Enkephalin, Methionine; Fluorouracil; Gemcitabine; Growth Substances; Humans; Male; Mice; Mice, Nude; Naloxone; Narcotics; Pancreatic Neoplasms; Receptors, Opioid; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Humans; Mitogen-Activated Protein Kinases; Neuropilin-1; Pancreatic Neoplasms; Phenotype; Signal Transduction; Transfection; Tumor Cells, Cultured; Up-Regulation | 2005 |
[Chemotherapy of pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiotherapy; Smoking; Tomography, X-Ray Computed | 2005 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2005 |
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Survival Analysis | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Techniques; Colonic Neoplasms; Cross-Priming; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Gemcitabine; HLA-A Antigens; HLA-A2 Antigen; HT29 Cells; Humans; Leucovorin; Leukocytes, Mononuclear; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes, Cytotoxic | 2005 |
Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
Current and future strategies for treating metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Management; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2004 |
Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pelvic Exenteration; Pilot Projects; Recurrence; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Uterine Cervical Neoplasms | 2005 |
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Chronic Disease; Deoxycytidine; Diterpenes; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Mitochondria; Oxidative Stress; Pain; Pancreas; Pancreatic Neoplasms; Pancreatitis; Prospective Studies; TRPV Cation Channels | 2006 |
[Two cases of advanced gallbadder cancer with para-aortic lymph node metastasis responding to intra-aortic infusion of gemcitabine and low-dose CDDP/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Chlorambucil; Cisplatin; Cross-Linking Reagents; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fanconi Anemia Complementation Group C Protein; Fanconi Anemia Complementation Group G Protein; Fanconi Anemia Complementation Group Proteins; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Melphalan; Mice; Mice, Nude; Mitomycin; Mutation; Paclitaxel; Pancreatic Neoplasms; Time Factors; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Herpesvirus 1, Human; Humans; Oncolytic Viruses; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Virus Replication | 2005 |
Myelopathy after radiation therapy and chemotherapy with capecitabine and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Middle Aged; Radiation Injuries; Radiation-Sensitizing Agents; Spinal Cord Diseases | 2005 |
Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Outcome | 2006 |
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreas; Pancreatic Neoplasms; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2006 |
Radiotherapy and chemotherapy in pancreatic cancer. Topical issues and future perspectives.
Topics: Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Male; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Computer-Assisted; Survival Rate | 2006 |
A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Ribonucleotide Reductases; Sulfonamides; Tetrazolium Salts; Thiazoles | 2006 |
Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Interferons; Pancreatic Neoplasms; Receptors, Interferon | 2006 |
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Taxoids; Treatment Outcome; X-Rays; Xenograft Model Antitumor Assays | 2006 |
Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Survival Rate | 2006 |
Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Data Interpretation, Statistical; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Time Factors | 2006 |
XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gemcitabine; Gene Expression; GPI-Linked Proteins; Hepatocytes; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Organoplatinum Compounds; Oxaliplatin; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2006 |
[Present and future home therapy in advanced stage of pancreatic cancer].
Topics: Ambulatory Care; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fluorouracil; Forecasting; Gemcitabine; Home Care Services, Hospital-Based; Humans; Neoplasm Staging; Pain; Pancreatic Neoplasms; Quality of Life | 2006 |
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Taxoids; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Thrombocytopenia | 2006 |
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA, Messenger; Tegafur; Uracil; Xenograft Model Antitumor Assays | 2006 |
Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2.
Topics: Antimetabolites, Antineoplastic; Caspase 2; Caspase Inhibitors; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kinetics; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
[Gemcitabine versus combined chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2006 |
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt | 2006 |
[A pilot study on the impact of the drug resistance on the radioresistance in human pancreatic cancer cell lines].
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation Tolerance | 2006 |
Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Down-Regulation; Drug Interactions; Fluoresceins; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Tannins | 2007 |
Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis | 2006 |
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms | 2006 |
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2006 |
Combination therapy with gemcitabine and 5-Fluorouracil: unblocking the pathways to survivin?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin | 2006 |
Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Markov Chains; Medicare; Models, Economic; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2007 |
Adjuvant therapy for pancreatic cancer: a time that has not yet come.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage | 2007 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms | 2006 |
A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2006 |
Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cobalt Radioisotopes; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gamma Rays; Gemcitabine; Glucose Transporter Type 1; Humans; Rhenium; Topotecan | 2006 |
Data acquisition for the histoculture drug response assay in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Probability; Retrospective Studies; Sensitivity and Specificity; Tumor Cells, Cultured | 2007 |
Integrating Chinese and conventional medicine in colorectal cancer treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Medicine, Chinese Traditional; Middle Aged | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Japan; Male; Middle Aged; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; RNA, Messenger; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome | 2007 |
3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Deoxycytidine; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; p21-Activated Kinases; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Thyroid Hormone; Triiodothyronine | 2007 |
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2007 |
In vitro simulation study of individualized chemotherapy in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2007 |
[Establishment of a multi drug-resistant human lung adenocarcinoma cell line and biological characteristics there of].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Microscopy, Electron; Vinblastine | 2007 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2007 |
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Contraindications; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prodrugs; Prospective Studies; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2008 |
Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies | 2007 |
The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Laryngeal Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamine 123 | 2007 |
Surgery combined with intra-arterial chemotherapy for stage iv advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2007 |
Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Drainage; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Predictive Value of Tests; Stents; Treatment Outcome | 2007 |
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Oxonic Acid; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pharmacogenetics; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome | 2007 |
Combined systemic therapy and radiotherapy for bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Salvage Therapy; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Inoperable pancreatic cancer: standard of care.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Platinum Compounds; Tomography, X-Ray Computed | 2007 |
Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Retrospective Studies; Taxoids | 2007 |
Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Random Allocation; Sesquiterpenes; Xenograft Model Antitumor Assays | 2008 |
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
Topics: Angiotensin II; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2007 |
Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2008 |
Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Patient Selection; Survival Analysis; Survivors; Treatment Outcome | 2008 |
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Colonic Neoplasms; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interleukin-2; Leucovorin; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cells, Cultured; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lasers; Male; Microdissection; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; RNA, Messenger; Tetrazolium Salts; Thiazoles | 2008 |
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Time Factors | 2007 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Survival; Cetuximab; Cisplatin; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Myeloid Cell Leukemia Sequence 1 Protein; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2008 |
Pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Naturopathy; Pancreatic Neoplasms; Pastoral Care; Physical Therapy Modalities | 2008 |
[Outpatient chemotherapy and oncology network : Onco Pays-de-la-Loire experiment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Home Care Services; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Trastuzumab | 2008 |
Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Proliferation; Deoxycytidine; eIF-2 Kinase; Electrophoretic Mobility Shift Assay; Enzyme Activation; Fluorouracil; Gemcitabine; Mice; Neoplasms, Experimental; NF-kappa B; Phosphorylation; Proteasome Endopeptidase Complex; Protein Biosynthesis; Protein Kinase Inhibitors; Ribonucleotide Reductases; RNA, Double-Stranded | 2009 |
Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Analysis | 2008 |
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Pancreatic Neoplasms; Survival Analysis | 2008 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2008 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2008 |
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Curcumin; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Herbal Medicine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Plant Preparations | 2008 |
Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Digestive System Neoplasms; Fluorouracil; Gemcitabine; Humans; Pyrans; Quinolones; Rutaceae | 2008 |
Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2008 |
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cations; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-beta; Irinotecan; Kidney Neoplasms; Liposomes; Mice; Mice, SCID; Paclitaxel; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2008 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
[An autopsy case of pancreatic cancer with poor performance status due to peritonitis carcinomatosa treated successfully with continuous infusion of low-dose 5-FU with octreotide].
Topics: Antimetabolites, Antineoplastic; Ascites; Autopsy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Peritonitis | 2008 |
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Lung; Male; Oxygen Inhalation Therapy; Pancreatic Neoplasms; Pneumonia; Tomography, X-Ray Computed | 2008 |
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; International Normalized Ratio; Pancreatic Neoplasms; Prothrombin Time; Stents; Warfarin | 2008 |
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Mastectomy, Radical; Neoplasm Invasiveness; Radiography; Radiotherapy, Adjuvant; Renal Veins; Vena Cava, Inferior; Venous Thrombosis | 2008 |
Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Europe; Fluorouracil; Gemcitabine; Humans; Incidence; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome; United States | 2008 |
Personalized medicine for pancreatic cancer: a step in the right direction.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms | 2009 |
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Palliative Care; Pyrimidinones; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 2008 |
Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry.
Topics: Adsorption; Chromatography, Liquid; Cytostatic Agents; Deoxycytidine; Drug Residues; Floxuridine; Fluorouracil; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Linear Models; Models, Molecular; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Water; Water Pollutants, Chemical | 2009 |
Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Analysis | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Camellia sinensis; Catechin; Cell Line, Tumor; Cholangiocarcinoma; Cytochromes c; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mitomycin; Plant Extracts | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
Quantitative phosphorus metabolomics using nanoflow liquid chromatography-tandem mass spectrometry and culture-derived comprehensive global internal standards.
Topics: Cell Line, Tumor; Chromatography, Liquid; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Metabolomics; Methotrexate; Phosphorus; Reference Standards; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2009 |
Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Cell Cycle; Cholangiocarcinoma; Deoxycytidine; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; In Vitro Techniques; Palliative Care; Radioisotopes; Rhenium; Stents; Tumor Cells, Cultured | 2009 |
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Regression Analysis; Retrospective Studies; Treatment Outcome | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD8-Positive T-Lymphocytes; Cisplatin; Combined Modality Therapy; Cytotoxicity, Immunologic; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-gamma; Interleukin-12 Subunit p40; Killer Cells, Lymphokine-Activated; Lipopolysaccharides; Liver Neoplasms; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pilot Projects; Prognosis; Survival Rate; T-Lymphocytes; Treatment Outcome | 2009 |
Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome; Vitamin B Complex | 2009 |
Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.
Topics: Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Purinergic P2; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction | 2009 |
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Germany; Health Care Surveys; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Radiotherapy Dosage; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Treatment Outcome | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Sirolimus; Treatment Outcome | 2009 |
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Probability; Prognosis; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Survival Analysis | 2009 |
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Topics: Antineoplastic Agents; Blotting, Western; Cadherins; Cell Line, Tumor; Cisplatin; Cluster Analysis; Deoxycytidine; Drug Resistance, Neoplasm; Epithelium; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Immunohistochemistry; Mesoderm; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2009 |
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Mass flows of X-ray contrast media and cytostatics in hospital wastewater.
Topics: Contrast Media; Cytostatic Agents; Deoxycytidine; Environmental Monitoring; Floxuridine; Fluorouracil; Gemcitabine; Hospitals; Medical Waste Disposal; Waste Disposal, Fluid; Water Pollutants; Water Pollution, Chemical; Water Purification; X-Rays | 2009 |
Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Copper; Deoxycytidine; Disulfiram; Drug Resistance, Neoplasm; Drug Synergism; Electrophoretic Mobility Shift Assay; Female; Fluorouracil; Gemcitabine; Humans; NF-kappa B; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tumor Suppressor Proteins | 2010 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Thymidylate Synthase; Treatment Outcome | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Acute aortic dissection during sorafenib-containing therapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Periodicals as Topic; Sensitivity and Specificity; Survival Analysis; Total Quality Management; Treatment Outcome | 2009 |
What does similarity mean in clinical trials?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids | 2009 |
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Forecasting; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2009 |
Patterns of radiotherapy practice for pancreatic cancer in Japan: results of the Japanese Radiation Oncology Study Group (JROSG) survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Surveys; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Practice Patterns, Physicians'; Radiation Oncology; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2010 |
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2010 |
[A case of postoperative multiple liver metastases of pancreatic cancer successfully treated by combination chemotherapy with weekly high-dose 5-FU hepatic arterial infusion plus systemic infusion of gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Male; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Period | 2009 |
Pancreatic cancer: progress made.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Early Detection of Cancer; Endosonography; Fluorouracil; Gemcitabine; Humans; Jejunostomy; Laparoscopy; Magnetic Resonance Imaging; Neoplasm Staging; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Proto-Oncogene Proteins c-akt; Pteridines; Pyrimidines; Pyrroles; Receptor, IGF Type 1 | 2010 |
Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Cholestasis, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Duodenoscopy; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Hematoporphyrins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Photochemotherapy; Photosensitizing Agents; Stents; Treatment Outcome | 2010 |
Memoirs of differential radiation doses: Gemcitabine induced radiation recall.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Mastectomy; Radiodermatitis; Radiotherapy; Radiotherapy Dosage | 2010 |
Renal atrophy secondary to chemoradiotherapy of abdominal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atrophy; Capecitabine; Cisplatin; Combined Modality Therapy; Creatinine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Gemcitabine; Humans; Kidney; Male; Middle Aged; Organ Size; Radiation Injuries; Radiography; Regression Analysis; Retrospective Studies; ROC Curve | 2010 |
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Gemcitabine; Histones; Humans; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Array Analysis | 2010 |
Management of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2010 |
Update on adjuvant trials for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2010 |
Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged | 2010 |
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2010 |
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Deoxycytidine; Flow Cytometry; Fluorouracil; Gemcitabine; Immune System; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; T-Lymphocytes | 2010 |
Any progress in pancreatic cancer? Well, but progress for Acta Oncologica.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Journalism, Medical; Pancreatic Neoplasms; Quinazolines; Research Design; Treatment Failure | 2010 |
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2011 |
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Deoxycytidine; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Irinotecan; Killer Cells, Lymphokine-Activated; Mutation; Panitumumab; Up-Regulation | 2010 |
Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cholangiocarcinoma; Cytochrome P-450 Enzyme System; Deoxycytidine; Fluorouracil; Gemcitabine; Mice; Mice, Nude; Mitomycin; Resveratrol; Stilbenes | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Complications; Radiotherapy, Adjuvant | 2010 |
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; United Kingdom | 2010 |
Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites.
Topics: Animals; Antineoplastic Agents; Arabinofuranosyluracil; beta-Alanine; Chlorophyta; Cytarabine; Daphnia; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Growth Inhibitors; Mutagenicity Tests; Mutagens; Pseudomonas; Salmonella; Toxicity Tests | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; gamma-Aminobutyric Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pregabalin | 2010 |
Assessment of pancreatic carcinoma cell chemosensitivity using a three-dimensional culture system.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Spheroids, Cellular | 2010 |
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Epothilones; Everolimus; Female; Fluorouracil; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Nude; Paclitaxel; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Inhibitory Concentration 50; Male; Middle Aged; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; RNA Interference; Thymidylate Synthase | 2010 |
CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Glycoproteins; Humans; Hyaluronan Receptors; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Oncogene Proteins; Peptides; Spheroids, Cellular; Trans-Activators; Up-Regulation; Zinc Finger Protein GLI1 | 2010 |
Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Topics: Aged; Angiopoietins; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Deoxycytidine; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pilot Projects; Stem Cells; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D | 2010 |
Current status of adjuvant therapy for pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Injections, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Perioperative Period; Survival Rate; Treatment Outcome | 2011 |
Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells.
Topics: 2-Methoxyestradiol; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Cisplatin; Deoxycytidine; Drug Synergism; Estradiol; Female; Flow Cytometry; Fluorescent Antibody Technique; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Tubulin Modulators | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Pancreatic cancer: will incremental advances begin to make a difference?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2010 |
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Remission Induction; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2011 |
[Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged; Pancreatic Neoplasms; Radiosurgery | 2010 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Epidemiologic Methods; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Treatment Outcome | 2011 |
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Canada; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy; Treatment Outcome | 2011 |
Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Leucovorin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2011 |
Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Common Bile Duct Neoplasms; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mutation; Pancreatic Neoplasms; Translational Research, Biomedical; Treatment Outcome | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2011 |
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Topics: Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors | 2011 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Off-Label Use; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; RNA, Messenger | 2011 |
Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Chi-Square Distribution; Combined Modality Therapy; Contrast Media; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiography, Interventional; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2011 |
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Coatomer Protein; Deoxycytidine; Fluorouracil; Gemcitabine; Golgi Apparatus; Humans; Lysosomal Membrane Proteins; Lysosomes; Magnetic Resonance Spectroscopy; Male; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Omeprazole; Pancreatic Neoplasms; Ultracentrifugation | 2011 |
Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytokines; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Humans; Midkine; Pancreatic Neoplasms; Receptor, Notch2; RNA Interference; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2011 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Ipilimumab; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Topics: Adenocarcinoma; Adenoviruses, Human; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cytopathogenic Effect, Viral; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Deletion; Gene Expression Regulation, Viral; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Receptors, Virus; Retinoblastoma Protein; Virus Replication; Xenograft Model Antitumor Assays | 2011 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure | 2012 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
FOLFIRINOX: a small step or a great leap forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
Topics: Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines; Pyrroles; RNA, Messenger | 2011 |
Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2012 |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Republic of Korea; Treatment Outcome | 2011 |
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carboplatin; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male | 2011 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dissection; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2012 |
Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Radiotherapy: the importance of local control in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Smad4 Protein | 2011 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radium-loaded wires releasing alpha-emitting atoms.
Topics: Alpha Particles; Animals; Antimetabolites, Antineoplastic; Brachytherapy; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radium | 2012 |
Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Janus Kinases; Signal Transduction; STAT Transcription Factors | 2012 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate | 2012 |
Mutagen-mediated enhancement of HIV-1 replication in persistently infected cells.
Topics: Cell Line; Deoxycytidine; Fluorouracil; Gemcitabine; HIV Infections; HIV-1; Humans; Mutagens; Mutation; Mutation Rate; RNA, Viral; Virus Replication | 2012 |
Analysis of local control in patients receiving IMRT for resected pancreatic cancers.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Failure | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Treatment Outcome; Young Adult | 2012 |
Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Analysis | 2012 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Hedgehog Proteins; Humans; Immunoblotting; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; RNA Interference; Smoothened Receptor; Transcription Factors; Veratrum Alkaloids; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Retrospective Studies; Survival Analysis | 2012 |
A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Fluorouracil; Gemcitabine; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Proto-Oncogene Proteins; Tumor Burden; Tumor Suppressor Protein p53 | 2012 |
Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine.
Topics: Antimetabolites, Antineoplastic; Contrast Media; Deoxycytidine; Embolization, Therapeutic; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Radiography, Interventional; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Retrospective Studies | 2012 |
Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dexamethasone; Drug Eruptions; Drug Hypersensitivity; Female; Fluorouracil; Gemcitabine; Glucocorticoids; Histamine H1 Antagonists; Humans; Hydrocortisone; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prevalence; Republic of Korea; Retrospective Studies; Risk Factors | 2012 |
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Photochemotherapy; Photosensitizing Agents; Porphyrins; Proliferating Cell Nuclear Antigen; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Survivin | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies | 2012 |
Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs.
Topics: Antineoplastic Agents; Apoptosis; Aquaporin 3; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Size; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; fas Receptor; Floxuridine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; MCF-7 Cells; Nucleosides; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Up-Regulation | 2012 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deglutition Disorders; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Remission Induction; Safety; Stomatitis; Survival Rate; Treatment Outcome; Xerostomia | 2013 |
Endoscopic self-expandable metallic stent placement in malignant pyloric or duodenal obstruction: does chemotherapy affect stent patency?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Deoxycytidine; Duodenal Obstruction; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Intestinal Obstruction; Male; Palliative Care; Pancreatic Neoplasms; Prognosis; Pylorus; Stents; Stomach Neoplasms | 2013 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Carrier Proteins; Caspase 1; Cathepsin B; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Inflammasomes; Interleukin-17; Interleukin-1beta; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; NLR Family, Pyrin Domain-Containing 3 Protein; Receptors, Interleukin-1; RNA Interference; RNA, Small Interfering; Signal Transduction | 2013 |
Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Endoscopy; Female; Fluorouracil; Gemcitabine; Germany; Health Care Surveys; Humans; Male; Medical Oncology; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Patterns, Physicians'; Treatment Outcome; Young Adult | 2012 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; CA-125 Antigen; Capecitabine; Carcinoembryonic Antigen; Carrier Proteins; CDX2 Transcription Factor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cytokines; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Glycoproteins; Hepatectomy; Homeodomain Proteins; Humans; Immunohistochemistry; Keratin-20; Keratins; Liver; Liver Neoplasms; Lymph Node Excision; Magnetic Resonance Imaging; Membrane Transport Proteins; Phenotype; Portal Vein; Pregnancy; Receptors, Estrogen; Receptors, Progesterone | 2012 |
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2012 |
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Survival; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Glycation End Products, Advanced; HMGB1 Protein; Humans; Pancreatic Neoplasms; Prospective Studies; Statistics, Nonparametric; Treatment Outcome | 2013 |
[Combination therapy for inoperable cholangiocellular carcinoma-systemic chemotherapy and hepatic arterial injection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged | 2012 |
[Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Neoplasms | 2012 |
Dual role of immunomodulation by anticancer chemotherapy.
Topics: Animals; Carrier Proteins; Caspase 1; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Inflammasomes; Neoplasms; NLR Family, Pyrin Domain-Containing 3 Protein | 2013 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Survival Rate | 2013 |
Severe or lethal toxicities with nucleosidic analogs: time for action.
Topics: Animals; Capecitabine; Cytidine Deaminase; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Nucleosides | 2013 |
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Mitochondria; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor | 2012 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hand-Foot Syndrome; Humans; Lethargy; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2013 |
Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Remission Induction; Treatment Outcome | 2013 |
[Regional chemotherapy in locally advanced and metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Remission Induction | 2013 |
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camptothecin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Tissue Scaffolds; Xenograft Model Antitumor Assays | 2013 |
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
Topics: Algorithms; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Transplantation; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2013 |
Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Grading; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Mice; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Tissue Distribution | 2013 |
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peptide Fragments; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Telomerase; Treatment Outcome; Vaccines | 2013 |
Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Osteonectin; Pancreatic Neoplasms; Pharmacogenetics; Transcriptome; Treatment Outcome | 2013 |
Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Luteolin; Pancreatic Neoplasms; Signal Transduction; Transcription Factor RelA | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prognosis; Retrospective Studies; Survival Rate | 2013 |
A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay.
Topics: Acid Phosphatase; Antimetabolites, Antineoplastic; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Spheroids, Cellular | 2013 |
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Line; Cell Proliferation; Cimicifuga; Deoxycytidine; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Humans; Male; Nucleosides; Phytotherapy; Plant Extracts; Prostate; Prostatic Neoplasms; RNA, Small Interfering; Saponins; Thymidine; Vidarabine | 2013 |
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2013 |
Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2013 |
Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Proteome; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2013 |
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Fusion Regulatory Protein-1; Gemcitabine; Humans; Kaplan-Meier Estimate; Large Neutral Amino Acid-Transporter 1; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Retrospective Studies; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hyperbilirubinemia; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms | 2014 |
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response.
Topics: Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Liposomes; Liver Neoplasms; Models, Theoretical; Nanomedicine; Nanoparticles | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Topics: Adjuvants, Immunologic; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD40 Antigens; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Immunotherapy; Macrophages; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nitrites; Oligodeoxyribonucleotides; Skin Neoplasms; Tumor Burden | 2013 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Time Factors | 2014 |
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD11b Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-6; Myeloid Cells; Pancreatic Neoplasms; Peptide Fragments; Telomerase; Vaccination | 2014 |
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2014 |
Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; RNA, Small Interfering; Survivin; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Sex Factors; Time Factors; Treatment Outcome | 2016 |
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2013 |
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2014 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Retrospective Studies; Survival Rate; Ultrasonography, Interventional; Viscum album | 2014 |
Non-invasive quantification of 5 fluorouracil and gemcitabine in aqueous matrix by direct measurement through glass vials using near-infrared spectroscopy.
Topics: Antineoplastic Agents; Calibration; Deoxycytidine; Flow Injection Analysis; Fluorouracil; Gemcitabine; Glass; Limit of Detection; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectroscopy, Near-Infrared; Water | 2014 |
Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX).
Topics: Animals; Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Luminescent Proteins; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Red Fluorescent Protein; Salmonella Infections; Salmonella typhimurium; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2014 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; NAD(P)H Dehydrogenase (Quinone); RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Science to practice: Can we turn the undesired heating effects of MR imaging into effective cancer therapies?
Topics: Animals; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging | 2014 |
Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Chromatography, High Pressure Liquid; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Mice; Radio Waves; Swine | 2014 |
Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Ampulla of Vater; Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Glycogen; Glypicans; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2014 |
Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.
Topics: Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Forkhead Box Protein O3; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; rho GTP-Binding Proteins; RNA Interference; Sirtuin 1; Tumor Suppressor Protein p53 | 2014 |
Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Microtubule-Associated Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Wortmannin | 2014 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure | 2014 |
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Calcium Signaling; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Proteins; ORAI1 Protein; Pancreatic Neoplasms; RNA, Small Interfering; Stromal Interaction Molecule 1 | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
Patients with advanced disease: the value of patient reported outcomes.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Pain; Pancreatic Neoplasms; Quality of Life | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Chemoradiotherapy; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; ELAV Proteins; ELAV-Like Protein 1; Fluorouracil; Follow-Up Studies; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Protein Transport; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Male; Middle Aged; Models, Statistical; Pancreatic Neoplasms; Platinum Compounds; Pulmonary Embolism; Retrospective Studies; Risk Assessment; Venous Thromboembolism; Venous Thrombosis | 2014 |
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Busulfan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2014 |
Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Photochemotherapy; Treatment Outcome | 2014 |
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospital Mortality; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2014 |
Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Severity of Illness Index | 2014 |
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phenotype; Side-Population Cells; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2015 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, Lewis Lung; CD3 Complex; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Lymphocyte Count; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mitomycin; Mitoxantrone; Neoplasm Transplantation; Neoplasms, Experimental; Protein Transport; T-Lymphocytes; Tumor Microenvironment | 2015 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signaling in GBC-SD gallbladder cancer cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxyadenosines; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Locally advanced unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Treatment Outcome | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Role of neoadjuvant therapy in management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2014 |
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxaloacetates; Pancreatic Neoplasms; Retrospective Studies; Vomiting | 2014 |
Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; PPAR gamma; Prognosis; Retrospective Studies; Tumor Cells, Cultured; Up-Regulation | 2015 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Gemcitabine; HLA-DR Antigens; Humans; Immunotherapy; Interferon-gamma; Lymphatic Metastasis; Middle Aged; Mucin-1; Peritoneal Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; WT1 Proteins | 2014 |
Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Calcineurin Inhibitors; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Incidental Findings; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prognosis; Sirolimus; Survival Analysis; Treatment Outcome | 2014 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Immunoblotting; MAP Kinase Kinase 4; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; RNA, Small Interfering; Transfection | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming Units Assay; Deoxycytidine; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Heterografts; Humans; Immunohistochemistry; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenotype; Protein Array Analysis; Proteomics; Tumor Cells, Cultured | 2015 |
Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavones; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Mice, Nude; Signal Transduction; Transcriptional Activation; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Matrix Metalloproteinase 13; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mucin-1; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2015 |
Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Adenosquamous; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Salvage Therapy | 2015 |
Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Pancreaticoduodenectomy; Retrospective Studies; Risk Assessment; Survival Rate | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Knockdown Techniques; Glutamate-Cysteine Ligase; Glutathione S-Transferase pi; Heme Oxygenase-1; Humans; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; RNA, Messenger; RNA, Small Interfering | 2015 |
Cleaning Efficiencies of Three Cleaning Agents on Four Different Surfaces after Contamination by Gemcitabine and 5-fluorouracile.
Topics: Alcohols; Antineoplastic Agents; Decontamination; Deoxycytidine; Equipment Contamination; Fluorouracil; Gemcitabine; Glass; Occupational Exposure; Polyvinyl Chloride; Stainless Steel; Surface-Active Agents; Water; Wood | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis | 2015 |
Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2014 |
Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; India; Insecticide-Treated Bednets; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Colectomy; Deoxycytidine; Diazoxide; Disease Progression; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Gemcitabine; Humans; Hypoglycemia; Lung Neoplasms; Mitomycin; Nephrectomy; Octreotide; Pancreatectomy; Pancreatic Neoplasms | 2015 |
[FOLFIRINOX, nab-paclitaxel + gemcitabine].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Organoplatinum Compounds; Pancreaticoduodenectomy; Pylorus; Retrospective Studies; Treatment Outcome | 2015 |
Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Gemcitabine; Glycosides; Humans; Lipid Peroxidation; Mice; Mice, Nude; Pancreatic Neoplasms; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Lymphocyte Activation; MAP Kinase Signaling System; Monocytes; Myeloid Cells; NF-kappa B; Pancreatic Neoplasms; T-Lymphocytes; Tissue Array Analysis; Tumor Microenvironment | 2015 |
Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced pancreatic cancer: a case report.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Paclitaxel; Perioperative Care; Retrospective Studies; Urethra; Urethral Neoplasms; Urinary Diversion | 2015 |
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Paclitaxel | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Retinoic Acid Reduces Stem Cell-Like Features in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Signal Transduction; Time Factors; Transcription Factors; Tretinoin | 2015 |
Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane Permeability; Deoxycytidine; DNA Replication; Etoposide; Fluorouracil; Gemcitabine; Humans; Minichromosome Maintenance Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Analysis | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
Clinical Significance of Adjuvant Surgical Resection for Initially Unresectable Pancreatic Cancer Responsive to Arterial Infusion Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome | 2016 |
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Veins | 2015 |
The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Male; Mice, Nude; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Proto-Oncogene Proteins c-met; Receptor, ErbB-3; Retinoids; Signal Transduction; Transcriptional Activation; Tretinoin; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2015 |
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Mucins; Neoplasm Transplantation; Phthalazines; Pyridines | 2015 |
FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Platinum Compounds; Treatment Failure; Treatment Outcome | 2016 |
[The progress of chemotherapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Male; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Endoscopy, Digestive System; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Photochemotherapy; Randomized Controlled Trials as Topic; Stents; Treatment Outcome | 2016 |
Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreas, Exocrine; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Propensity Score; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Retrospective Studies | 2016 |
Optimizing initial chemotherapy for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms | 2016 |
Enriched environment housing enhances the sensitivity of mouse pancreatic cancer to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Deoxycytidine; Fluorouracil; Gemcitabine; Housing, Animal; Male; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Stress, Psychological | 2016 |
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Male; Middle Aged; Palliative Care; Retrospective Studies; Treatment Outcome | 2016 |
Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis | 2016 |
Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia-Inducible Factor 1; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Prodrugs; Recombinant Fusion Proteins; Silicates; Survival Analysis; Titanium; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2016 |
Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Mice; Organoplatinum Compounds; Oxaliplatin; Tea Tree Oil; Terpenes; Xenograft Model Antitumor Assays | 2016 |
Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study.
Topics: Antineoplastic Agents; Camptothecin; Cyclophosphamide; Cytarabine; Deoxycytidine; Drug Compounding; Drug Contamination; Fluorouracil; Ganciclovir; Gemcitabine; Humans; Ifosfamide; Irinotecan; Methotrexate; Occupational Exposure; Prospective Studies | 2016 |
A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antimetabolites, Antineoplastic; Deoxycytidine; Feasibility Studies; Female; Fever; Fluorouracil; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Injections, Intra-Arterial; Intestinal Obstruction; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Retrospective Studies; Treatment Outcome | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA, Viral; Epstein-Barr Virus Infections; Female; Fluorouracil; Gemcitabine; Herpesvirus 4, Human; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutrophils; Prognosis; Proportional Hazards Models; Radiotherapy; Randomized Controlled Trials as Topic; Singapore; Survival Rate | 2016 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, Community; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Intraoperative Care; Laparotomy; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents.
Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Cysteine Endopeptidases; Deoxycytidine; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Enbucrilate; Etoposide; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Poly (ADP-Ribose) Polymerase-1; Ubiquitin; Ubiquitin-Conjugating Enzymes; Vincristine | 2017 |
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Recurrence | 2017 |
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Rate | 2017 |
Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colitis; Deoxycytidine; Feasibility Studies; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Thrombocytopenia; Treatment Outcome | 2016 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Erlotinib Hydrochloride; Europe; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires | 2016 |
Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tertiary Care Centers | 2017 |
Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?
Topics: Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2017 |
The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2017 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; France; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2017 |
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Delivery of Health Care; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Length of Stay; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Time Factors | 2017 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pain; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Irinotecan; Jaundice; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Smoking; Survival Rate | 2017 |
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Retrospective Studies | 2017 |
Effect of nucleoside analogue antimetabolites on the structure of PEO-PPO-PEO micelles investigated by SANS.
Topics: Antimetabolites; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Micelles; Neutron Diffraction; Poloxamer; Polyethylene Glycols; Propylene Glycols; Scattering, Small Angle; Transition Temperature; Water | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proto-Oncogene Proteins p21(ras); Translational Research, Biomedical | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Calcium Compounds; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Phosphorylation; Silicates; Xenograft Model Antitumor Assays | 2017 |
Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Pancreatic Neoplasms; Perioperative Period; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2017 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Renal Insufficiency; Tegafur | 2017 |
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mice; Thymidine Kinase; Thymidylate Synthase; Thymine Nucleotides; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Damage; Fluorouracil; Gemcitabine; Gene Expression; Genomic Instability; Humans; Immunohistochemistry; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phthalazines; Piperazines | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Cost of Illness; Deoxycytidine; Drug Costs; Female; Filgrastim; Fluorouracil; Gemcitabine; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Second Primary; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiosurgery; Radiotherapy, Intensity-Modulated; Survival Rate | 2018 |
Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.
Topics: Administration, Cutaneous; Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Polyesters; Survival Rate; Transdermal Patch; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Monitoring Surface Contamination by Antineoplastic Drugs in Italian Hospitals: Performance-Based Hygienic Guidance Values (HGVs) Project.
Topics: Antineoplastic Agents; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Packaging; Environmental Monitoring; Equipment Contamination; Fluorouracil; Gemcitabine; Hospitals; Humans; Occupational Exposure | 2017 |
Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Peritoneal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; Tomography, X-Ray Computed | 2018 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; China; Deoxycytidine; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2018 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Platelet Count; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2018 |
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Young Adult | 2018 |
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Array Analysis | 2018 |
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2018 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2018 |
Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Glycosides; HCT116 Cells; HT29 Cells; Humans; Organoplatinum Compounds; Oxaliplatin; Triterpenes | 2018 |
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Failure | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Laparotomy; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Survival Rate; Tegafur | 2018 |
Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Immunoconjugates; Mice; Mice, Nude; Oligopeptides; Oxaliplatin; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2018 |
A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Healthcare Disparities; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Rural Health; Rural Population; Urban Health; Urban Population | 2018 |
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3; Humans; Irinotecan; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Signal Transduction | 2018 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Oxaliplatin; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Laparotomy; Leucovorin; Lymph Nodes; Male; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2019 |
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Diseases; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, High-Energy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Ulcer | 2018 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Electronic Health Records; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Quality of Life; Retrospective Studies | 2019 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; United States | 2018 |
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genome, Human; Humans; Machine Learning; Neoplasms; Ovarian Neoplasms; Precision Medicine; Predictive Value of Tests; Support Vector Machine; Transcriptome | 2018 |
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2019 |
FOLFIRINOX goes adjuvant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Random Allocation; Survival Analysis; Treatment Outcome | 2019 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2018 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms | 2018 |
Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2019 |
[FOLFIRINOX after resection of pancreatic cancer sets new standards-systemic therapy providing an impulse for local treatment in resectable pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms | 2019 |
Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Docetaxel; Epirubicin; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Polyethyleneimine; Viral Proteins | 2019 |
Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden | 2019 |
The Water Extract of
Topics: A549 Cells; Cell Death; Cell Survival; Cytostatic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Hep G2 Cells; Humans; Juniperus; Nuclear Proteins; Phosphoprotein Phosphatases; Plant Extracts; Proto-Oncogene Proteins c-akt; Tumor Suppressor Protein p53 | 2019 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fatal Outcome; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Selection Bias; Survival Analysis; Survival Rate; Treatment Outcome | 2020 |
Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.
Topics: Animals; Annexin A1; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase 4; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Kinase C; Signal Transduction | 2020 |
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Propensity Score; Retrospective Studies; Survival Rate; United States | 2019 |
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Risk Factors; Time Factors | 2019 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Humans; Male; Markov Chains; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Standard of Care | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Microvessels; Neovascularization, Pathologic; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure | 2019 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cause of Death; Combined Modality Therapy; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
Chemotherapy Toxicity Confirms Diagnosis of Urachal Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystoscopy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Image-Guided Biopsy; Leucovorin; Male; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2019 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2019 |
Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2020 |
Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2019 |
Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy.
Topics: Adipogenesis; Antimetabolites; Bone Marrow Cells; Cell Adhesion; Cell Differentiation; Cell Survival; Cells, Cultured; Deoxycytidine; Fibroblasts; Fluorouracil; Gemcitabine; Humans; Mesenchymal Stem Cells; Multidrug Resistance-Associated Proteins | 2019 |
Antineoplastic drug occupational exposure: a new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker.
Topics: Adult; Antineoplastic Agents; Biomarkers; Case-Control Studies; Deoxycytidine; DNA Glycosylases; Environmental Monitoring; Female; Fluorouracil; Gemcitabine; Humans; Italy; Male; Micronuclei, Chromosome-Defective; Micronucleus Tests; Middle Aged; Mouth Mucosa; Nursing Staff, Hospital; Occupational Exposure; Occupational Health; Oncology Nursing; Polymorphism, Genetic; Risk Assessment; Risk Factors; Urinalysis; X-ray Repair Cross Complementing Protein 1 | 2019 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Diet, Ketogenic; Female; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia, Induced; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survivors | 2020 |
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Keratins, Hair-Specific; Keratins, Type II; Leucovorin; Machine Learning; Male; Middle Aged; Neoplasm Proteins; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Survival Rate | 2019 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure | 2020 |
Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time-to-Treatment; Treatment Outcome | 2020 |
Sample preparation strategies for high-throughput mass spectrometry imaging of primary tumor organoids.
Topics: Centrifugation; Collagen; Deoxycytidine; Drug Combinations; Extracellular Matrix; Fluorouracil; Gemcitabine; Humans; Laminin; Neoplasms; Organoids; Proteoglycans; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Array Analysis; Workflow | 2020 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome | 2019 |
Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Neoplasm Proteins; Pancreatic Neoplasms | 2019 |
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2019 |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Knockdown Techniques; Humans; Integrin alpha3; Integrin beta1; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; Spheroids, Cellular; STAT3 Transcription Factor; Survival Rate; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Emergency Service, Hospital; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score; Treatment Outcome | 2020 |
Effect of Chemotherapeutic Agents on the Expression of Retinoid Receptors and Markers of Cancer Stem Cells and Epithelial-Mesenchymal Transition.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Cell Line, Tumor; Deoxycytidine; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplastic Stem Cells; Retinoid X Receptor beta; S Phase Cell Cycle Checkpoints | 2019 |
The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Molecular Typing; Oxaliplatin; Pancreatic Neoplasms; Proteome; Proteomics; Survival Rate; Treatment Outcome | 2020 |
Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Knockout; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Osteoblasts; Tumor Microenvironment | 2020 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Decision Rules; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Internationality; Lymph Nodes; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy; Reproducibility of Results; Retrospective Studies | 2020 |
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Staff, Hospital; Middle Aged; Netherlands; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Regression Analysis; Young Adult | 2020 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Markov Chains; Middle Aged; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Randomized Controlled Trials as Topic; Young Adult | 2020 |
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; SEER Program; Survival Rate; United States | 2020 |
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Topics: Aged; Aged, 80 and over; Albumins; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Duration of Therapy; Emergency Service, Hospital; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Insurance, Health; Irinotecan; Leucovorin; Male; Medicare Part C; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2020 |
[Biliary tract cancer: on the way to a personalized therapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Leucovorin; Organoplatinum Compounds; Palliative Care; Precision Medicine | 2020 |
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Glucose; Glycolysis; Humans; Irinotecan; Lactic Acid; Leucovorin; Male; Mice, Nude; Mucin-1; Neoplasm Transplantation; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2020 |
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Substitution; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Salvage Therapy | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Diagnostic Techniques, Radioisotope; Disease Models, Animal; Fluorouracil; Gemcitabine; Mice; Mice, Inbred C57BL; Organoids; Pancreatic Neoplasms | 2020 |
The yield of chest computed tomography in patients with locally advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Multiple Pulmonary Nodules; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2020 |
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Linear Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Adjuvant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Coronavirus Infections; COVID-19; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pandemics; Pneumonia, Viral; Romania; SARS-CoV-2 | 2020 |
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; High-Throughput Screening Assays; Humans; Keratin-17; Mice, Inbred C57BL; Microtubules; Paclitaxel; Pancreatic Neoplasms; Podophyllotoxin; Tumor Burden | 2020 |
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Retrospective Studies; Treatment Outcome | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio
Topics: Aged; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Prognosis | 2020 |
Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Survival Rate; United Kingdom | 2020 |
Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Diagnostic Imaging; Dose Fractionation, Radiation; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoadjuvant Therapy; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Radiosurgery | 2020 |
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiography; Survival Rate; Treatment Outcome | 2020 |
Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Europe; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Taxoids; Time Factors | 2020 |
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Margins of Excision; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Survival Rate | 2020 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome | 2020 |
Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
The economic burden of metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost of Illness; Costs and Cost Analysis; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Health Resources; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Needs Assessment; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Mice; Oxaliplatin; Stomach; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Leveraging TCGA gene expression data to build predictive models for cancer drug response.
Topics: Antineoplastic Agents; Area Under Curve; Cluster Analysis; Databases, Genetic; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Machine Learning; Neoplasms; ROC Curve | 2020 |
Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Retrospective Studies; Survival Rate | 2021 |
Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Calcium Channel Blockers; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Deoxycytidine; Diltiazem; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Antimicrobial Peptide Induced-Stress Renders
Topics: Anti-Bacterial Agents; Antimetabolites; Antimicrobial Cationic Peptides; Bacterial Proteins; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Microbial Viability; Nucleosides; Proteome; Staphylococcus aureus; Stress, Physiological; Thioguanine; Uracil | 2020 |
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Adult; Aged; Albumins; Alleles; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cytidine Deaminase; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Pharmacogenomic Testing; Polymorphism, Genetic | 2021 |
Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinom
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Progression-Free Survival; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Germ-Line Mutation; Homologous Recombination; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Recombinational DNA Repair; Sensitivity and Specificity; Survival Rate; Tumor Suppressor Protein p53; Whole Genome Sequencing | 2021 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2021 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer: A Letter to the Editor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diet, Ketogenic; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Quality control of cytostatic drug preparations-comparison of workflow and performance of Raman/UV and high-performance liquid chromatography coupled with diode array detection (HPLC-DAD).
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cyclophosphamide; Cytostatic Agents; Deoxycytidine; Drug Compounding; Drug Stability; Drug Storage; Fluorouracil; Gemcitabine; Irinotecan; Quality Control; Spectrophotometry, Ultraviolet; Spectrum Analysis, Raman; Workflow | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Veterans | 2021 |
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Prospective Studies; Staining and Labeling | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors | 2021 |
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Hepatitis A Virus Cellular Receptor 2; Humans; Immune Checkpoint Proteins; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Programmed Cell Death 1 Receptor; Progression-Free Survival; Prospective Studies; T-Lymphocytes, Regulatory | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus; Dietary Supplements; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3 beta; Glycolysis; Humans; Inhibitory Concentration 50; Malaria; MCF-7 Cells; Metformin; Molecular Targeted Therapy; Neoplasm Metastasis; Nitrophenols; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thiadiazoles; Tumor Stem Cell Assay | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2021 |
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score | 2021 |
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Carcinoma, Pancreatic Ductal; Deoxycytidine; Epidemiologic Methods; Female; Fluorouracil; Gastrointestinal Microbiome; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Venous Thromboembolism | 2022 |
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Retrospective Studies | 2021 |
New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Models, Biological; Neoplasms | 2021 |
The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Proteins; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2022 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
Topics: Antineoplastic Agents; Autophagy; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Glycine; Humans; Radiation-Sensitizing Agents; Sulfones | 2021 |
Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2021 |
Reviewing the Outcomes of Different Treatment Approaches in Elderly Pancreatic Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoplasm Staging; Outcome Assessment, Health Care; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2021 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Nanoconjugates; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2021 |
Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors | 2022 |
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Nomograms; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Treatment Outcome | 2022 |
FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Nausea; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2022 |
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Retrospective Studies; Treatment Outcome | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tubulin | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Registries | 2022 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Quality of Life | 2023 |
Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.
Topics: Antineoplastic Agents; Asparaginase; Brain Diseases; Cisplatin; Cytarabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2022 |
Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gemcitabine; Mice; Pancreatic Neoplasms | 2022 |
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2023 |
Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2023 |
The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Extracellular vesicles derived from dental mesenchymal stem/stromal cells with gemcitabine as a cargo have an inhibitory effect on the growth of pancreatic carcinoma cell lines in vitro.
Topics: Cell Line; Culture Media, Conditioned; Extracellular Vesicles; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs; Stromal Cells | 2023 |
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Evaluation of long-term data on surface contamination by antineoplastic drugs in pharmacies.
Topics: Antineoplastic Agents; Cyclophosphamide; Environmental Monitoring; Equipment Contamination; Fluorouracil; Gemcitabine; Humans; Occupational Exposure; Pharmacies; Platinum | 2023 |
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Medicare; Pancreatic Neoplasms; Retrospective Studies; United States | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival | 2022 |
Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Oxaliplatin; Pancreatic Neoplasms | 2023 |
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Japan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Serum Albumin | 2023 |
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient Care; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Pancreatic Neoplasms | 2023 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infant; Leucovorin; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Republic of Korea; Retrospective Studies | 2023 |
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cicatrix; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Mice; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polymers | 2023 |
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Effects of six pyrimidine analogs on the growth of Tetrahymena thermophila and their implications in pyrimidine metabolism.
Topics: Antimetabolites; Cytarabine; Floxuridine; Fluorouracil; Gemcitabine; Nucleosides; Pyrimidines; Tetrahymena thermophila; Thymine; Uracil | 2023 |
A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ergocalciferols; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Pilot Projects | 2023 |
Retrospective Evaluation of the Efficacy of Gemcitabine-Based Therapies After FOLFIRINOX Failure in Advanced Pancreatic Cancer, Multi-Center Real-Life Data.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
[Resection of locally advanced pancreatic cancer: careful selection and shared decision making].
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making, Shared; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2023 |